c-MYC mRNA Translation Regulatory Factor and Its Use in Cancer Therapy

Abstract

The present invention relates to a novel c-MYC mRNA translation regulator, a composition containing the same, a method for preparing the same, and use thereof in cancer treatment.

Description

Technical Field

[0001] The present invention relates to a novel c-MYC mRNA translation regulator, a composition containing the same, a method for preparing the same, and its use in cancer treatment.

Background Art

[0002] Cancer is the second leading cause of death in the United States after heart disease. In the United States, one in four deaths is due to cancer. The 5-year relative survival rate for all cancer patients diagnosed between 1996 and 2003 was 66%, up from 50% in 1975-1977 ("Cancer Facts & Figures American Cancer Society: Atlanta, GA (2008)"). Between 2000 and 2009, the annual incidence rate of new cancer cases in men decreased by an average of 0.6% per year, while it remained unchanged in women. Between 2000 and 2009, the mortality rate due to all cancers decreased by an average of 1.8% per year in men and 1.4% per year in women. This improvement in survival reflects advances in early diagnosis and improvements in treatment methods. Discovering highly effective anti-cancer agents with low toxicity is a major goal in cancer research.

[0003] The Myc family includes three major members, namely, the proto-oncogene c-Myc (cellular myelocytomatosis, abbreviation: Myc), L-Myc, and N-Myc. These three Myc homologs are involved in the initial stages of carcinogenesis and metastatic spread in most human cancers. In most types of tumors, the Myc gene has no mutations or duplications, but its mRNA and / or protein levels are increased, indicating that Myc overexpression is induced at the transcriptional, mRNA steady-state, and translational levels in cancer. In fact, the expression of the Myc gene is usually dependent on growth factor signaling, and the half-lives of both Myc mRNA and Myc protein are very short (30 minutes and 20 minutes, respectively) [Dang, C. V. (2012). MYC on the path to cancer. Cell 149, 22-35]. However, in tumor cells, the intracellular level of Myc is independent of such signaling and regulation, and as a result, the function of Myc deteriorates, driving intracellular and extracellular transcriptional programs that enable tumor growth and proliferation. However, for cancer to be strongly dependent on Myc activity, Myc does not necessarily have to be overexpressed. According to the study by Soucek et al. (Nature (2008) 455(7213):679-83), tumors expressing c-Myc at endogenous levels have been reported to show tumor regression upon Myc inhibition via a genetically engineered system. Therefore, treatment with Myc inhibitors is not necessarily limited to cancers that overexpress Myc. The compounds of the present invention can also be used to regulate the translation of Myc mRNA. In that case, the direct target of the compound is a protein or RNA that regulates the translation of Myc mRNA, and such Myc-dependent tumors will benefit from the therapeutic utility of the compounds of the present invention.

[0004] Myc is an important target for anticancer drugs due to its broad pathogenic importance. Dysregulation of the Myc gene is seen in a wide range of human hematological malignancies and solid tumors, particularly in breast cancer, ovarian cancer, acute myeloid leukemia, chronic myeloid leukemia, Hodgkin lymphoma, Burkitt lymphoma, diffuse large B-cell lymphoma, prostate cancer, colon cancer, gastric cancer, primary central nervous system lymphoma, glioblastoma, medulloblastoma, melanoma, non-small cell lung cancer, germinal center-derived lymphoma, esophageal squamous cell carcinoma, osteosarcoma, bladder cancer, pancreatic cancer, and lung adenocarcinoma, among others. Recent studies have also shown that deregulation of c-MYC is associated with the development of BRAFV600E thyroid cancer, choroid plexus carcinoma, and colitis-associated cancer. In addition, amplification of the MYC gene was observed in a significant number of cases of epithelial ovarian cancer. In the TCGA dataset, amplification of Myc occurs in several cancer types such as breast cancer, colon cancer, pancreatic cancer, gastric cancer, and uterine cancer.

[0005] The Myc gene is a very important oncogene and is considered a driver of carcinogenesis. The MYC protein is an important transcription factor that widely targets various genes, but it is still difficult to rationally design direct Myc inhibitors. This is mainly because the MYC protein lacks structural regions suitable for therapeutic inhibition by small molecules and is considered a difficult target for drug development [BioDrugs (2019) 33:539-553].

[0006] The design and development of MYC regulators are difficult. The main reason is that the MYC protein has a disordered structure lacking pockets or grooves that function as binding sites for regulators. Inhibiting the transcription of MYC, inhibiting the protein-protein interaction (PPI) between MYC and its cofactors, or affecting the signaling pathways associated with MYC have been previously used as potential regulatory targets but have not been developed into drug candidates. Myc PPI inhibitors require a high target occupancy to promote efficacy and thus could not show sufficient efficacy in cell-based assays or animal models. Regulators of signaling pathways upstream of Myc, such as mTOR regulators, failed due to a lack of target specificity.

[0007] Nevertheless, therapeutic approaches targeting c-Myc remain unexplained. The absence of a clear ligand-binding domain represents a major obstacle to direct inhibition, which is a difficult feature common to many potent transcriptional targets in cancer. Thus, as outlined herein, another means of targeting Myc, namely a compound that modulates the translation of Myc mRNA, is needed. SUMMARY OF THE INVENTION MEANS FOR SOLVING THE PROBLEM

[0008] The present invention provides a compound represented by structural formula I(j), I(n), and / or I(o) as defined below, and a compound represented by the structural formula listed in Table 1, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, N-oxide, reverse amide analog, prodrug, isotope variant (e.g., deuterated analog), PROTAC, pharmaceutical product, or any combination thereof. In various embodiments, the compounds of the present invention are c-MYC mRNA translation regulators. In various embodiments, the compounds of the present invention are c-MYC mRNA transcription regulators. In various embodiments, the compounds of the present invention are c-MYC inhibitors. In various embodiments, the compounds of the present invention are any combination of c-MYC mRNA transcription regulators, c-MYC mRNA transcription regulators, and c-MYC inhibitors.

[0009] The present invention also provides a pharmaceutical composition comprising a compound represented by structural formula I(j), I(n), and / or I(o) as defined below, and a compound represented by the structural formula listed in Table 1, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, N-oxide, prodrug, isotope variant (e.g., deuterated analog), PROTAC, pharmaceutical product, or any combination thereof.

[0010] The present invention also provides a method for treating, suppressing, reducing the severity of, reducing the risk of onset of, or inhibiting cancer, which comprises administering to a subject suffering from cancer a compound represented by structural formula I(j), I(n), and / or I(o) as defined below, and a compound represented by the structural formula listed in Table 1, under conditions effective for treating, suppressing, reducing the severity of, reducing the risk of onset of, or inhibiting cancer in the subject.

[0011] The present invention also provides a method for suppressing, reducing, or inhibiting tumor growth, which comprises administering to a subject having tumor growth a compound represented by structural formula I(j), I(n), and / or I(o) as defined below, and a compound represented by the structural formula listed in Table 1, under conditions effective for suppressing, reducing, or inhibiting tumor growth in the subject. In some embodiments, the tumor is cancer. In some embodiments, the subject is suffering from cancer.

[0012] The present invention also provides a method for regulating c-MYC mRNA translation in a cell, which comprises contacting the cell with a compound represented by structural formula I(j), I(n), and / or I(o) as defined below, and a compound represented by the structural formula listed in Table 1, thereby regulating c-MYC mRNA translation in the cell.

[0013] The present invention also provides a method for regulating c-MYC mRNA transcription in a cell, which comprises contacting the cell with a compound represented by structural formula I(j), I(n), and / or I(o) as defined below, and a compound represented by the structural formula listed in Table 1, thereby regulating c-MYC mRNA transcription in the cell. BRIEF DESCRIPTION OF THE DRAWINGS

[0014] This patent or application claims the benefit of, and priority to, at least one color drawing. Copies of this patent or patent application publication with color drawing(s) will be provided by the Patent and Trademark Office upon request and payment of the necessary fee.

[0015]

Figure 1

Figure 2

Figure 3

Figure 4

Mode for Carrying Out the Invention

[0016] In various embodiments, the present invention relates to a compound represented by the following structural formula I, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, N-oxide, reverse amide analog, prodrug, isotopic variant (e.g., deuterated analog), PROTAC, pharmaceutical, or any combination thereof.

[0017]

Chemical formula

[0018] Wherein, X2, X3, and X4 are each independently nitrogen or CH; X5, X6, X7, X8, and X9 are each independently a nitrogen atom or a carbon atom; X 10 is N, CH, or C(R) (e.g., C(CH2)OH, C(CH2)2-OH, C(NH-CH2-cyclopropyl), C(CH3), C(cyclopropyl), C(isopropoxy), C(COOH)); R5 is H, or a C1-C5 straight-chain or branched-chain alkyl (e.g., methyl); R6 is H, F, Cl, Br, I, OH, SH, R8-OH, R8-SH, -R8-O-R 10 (e.g., CH2-O-CH3, (CH2)2-O-CH3, (CH2)3-O-CH3, (CH3)2-O-CH(CH3)2), R8-S-R 10 (e.g., (CH2)3-S-(CH2)2CH3), R8-NHC(O)-R 10 , -O-R8-R 10, R8-(C3-C8 substituted or unsubstituted cycloalkyl) (e.g., CH2-cyclopropyl, CH2-cyclobutanol, CH2-difluorocyclopropyl, CH2-methylcyclopropyl, CH2-dimethylamino-cyclohexyl, (CH2)2-cyclopentanol, CH2-cyclohexanol), R8-(substituted or unsubstituted saturated, unsaturated or aromatic monocyclic, fused ring or spiro ring 3- to 10-membered heterocyclic ring) (e.g., (CH2)3-pyran, (CH2)2-pyrazole, (CH2)2-imidazole, CH2-tetrahydrofuran, CH2-dioxane, CH2-oxetane, CH2-piperidine, CH2-triazole, CH2-1-oxa-8-azaspiro[4.5]decane, (CH2)3-diazabicyclo[2.2.1]heptane, CH2-methyl-THF, CH2-ethyl-piperidine, CH2-oxa-azaspirodecan, (CH2)3-dimethylpyrazole, CH2-2-oxo-methylpyrrolidine, CH2-methyl-azetidine, CH2-azaspiroheptane), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ) (e.g., (CH2)3-4-fluoropiperidine, (CH2)3-N(CH2CH3)2, (CH2)3-N(CH(CH3)2)2, (CH2)3-piperidine, (CH2)4-NH(CH3), (CH2)3-NH-CH3, (CH2)3-NH-CH2CH3, (CH2)3-N(CCH2CH3)2, (CH2)3-NH2, (CH2)3-N(CH2CH3)(CH2CF3)), R8-C(O)N(R 10 )(R 11 ) (e.g., (CH2)2-C(O)-piperidine), R9-R8-N(R 10 )(R 11 ) (e.g., (CH2)2-C(O)-piperidine), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R10 , R8-C(O)-R 10 , C(O)H, C(O)-R 10 , a straight-chain or branched-chain C1-C5 C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10), C1-C5 linear or branched substituted or unsubstituted alkyl (e.g., CH(CH3)CH2OCH3, CH(CH3)CH2NH2, CH(CH3)C(O)N(CH3)2, CH2-CH(OH)Ph, (CH2)3N(H)CH2CH3, CH(CH3)(CH2)2OH, CH(CH2OH)(CH2CH3), (CH2)3-OCH3, (CH2)2-OCH3, (CH2)2-OCH(CH3)2, CH(CH2OH)(CH2CH(CH3)2), CH2CH(CH3)(OCH3), CH2CH(N(CH3)2)(CH2CH3), benzyl, methyl, ethyl, CH2-CH2-CH2-O-CH3, CH(CH3)C(O)N(CH3)2), C1-C5 linear or branched substituted or unsubstituted alkenyl, C1-C5 linear or branched or C3-C8 cyclic haloalkyl, C1-C5 linear or branched substituted or unsubstituted or C3-C8 cyclic alkoxy (e.g., methoxy, O-(CH2)2-O-CH3) (optionally, at least one methylene group (CH2) in the alkoxy is replaced by an oxygen atom), C1-C5 linear or branched thioalkoxy, C1-C5 linear or branched haloalkoxy, C1-C5 linear or branched alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclohexyl, methoxycyclopropyl, methylcyclobutyl, aminomethyl-cyclobutyl, methoxycyclobutyl, 2,3-dihydro-1H-indenol), R8-(C3-C8 substituted or unsubstituted cycloalkyl), substituted or unsubstituted saturated, unsaturated or aromatic monocyclic, fused ring, bridged ring or spiro ring 3- to 10-membered heterocyclic ring (e.g., piperidine, 1-methylpiperidine, 3-fluoro-1-methylpiperidine, azetidine, 1-methyl-azetidine, morpholine, pyrrolidine, pyrrolidinone, quinuclidine, tetrahydropyran, tetrahydrofuran, azaspiro[3.3]heptane, 8-methyl-8-azabicyclo[3.2.1) is octane, 1,3-dioxane, imidazole, trifluoromethyl-oxetane, hydroxy-tetrahydrofuran, azepan-2-one, azabicyclohexane), substituted or unsubstituted aryl, substituted or unsubstituted R8-aryl (e.g., benzyl), or substituted or unsubstituted benzyl;. Or, R6 and R5 are bonded to each other to form a substituted or unsubstituted 5- to 8-membered heterocyclic ring (e.g., azepane, piperazine, 2-(piperazin-1-yl)acetamide); Or, R6 is represented by the following structural formula B or structural formula Bi:

[0019]

Chemical formula

[0020] In the formula, m is 0 or 1; R 12 is R 20 , or C1-C5 C(O)-alkyl, and R 13 is R 30 ; Or, both R 12 and R 13 are H; Or, R 12 and R 13 are, independently of each other, H, or C1-C5 substituted or unsubstituted alkyl (e.g., ethyl, trifluoroethyl); Or, R 12 and C3 are bonded to each other to form ring A, and R 13 is R 30 ; Or, R 12 and R 13 are bonded to each other to form ring B; Or, R 12 and C1 are bonded to each other to form ring C, and R 13 is R 30 ; Or, C1 and C3 are bonded to each other to form ring D, and R 12 and R 13are independently of each other R 30 ; or, R 13 and C2 are bonded to each other to form an E ring, m is 1, and R 12 is R 30 ; or, R 12 and R 13 are bonded to each other to form a B ring, and C1 and C3 are bonded to each other to form a D ring; The A ring, C ring, and E ring are, independently of each other, a substituted or unsubstituted monocyclic, spiro, or fused 3- to 8-membered heterocyclic ring (e.g., A: pyrrolidine, methylpyrrolidine, ethylpyrrolidine; C: piperidine, pyrrolidine, methyl-2-oxopyrrolidine, pyran-pyrrolidine, methyl-azetidine, azabicyclooctane, 2-azabicyclo[2.1.1]hexane, 2-azaspiro[3.3]heptane; E: pyrrolidine, azetidine, ethylpyrrolidine, oxopyrrolidine, methylpiperidine); The B ring is a substituted or unsubstituted monocyclic, spiro, or fused 3- to 8-membered heterocyclic ring (B: piperidine, piperidin-2-one, 4-fluoropiperidin-2-one, piperidine-4-carbonitrile, 4-fluoropiperidine, 4-fluoro-2-methylpiperidine, methylpiperidine, fluoropiperidine, difluoropiperidine, pyrrolidine, piperazine, methylpyrrolidine, thiomorpholine 1,1-dioxide, 2-oxa-6-azaspiro[3.3]heptane, methylpiperazine, dimethylpyrazole, imidazole, 2-methyl-2,5-diazabicyclo[2.2.1]heptane, hydroxymethyl-pyrrolidine, 6-fluoro-3-azabicyclo[3.1.1]heptane); The D ring is a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclobutane, cyclohexane); R7 is H, F, Cl, Br, I, OH, O-R 20 SH, R8-OH, R8-SH, SR 10 -R8-O-R 10 -R8-S-R 10, R8-(C3-C8 cycloalkyl), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R 10 )(R 11 ), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 (COO-CH3), R8-C(O)-R 10 , C(O)H, C(O)-R 10 , C1-C5 straight-chain or branched C(O)-haloalkyl, -C(O)NH2, C(O)NHR (e.g., C(O)NH(CH3)), C(O)N(R 10 )(R 11 )(e.g., C(O)NH(CH3), C(O)NH(CH2CH3), C(O)NH(CH2CH2OCH3), C(O)NH(CH2CH2OH)), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10) C1-C5 linear or branched, substituted or unsubstituted alkyl (e.g., methylimidazole, methyl, ethyl), C1-C5 linear or branched, substituted or unsubstituted alkenyl, C1-C5 linear or branched or C3-C8 cyclic haloalkyl (e.g., CHF2), C1-C5 linear or branched or C3-C8 cyclic alkoxy (e.g., methoxy, ethoxy) (optionally, at least one methylene group (CH2) in the alkoxy is substituted by an oxygen atom), C1-C5 linear or branched thioalkyl, C1-C5 linear or branched thioalkoxy, C1-C5 linear or branched haloalkoxy, C1-C5 linear or branched alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclopropanol, cyclohexyl, bicyclo[1.1.1]pentane), substituted or unsubstituted 4- to 7-membered heterocyclic ring (e.g., morpholine, tetrahydropyran, tetrahydropyran, oxetane, oxetan-3-ol, pyrrolidine, pyrrolidin-2-ol, pyrrolidin-3-ol, 1-methylpyrrolidine, pyrrolidin-2-one, pyrrolidin-3-one, 3-cyanopyrrolidine, pyrrolidinone, imidazole, pyrazole, isoxazolidine, piperazine, piperidine, piperidin-3-ol, piperidin-4-ol, piperidin-2-one, piperidin-4-carbonitrile, 4-fluoropiperidine, oxadiazole, triazole, pyrazole, 2-oxopyrrolidine, 4,7-diazaspiro[2.5]octane, 2,5-diazabicyclo[2.2.1]heptane, piperazin-2-one), R8-(substituted or unsubstituted monocyclic, fused-ring or spiro-ring 3- to 8-membered heterocyclic ring), substituted or unsubstituted aryl, or substituted or unsubstituted benzyl; Or, R7 is represented by the following structural formula A:

[0021]

Chemical formula

[0022] In the formula, X1 is N or O; R1 and R2 are, independently of one another, H, F, Cl, Br, I, OH, SH, CF3, C1-C5 substituted or unsubstituted alkyl (e.g., CH2OH), C1-C5 straight-chain or branched-chain, or C3-C8 cyclic haloalkyl, C1-C5 straight-chain or branched-chain substituted or unsubstituted or C3-C8 cyclic alkoxy; or R1 and R2 are bonded to one another to form =O, or a C3-C8 carbocyclic or heterocyclic ring (e.g., cyclopropyl); R3 and R4 are, independently of one another, H, Me, C1-C5 substituted or unsubstituted alkyl (e.g., methoxyethylene, methylaminoethyl, aminoethyl), -R8-O-R 10 (e.g., (CH2)2-O-CH3), R8-N(R 10 )(R 11 (e.g., (CH2)2-NH(CH3)), C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl), substituted or unsubstituted 5- to 7-membered heterocyclic ring (e.g., pyrrolidine, methylpyrrolidine, piperidine), or R 20 ; or R3 and R4 are bonded to one another to form a 3- to 8-membered heterocyclic ring (e.g., pyrrolidine, pyrrolidone, 2-oxopyrrolidine, piperidine, morpholine, piperazine, imidazole); or R2 and R4 are bonded to one another to form a substituted or unsubstituted saturated or unsaturated 4- to 8-membered heterocyclic or carbocyclic ring (e.g., pyrrolidine, morpholine, 1-methylpyrrolidine, pyrrolidin-2-one, pyrrolidin-3-one, 3,3-difluoropyrrolidine, pyrrolidin-3-ol, 3-methoxypyrrolidine, 3-(difluoromethyl)pyrrolidine, pyrrolidine-3-carbonitrile, pyridine, piperidine, piperidin-2-one, imidazole, pyrimidine, triazole, oxadiazole, pyrazole). However, when the ring is an aromatic ring, R1 and / or R3 do not exist; however, when X1 is O, R4 does not exist; R7´ is H, F, Cl, Br, I, OH, O-R20 , SH, R8-OH, R8-SH, -R8-O-R 10 , R8-(C3-C8 cycloalkyl), R8-(3- to 8-membered heterocyclic ring), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R 10 )(R 11 ), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 , R8-C(O)-R 10 , C(O)H, C(O)-R 10 , C1-C5 linear or branched C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10) C1-C5 linear or branched substituted or unsubstituted alkyl (e.g., isopropyl, methyl, ethyl), C1-C5 linear or branched substituted or unsubstituted alkenyl, C1-C5 linear or branched or C3-C8 cyclic haloalkyl (e.g., CHF2), C1-C5 linear or branched or C3-C8 cyclic alkoxy (e.g., methoxy) (optionally, at least one methylene group (CH2) in the alkoxy is replaced by an oxygen atom), C1-C5 linear or branched thioalkoxy, C1-C5 linear or branched haloalkoxy, C1-C5 linear or branched alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclohexyl), substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., morpholine, pyran, oxetane, pyrrolidine, 3,3-difluoropyrrolidine, imidazole, pyrazole, triazole, piperazine, piperidine, piperidin-2-one, piperidin-4-ol, dioxazole, 2-oxopyrrolidine), substituted or unsubstituted aryl, or substituted or unsubstituted benzyl; or, R7 and R7' are bonded to each other to form a substituted or unsubstituted saturated, unsaturated or aromatic 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); R 20 is represented by the following structural formula:

[0023] [Chemical formula]

[0024] wherein, R 30 is H, R 20 , F, Cl, Br, I, OH, SH, alkoxy, N(R)2, NH(R 10 ), N(R 10 )(R 11)、CF3, CN, NO2, C1-C5 linear or branched substituted or unsubstituted alkyl (e.g., methyl, ethyl, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), C1-C5 linear or branched alkoxy, C1-C5 linear or branched haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , -R8-R 10 (e.g., (CH2)2-O-CH3), substituted or unsubstituted aryl (e.g., phenyl), or substituted or unsubstituted heteroaryl (e.g., pyridine (2-pyridine, 3-pyridine, or 4-pyridine)); R is H, F, Cl, Br, I, OH, SH, alkoxy, NH(R 10 ), NH-CH2-cyclopropyl, N(R 10 )(R 11 ), CF3, CN, NO2, COOH, CO(R 10 )(e.g., C(O)CH3), C1-C5 linear or branched substituted or unsubstituted alkyl (e.g., methyl, ethyl, CH2-OH, CH2-CH2-OH, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), C3-C8 substituted or unsubstituted cycloalkyl, cyclopropyl, C1-C5 linear or branched alkoxy, isopropoxy, C1-C5 linear or branched haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , -R8-R 10(For example, (CH2)2-O-CH3), a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2-pyridine, 3-pyridine, or 4-pyridine)); Each R8 is, independently of one another, [CH2] p and p is from 1 to 10; R9 is [CH] q or [C] q and q is from 2 to 10; R 10 and R 11 are, independently of one another, H, a straight-chain or branched-chain substituted or unsubstituted alkyl having 1 to 5 carbon atoms (e.g., methyl, ethyl, CH2-cyclopropyl, CH2-CH2-O-CH3), a straight-chain or branched-chain substituted or unsubstituted haloalkyl having 1 to 5 carbon atoms (e.g., CH2CF3), a straight-chain or branched-chain alkoxy having 1 to 5 carbon atoms (e.g., O-CH3), R 20 , C(O)R, or S(O)2R; or R 10 and R 11 are joined to each other to form a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., piperazine, piperidine); n is an integer from 0 to 4 (e.g., 1, 2).

[0025] In various embodiments, the present invention relates to a compound represented by the following structural formula I(a), or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, N-oxide, reverse amide analog, prodrug, isotope variant (e.g., deuterated analog), PROTAC, pharmaceutical, or any combination thereof.

[0026]

Chemical formula

[0027] In the formula, X2, X3, and X4 are, independently of one another, nitrogen or CH; X5, X6, X7, X8, and X9 are, independently of one another, a nitrogen atom or a carbon atom; X 10 is N, CH, or C(R) (for example, C(CH2)OH, C(CH2)2-OH, C(NH-CH2-cyclopropyl), C(CH3), C(cyclopropyl), C(isopropoxy), C(COOH)); R5 is H, or a straight-chain or branched-chain C1-C5 alkyl (for example, methyl); R6 is H, F, Cl, Br, I, OH, SH, R8-OH, R8-SH, -R8-O-R 10 (for example, CH2-O-CH3, (CH2)2-O-CH3, (CH2)3-O-CH3, (CH3)2-O-CH(CH3)2), R8-S-R 10 (for example, (CH2)3-S-(CH2)2CH3), R8-NHC(O)-R 10 , -O-R8-R 10 , R8-(a C3-C8 substituted or unsubstituted cycloalkyl) (for example, CH2-cyclopropyl, CH2-cyclobutanol, CH2-difluorocyclopropyl, CH2-methylcyclopropyl, CH2-dimethylamino-cyclohexyl, (CH2)2-cyclopentanol, CH2-cyclohexanol), R8-(a substituted or unsubstituted saturated, unsaturated or aromatic monocyclic, fused-ring or spiro-ring 3- to 10-membered heterocyclic ring) (for example, (CH2)3-pyran, (CH2)2-pyrazole, (CH2)2-imidazole, CH2-tetrahydrofuran, CH2-dioxane, CH2-oxetane, CH2-piperidine, CH2-triazole, CH2-1-oxa-8-azaspiro[4.5]decane, (CH2)3-diazabicyclo[2.2.1]heptane, CH2-methyl-THF, CH2-ethyl-piperidine, CH2-oxa-azaspirodecane, (CH2)3-dimethylpyrazole, CH2-2-oxo-methylpyrrolidine, CH2-methyl-azetidine, CH2-azaspiroheptane), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R10 )(R 11 )(e.g., (CH2)3 - 4 - fluoropiperidine, (CH2)3 - N(CH2CH3)2, (CH2)3 - N(CH(CH3)2)2, (CH2)3 - piperidine, (CH2)4 - NH(CH3), (CH2)3 - NH - CH3, (CH2)3 - NH - CH2CH3, (CH2)3 - N(CCH2CH3)2, (CH2)3 - NH2, (CH2)3 - N(CH2CH3)(CH2CF3)), R8 - C(O)N(R 10 )(R 11 )(e.g., (CH2)2 - C(O) - piperidine), R9 - R8 - N(R 10 )(R 11 )(e.g., (CH2)2 - C(O) - piperidine), B(OH)2, - OC(O)CF3, - OCH2Ph, NHC(O) - R 10 、NHCO - N(R 10 )(R 11 ), COOH, - C(O)Ph, C(O)O - R 10 、R8 - C(O) - R 10 、C(O)H, C(O) - R 10 、a C1 - C5 straight or branched chain C(O) - haloalkyl, - C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH - R 10), a straight-chain or branched-chain, substituted or unsubstituted C1-C5 alkyl (e.g., CH(CH3)CH2OCH3, CH(CH3)CH2NH2, CH(CH3)C(O)N(CH3)2, CH2-CH(OH)Ph, (CH2)3N(H)CH2CH3, CH(CH3)(CH2)2OH, CH(CH2OH)(CH2CH3), (CH2)3-OCH3, (CH2)2-OCH3, (CH2)2-OCH(CH3)2, CH(CH2OH)(CH2CH(CH3)2), CH2CH(CH3)(OCH3), CH2CH(N(CH3)2)(CH2CH3), benzyl, methyl, ethyl, CH2-CH2-CH2-O-CH3, CH(CH3)C(O)N(CH3)2), a straight-chain or branched-chain, substituted or unsubstituted C1-C5 alkenyl, a straight-chain or branched-chain C1-C5 or cyclic C3-C8 haloalkyl, a straight-chain or branched-chain, substituted or unsubstituted C1-C5 or cyclic C3-C8 alkoxy (e.g., methoxy, O-(CH2)2-O-CH3) (optionally, at least one methylene group (CH2) in the alkoxy is substituted with an oxygen atom), a straight-chain or branched-chain C1-C5 thioalkoxy, a straight-chain or branched-chain C1-C5 haloalkoxy, a straight-chain or branched-chain C1-C5 alkoxyalkyl, a substituted or unsubstituted C3-C8 cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclohexyl, methoxycyclopropyl, methylcyclobutyl, aminomethyl-cyclobutyl, methoxycyclobutyl, 2,3-dihydro-1H-indenol), R8-(substituted or unsubstituted C3-C8 cycloalkyl), a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., piperidine, 1-methylpiperidine, 3-fluoro-1-methylpiperidine, azetidine, 1-methyl-azetidine, morpholine, pyrrolidine, pyrrolidinone, quinuclidine, tetrahydropyran, tetrahydrofuran, azaspiro[3.3]heptane, 8-methyl-8-azabicyclo[3.2.1) It is octane, 1,3 - dioxane, imidazole, trifluoromethyl - oxetane, hydroxy - tetrahydrofuran, azepan - 2 - one, azabicyclohexane), a substituted or unsubstituted aryl, a substituted or unsubstituted R8 - aryl (e.g., benzyl), or a substituted or unsubstituted benzyl;. Or, R6 and R5 are bonded to each other to form a substituted or unsubstituted 5 - to 8 - membered heterocyclic ring (e.g., azepane, piperazine, 2 - (piperazin - 1 - yl) acetamide); Or, R6 is represented by the following structural formula B or structural formula Bi:

[0028]

Chemical formula

[0029] In the formula, m is 0 or 1; R 12 is R 20 , or C1 - C5 C(O) - alkyl, and R 13 is R 30 ; Or, both R 12 and R 13 are H; Or, R 12 and R 13 are, independently of each other, H, or C1 - C5 substituted or unsubstituted alkyl (e.g., ethyl, trifluoroethyl); Or, R 12 and C3 are bonded to each other to form ring A, and R 13 is R 30 ; Or, R 12 and R 13 are bonded to each other to form ring B; Or, R 12 and C1 are bonded to each other to form ring C, and R 13 is R 30 ; Or, C1 and C3 are bonded to each other to form ring D, and R 12 and R 13are independent of each other and are R 30 ; or, R 13 and C2 are bonded to each other to form an E ring, m is 1, and R 12 is R 30 ; or, R 12 and R 13 are bonded to each other to form a B ring, and C1 and C3 are bonded to each other to form a D ring; The A ring, C ring, and E ring are, independent of each other, a substituted or unsubstituted monocyclic, spiro, or fused 3- to 8-membered heterocyclic ring of a monocyclic ring (e.g., A: pyrrolidine, methylpyrrolidine, ethylpyrrolidine; C: piperidine, pyrrolidine, methyl-2-oxopyrrolidine, pyran-pyrrolidine, methyl-azetidine, azabicyclooctane, 2-azabicyclo[2.1.1]hexane, 2-azaspiro[3.3]heptane; E: pyrrolidine, azetidine, ethylpyrrolidine, oxopyrrolidine, methylpiperidine); The B ring is a substituted or unsubstituted monocyclic, spiro, or fused 3- to 8-membered heterocyclic ring (B: piperidine, piperidin-2-one, 4-fluoropiperidin-2-one, piperidine-4-carbonitrile, 4-fluoropiperidine, 4-fluoro-2-methylpiperidine, methylpiperidine, fluoropiperidine, difluoropiperidine, pyrrolidine, piperazine, methylpyrrolidine, thiomorpholine 1,1-dioxide, 2-oxa-6-azaspiro[3.3]heptane, methylpiperazine, dimethylpyrazole, imidazole, 2-methyl-2,5-diazabicyclo[2.2.1]heptane, hydroxymethyl-pyrrolidine, 6-fluoro-3-azabicyclo[3.1.1]heptane); The D ring is a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclobutane, cyclohexane); R7 is O-R 20 , SH, R8-OH, R8-SH, SR 10 , -R8-O-R 10 , -R8-S-R 10 , R8-(C3-C8 cycloalkyl), CD3, OCD3, NO2, -CH2CN, -R8CN, R8-N(R 10)(R 11 ), R9 - R8 - N(R 10 )(R 11 ), B(OH)2, -OC(O)CF3, -OCH2Ph, NHCO - N(R 10 )(R 11 ), R8 - C(O) - R 10 , SO2N(R 10 )(R 11 ), CH(CF3)(NH - R 10 ), a C1 - C5 straight-chain or branched-chain substituted or unsubstituted alkenyl, a C1 - C5 straight-chain or branched-chain thioalkoxy, a C1 - C5 straight-chain or branched-chain alkoxyalkyl, a substituted or unsubstituted 4- to 7-membered heterocyclic ring (e.g., morpholine, tetrahydropyran, tetrahydropyran, oxetane, oxetan-3-ol, pyrrolidine, pyrrolidin-2-ol, pyrrolidin-3-ol, 1-methylpyrrolidine, pyrrolidin-2-one, pyrrolidin-3-one, pyrrolidin-3-carbonitrile, 3-cyanopyrrolidine, pyrrolidinone, imidazole, pyrazole, isoxazolidine, piperazine, piperidine, piperidin-3-ol, piperidin-4-ol, piperidin-2-one, piperidin-4-carbonitrile, 4-fluoropiperidine, oxadiazole, triazole, pyrazole, 2-oxopyrrolidine, 4,7-diazaspiro[2.5]octane, 2,5-diazabicyclo[2.2.1]heptane, piperazin-2-one), R8-(a substituted or unsubstituted monocyclic, fused-ring or spiro-ring 3- to 8-membered heterocyclic ring), a substituted or unsubstituted aryl, or a substituted or unsubstituted benzyl; or, R7 is represented by the following structural formula A:

[0030]

Chemical formula

[0031] In the formula, X1 is N or O; R1 and R2 are, independently of each other, H, F, Cl, Br, I, OH, SH, CF3, a substituted or unsubstituted alkyl of C1-C5 (e.g., CH2OH), a linear or branched C1-C5, or a cyclic haloalkyl of C3-C8, a linear or branched substituted or unsubstituted or cyclic alkoxy of C1-C5 or C3-C8; or, R1 and R2 are bonded to each other to form a carbocyclic or heterocyclic ring of C3-C8 (e.g., cyclopropyl); R3 and R4 are, independently of each other, H, Me, a substituted or unsubstituted alkyl of C1-C5 (e.g., methoxyethylene, methylaminoethyl, aminoethyl), -R8-O-R 10 (e.g., (CH2)2-O-CH3), R8-N(R 10 )(R 11 (e.g., (CH2)2-NH(CH3)), a substituted or unsubstituted cycloalkyl of C3-C8 (e.g., cyclopropyl), a substituted or unsubstituted 5- to 7-membered heterocyclic ring (e.g., pyrrolidine, methylpyrrolidine, piperidine), or, R 20 ; or, R3 and R4 are bonded to each other to form a heterocyclic ring of 3 to 8 members (e.g., pyrrolidine, pyrrolidone, 2-oxopyrrolidine, piperidine, morpholine, piperazine, imidazole); or, R2 and R4 are bonded to each other to form a substituted or unsubstituted saturated or unsaturated heterocyclic or carbocyclic ring of 4 to 8 members (e.g., pyrrolidine, morpholine, 1-methylpyrrolidine, pyrrolidin-2-one, pyrrolidin-3-one, 3,3-difluoropyrrolidine, pyrrolidin-3-ol, 3-methoxypyrrolidine, 3-(difluoromethyl)pyrrolidine, pyrrolidine-3-carbonitrile, pyridine, piperidine, piperidin-2-one, imidazole, pyrimidine, triazole, oxadiazole, pyrazole). However, when the ring is an aromatic ring, R1 and / or R3 do not exist; however, when X1 is O, R4 does not exist; R7´ is H, F, Cl, Br, I, OH, O-R 20 , SH, R8-OH, R8-SH, -R8-O-R10 , R8-(C3-C8 cycloalkyl), R8-(3- to 8-membered heterocyclic ring), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R 10 )(R 11 ), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 , R8-C(O)-R 10 , C(O)H, C(O)-R 10 , C1-C5 straight-chain or branched C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10), C1-C5 linear or branched substituted or unsubstituted alkyl (e.g., isopropyl, methyl, ethyl), C1-C5 linear or branched substituted or unsubstituted alkenyl, C1-C5 linear or branched or C3-C8 cyclic haloalkyl (e.g., CHF2), C1-C5 linear or branched or C3-C8 cyclic alkoxy (e.g., methoxy) (optionally, at least one methylene group (CH2) in the alkoxy is replaced by an oxygen atom), C1-C5 linear or branched thioalkoxy, C1-C5 linear or branched haloalkoxy, C1-C5 linear or branched alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclohexyl), substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., morpholine, pyran, oxetane, pyrrolidine, 3,3-difluoropyrrolidine, imidazole, pyrazole, triazole, piperazine, piperidine, piperidin-2-one, piperidin-4-ol, dioxazole, 2-oxopyrrolidine), substituted or unsubstituted aryl, or substituted or unsubstituted benzyl; or, R7 and R7' are bonded to each other to form a substituted or unsubstituted saturated, unsaturated or aromatic 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); R 20 is represented by the following structural formula:

[0032]

Chemical formula

[0033] In the formula, R is H, F, Cl, Br, I, OH, SH, alkoxy, NH(R 10 ), NH-CH2-cyclopropyl, N(R 10 )(R 11 ), CF3, CN, NO2, COOH, CO(R 10)(e.g., C(O)CH3), a C1-C5 straight-chain or branched-chain substituted or unsubstituted alkyl (e.g., methyl, ethyl, CH2-OH, CH2-CH2-OH, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a C3-C8 substituted or unsubstituted cycloalkyl, cyclopropyl, a C1-C5 straight-chain or branched-chain alkoxy, isopropoxy, a C1-C5 straight-chain or branched-chain haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , -R8-R 10 (e.g., (CH2)2-O-CH3), a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2-pyridine, 3-pyridine, or 4-pyridine)); R 30 is H, R 20 , F, Cl, Br, I, OH, SH, alkoxy, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), CF3, CN, NO2, a C1-C5 straight-chain or branched-chain substituted or unsubstituted alkyl (e.g., methyl, ethyl, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a C1-C5 straight-chain or branched-chain alkoxy, a C1-C5 straight-chain or branched-chain haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , -R8-R 10(For example, (CH2)2-O-CH3), a substituted or unsubstituted aryl (for example, phenyl), or a substituted or unsubstituted heteroaryl (for example, pyridine (2-pyridine, 3-pyridine, or 4-pyridine)); Each R8 is, independently of one another, [CH2] p and p is from 1 to 10; R9 is [CH] q or [C] q and q is from 2 to 10; R 10 and R 11 are, independently of one another, H, a straight-chain or branched-chain substituted or unsubstituted alkyl having 1 to 5 carbon atoms (for example, methyl, ethyl, CH2-cyclopropyl, CH2-CH2-O-CH3), a straight-chain or branched-chain substituted or unsubstituted haloalkyl having 1 to 5 carbon atoms (for example, CH2CF3), a straight-chain or branched-chain alkoxy having 1 to 5 carbon atoms (for example, O-CH3), R 20 , C(O)R, or S(O)2R; or R 10 and R 11 are joined to each other to form a substituted or unsubstituted 3- to 8-membered heterocyclic ring (for example, piperazine, piperidine); n is an integer from 0 to 4 (for example, 1, 2).

[0034] In various embodiments, the present invention relates to a compound represented by the following structural formula I(b), or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, N-oxide, reverse amide analogue, prodrug, isotopic variant (for example, deuterated analogue), PROTAC, pharmaceutical, or any combination thereof.

[0035]

Chemical formula

[0036] In the formula, X2, X3, and X4 are, independently of one another, nitrogen or CH; X5, X6, X7, X8, and X9 are, independently of one another, a nitrogen atom or a carbon atom; X 10 is N, CH, or C(R) (e.g., C(CH2)OH, C(CH2)2-OH, C(NH-CH2-cyclopropyl), C(CH3), C(cyclopropyl), C(isopropoxy), C(COOH)); R6 is H, F, Cl, Br, I, OH, SH, R8-OH, R8-SH, -R8-O-R 10 (e.g., CH2-O-CH3), R8-S-R 10 (e.g., (CH2)3-S-(CH2)2CH3), R8-NHC(O)-R 10 , -O-R8-R 10 , R8-(C3-C8 substituted or unsubstituted cycloalkyl) (e.g., CH2-cyclobutanol, CH2-difluorocyclopropyl, CH2-methylcyclopropyl, CH2-dimethylamino-cyclohexyl, (CH2)2-cyclopentanol, CH2-cyclohexanol, (CH2)3-pyran, CH2-tetrahydrofuran, CH2-dioxane, CH2-methyl-THF, CH2-oxa-azaspirodecan, (CH2)3-dimethylpyrazole, CH2-methyl-azetidine, CH2-azaspiroheptane), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R9-R8-N(R 10 )(R 11 )(e.g., (CH2)2-C(O)-piperidine), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 , R8-C(O)-R 10 , C(O)H, C(O)-R 10 , C1-C5 straight-chain or branched C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11)、SO2R、SO2N(R 10 )(R 11 )、CH(CF3)(NH-R 10)、C1-C5 linear or branched substituted or unsubstituted alkyl (e.g., CH(CH3)CH2OCH3, CH(CH3)CH2NH2, CH(CH3)C(O)N(CH3)2, CH2-CH(OH)Ph, (CH2)3N(H)CH2CH3, CH(CH3)(CH2)2OH, CH(CH2OH)(CH2CH3), (CH2)3-OCH3, (CH2)2-OCH3, (CH2)2-OCH(CH3)2, CH(CH2OH)(CH2CH(CH3)2), CH2CH(CH3)(OCH3), CH2CH(N(CH3)2)(CH2CH3), benzyl, methyl, ethyl, CH2-CH2-CH2-O-CH3), C1-C5 linear or branched substituted or unsubstituted alkenyl, C1-C5 linear or branched or C3-C8 cyclic haloalkyl, C1-C5 linear or branched substituted or unsubstituted or C3-C8 cyclic alkoxy (e.g., methoxy, O-(CH2)2-O-CH3) (optionally, at least one methylene group (CH2) in the alkoxy is replaced by an oxygen atom), C1-C5 linear or branched thioalkoxy, C1-C5 linear or branched haloalkoxy, C1-C5 linear or branched alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., methoxycyclopropyl, methylcyclobutyl, cyclopropyl, aminomethyl-cyclobutyl, methoxycyclobutyl, 2,3-dihydro-1H-indenol), R8-(C3-C8 substituted or unsubstituted cycloalkyl), substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., piperidine, 1-methylpiperidine, 3-fluoro-1-methylpiperidine, azetidine, 1-methyl-azetidine, morpholine, pyrrolidine, pyrrolidinone, quinuclidine, tetrahydropyran, tetrahydrofuran, azaspiro[3.3]heptane, 8-methyl-8-azabicyclo[3.2.1]octane, 1,3-dioxane, imidazole, trifluoromethyl-oxetane, hydroxy-tetrahydrofuran, azepan-2-one, azabicyclohexane), substituted or unsubstituted aryl, or substituted or unsubstituted benzyl; Alternatively, R6 and R5 are bonded to each other to form a substituted or unsubstituted 5- to 8-membered heterocyclic ring (e.g., azepane, piperazine, 2-(piperazin-1-yl)acetamide); Alternatively, R6 is represented by the following structural formula B or structural formula Bi:

[0037]

Chemical formula

[0038] In the formula, m is 0 or 1; R 12 is R 20 , or C1-C5 C(O)-alkyl, and R 13 is R 30 ; Alternatively, both R 12 and R 13 are H; Alternatively, R 12 and C3 are bonded to each other to form ring A, and R 13 is R 30 ; Alternatively, R 12 and R 13 are bonded to each other to form a substituted or unsubstituted pyrrolidine ring, piperazine, thiomorpholine 1,1-dioxide, 2-oxa-6-azaspiro[3.3]heptane, pyrazole, imidazole, 2,5-diazabicyclo[2.2.1]heptane or diazabicyclo[2.2.1]heptane; Alternatively, R 12 and C1 are bonded to each other to form ring C, and R 13 is R 30 ; Alternatively, C1 and C3 are bonded to each other to form ring D, and R 12 and R 13 are independently of each other R 30 ; Alternatively, R 13 and C2 are bonded to each other to form ring E, m is 1, and R 12 is R 30 ; Alternatively, R12 and R 13 are combined with each other to form ring B, and C1 and C3 are combined with each other to form ring D; Ring A, ring C, and ring E are, independently of each other, a substituted or unsubstituted monocyclic, spiro or fused 3- to 8-membered heterocyclic ring (e.g., A: pyrrolidine, methylpyrrolidine, ethylpyrrolidine; C: piperidine, pyrrolidine, methyl-2-oxopyrrolidine, pyran-pyrrolidine, methyl-azetidine, azabicyclooctane, 2-azabicyclo[2.1.1]hexane, 2-azaspiro[3.3]heptane; E: pyrrolidine, azetidine, ethylpyrrolidine, oxopyrrolidine, methylpiperidine); Ring B is a substituted or unsubstituted monocyclic, spiro or fused 3- to 8-membered heterocyclic ring (B: piperidine, piperidin-2-one, 4-fluoropiperidin-2-one, piperidine-4-carbonitrile, 4-fluoropiperidine, 4-fluoro-2-methylpiperidine, methylpiperidine, fluoropiperidine, difluoropiperidine, pyrrolidine, piperazine, methylpyrrolidine, thiomorpholine 1,1-dioxide, 2-oxa-6-azaspiro[3.3]heptane, methylpiperazine, dimethylpyrazole, imidazole, 2-methyl-2,5-diazabicyclo[2.2.1]heptane, hydroxymethyl-pyrrolidine, 6-fluoro-3-azabicyclo[3.1.1]heptane); Ring D is a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclobutane, cyclohexane); R7 is H, F, Cl, Br, I, OH, O-R 20 , SH, R8-OH, R8-SH, SR 10 , -R8-O-R 10 , -R8-S-R 10 , R8-(C3-C8 cycloalkyl), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R 10 )(R11 )、B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 (COO-CH3), R8-C(O)-R 10 , C(O)H, C(O)-R 10 , a straight-chain or branched C1-C5 C(O)-haloalkyl, -C(O)NH2, C(O)NHR (e.g., C(O)NH(CH3)), C(O)N(R 10 )(R 11 )(e.g., C(O)NH(CH3), C(O)NH(CH2CH2OCH3), C(O)NH(CH2CH2OH)), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10), C1-C5 linear or branched substituted or unsubstituted alkyl (e.g., methylimidazole, methyl, ethyl), C1-C5 linear or branched substituted or unsubstituted alkenyl, C1-C5 linear or branched or C3-C8 cyclic haloalkyl (e.g., CHF2), C1-C5 linear or branched or C3-C8 cyclic alkoxy (e.g., methoxy, ethoxy) (optionally, at least one methylene group (CH2) in the alkoxy is substituted with an oxygen atom), C1-C5 linear or branched thioalkyl, C1-C5 linear or branched thioalkoxy, C1-C5 linear or branched haloalkoxy, C1-C5 linear or branched alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclopropanol, cyclohexyl, bicyclo[1.1.1]pentane), substituted or unsubstituted 4- to 7-membered heterocyclic ring (e.g., morpholine, tetrahydropyran, tetrahydropyran, oxetane, oxetan-3-ol, pyrrolidine, pyrrolidin-2-ol, pyrrolidin-3-ol, 3-methoxypyrrolidine, pyrrolidine-3-carbonitrile, 3-cyanopyrrolidine, 1-methylpyrrolidine, pyrrolidin-2-one, pyrrolidin-3-one, pyrrolidinone, imidazole, pyrazole, isoxazolidine, piperazine, piperidine, piperidin-3-ol, piperidin-4-ol, piperidin-2-one, piperidin-4-carbonitrile, 4-fluoropiperidine, oxadiazole, triazole, pyrazole, 2-oxopyrrolidine, 4,7-diazaspiro[2.5]octane, 2,5-diazabicyclo[2.2.1]heptane, piperazin-2-one), R8-(substituted or unsubstituted monocyclic, fused-ring or spiro-ring 3- to 8-membered heterocyclic ring), substituted or unsubstituted aryl, or substituted or unsubstituted benzyl; Or, R7 is represented by the following structural formula A:

[0039]

Chemical formula

[0040] In the formula, X1 is N or O; R1 and R2 are each independently H, F, Cl, Br, I, OH, SH, CF3, a substituted or unsubstituted alkyl having 1 to 5 carbon atoms (for example, CH2OH), a linear or branched chain having 1 to 5 carbon atoms, or a cyclic haloalkyl having 3 to 8 carbon atoms, a linear or branched chain having 1 to 5 carbon atoms, a substituted or unsubstituted or cyclic alkoxy having 3 to 8 carbon atoms; or R1 and R2 are bonded to each other to form a carbocyclic or heterocyclic ring having 3 to 8 carbon atoms (for example, cyclopropyl); R3 and R4 are each independently H, Me, a substituted or unsubstituted alkyl having 1 to 5 carbon atoms (for example, methoxyethylene, methylaminoethyl, aminoethyl), -R8-O-R 10 (for example, (CH2)2-O-CH3), R8-N(R 10 )(R 11 )(for example, (CH2)2-NH(CH3)), a substituted or unsubstituted cycloalkyl having 3 to 8 carbon atoms (for example, cyclopropyl), a substituted or unsubstituted 5- to 7-membered heterocyclic ring (for example, pyrrolidine, methylpyrrolidine, piperidine), or R 20 ; or R3 and R4 are bonded to each other to form a 3- to 8-membered heterocyclic ring (for example, pyrrolidine, pyrrolidone, 2-oxopyrrolidine, piperidine, morpholine, piperazine, imidazole); or R2 and R4 are bonded to each other to form a substituted or unsubstituted saturated or unsaturated 4- to 8-membered heterocyclic or carbocyclic ring (for example, pyrrolidine, morpholine, 1-methylpyrrolidine, pyrrolidin-2-one, pyrrolidin-3-one, 3,3-difluoropyrrolidine, pyrrolidin-3-ol, 3-methoxypyrrolidine, 3-(difluoromethyl)pyrrolidine, pyrrolidine-3-carbonitrile, pyridine, piperidine, piperidin-2-one, imidazole, pyrimidine, triazole, oxadiazole, pyrazole). However, when the ring is an aromatic ring, R1 and / or R3 do not exist; however, when X1 is O, R4 does not exist; R7' is H, F, Cl, Br, I, OH, O-R 20 , SH, R8-OH, R8-SH, -R8-O-R 10 , R8-(C3-C8 cycloalkyl), R8-(3- to 8-membered heterocyclic ring), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R 10 )(R 11 ), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 , R8-C(O)-R 10 , C(O)H, C(O)-R 10 , C1-C5 linear or branched C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10) C1-C5 straight-chain or branched-chain substituted or unsubstituted alkyl (e.g., isopropyl, methyl, ethyl), C1-C5 straight-chain or branched-chain substituted or unsubstituted alkenyl, C1-C5 straight-chain or branched-chain or C3-C8 cyclic haloalkyl (e.g., CHF2), C1-C5 straight-chain or branched-chain or C3-C8 cyclic alkoxy (e.g., methoxy) (optionally, at least one methylene group (CH2) in the alkoxy is replaced by an oxygen atom), C1-C5 straight-chain or branched-chain thioalkoxy, C1-C5 straight-chain or branched-chain haloalkoxy, C1-C5 straight-chain or branched-chain alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclohexyl), substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., morpholine, pyran, oxetane, pyrrolidine, 3,3-difluoropyrrolidine, imidazole, pyrazole, triazole, piperazine, piperidine, piperidin-2-one, piperidin-4-ol, dioxazole, 2-oxopyrrolidine), substituted or unsubstituted aryl, or substituted or unsubstituted benzyl; or, R7 and R7´ are bonded to each other to form a substituted or unsubstituted saturated, unsaturated or aromatic 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); R 20 is represented by the following structural formula:

[0041] [Chemical formula]

[0042] In the formula, R 30 is H, R 20 , F, Cl, Br, I, OH, SH, alkoxy, N(R)2, NH(R 10 ), N(R 10 )(R 11)、CF3, CN, NO2, a linear or branched, substituted or unsubstituted C1-C5 alkyl (e.g., methyl, ethyl, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a linear or branched C1-C5 alkoxy, a linear or branched C1-C5 haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), an R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , -R8-R 10 (e.g., (CH2)2-O-CH3), a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2-pyridine, 3-pyridine, or 4-pyridine)); R is H, F, Cl, Br, I, OH, SH, alkoxy, NH(R 10 ), NH-CH2-cyclopropyl, N(R 10 )(R 11 ), CF3, CN, NO2, COOH, CO(R 10 )(e.g., C(O)CH3), a linear or branched, substituted or unsubstituted C1-C5 alkyl (e.g., methyl, ethyl, CH2-OH, CH2-CH2-OH, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a substituted or unsubstituted C3-C8 cycloalkyl, cyclopropyl, a linear or branched C1-C5 alkoxy, isopropoxy, a linear or branched C1-C5 haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), an R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , -R8-R 10(For example, (CH2)2-O-CH3), a substituted or unsubstituted aryl (for example, phenyl), or a substituted or unsubstituted heteroaryl (for example, pyridine (2-pyridine, 3-pyridine, or 4-pyridine)); Each R8 is, independently of one another, [CH2] p and p is from 1 to 10; R9 is [CH] q or [C] q and q is from 2 to 10; R 10 and R 11 are, independently of one another, H, a linear or branched substituted or unsubstituted C1-C5 alkyl (for example, methyl, ethyl, CH2-cyclopropyl, CH2-CH2-O-CH3), a linear or branched substituted or unsubstituted haloalkyl of C1-C5 (for example, CH2CF3), a linear or branched alkoxy of C1-C5 (for example, O-CH3), R 20 , C(O)R, or S(O)2R; Or R 10 and R 11 are joined to each other to form a substituted or unsubstituted 3- to 8-membered heterocyclic ring (for example, piperazine, piperidine); n is an integer from 0 to 4 (for example, 1, 2).

[0043] In various embodiments, the present invention relates to a compound represented by the following structural formula I(c), or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, N-oxide, reverse amide analog, prodrug, isotope variant (for example, deuterated analog), PROTAC, pharmaceutical, or any combination thereof.

[0044]

Chemical formula

[0045] Wherein, X2, X3, and X4 are, independently of one another, nitrogen or CH; X5, X6, X7, X8, and X9 are, independently of one another, a nitrogen atom or a carbon atom; X 10 is N, CH, or C(R) (for example, C(CH2)OH, C(CH2)2-OH, C(NH-CH2-cyclopropyl), C(CH3), C(cyclopropyl), C(isopropoxy), C(COOH)); R5 is H, or a linear or branched C1-C5 alkyl (for example, methyl); R6 is H, F, Cl, Br, I, OH, SH, R8-OH, R8-SH, -R8-O-R 10 (for example, CH2-O-CH3, (CH2)2-O-CH3, (CH2)3-O-CH3, (CH3)2-O-CH(CH3)2), R8-S-R 10 (for example, (CH2)3-S-(CH2)2CH3), R8-NHC(O)-R 10 , -O-R8-R 10 , R8-(a substituted or unsubstituted C3-C8 cycloalkyl) (for example, CH2-cyclopropyl, CH2-cyclobutanol, CH2-difluorocyclopropyl, CH2-methylcyclopropyl, CH2-dimethylamino-cyclohexyl, (CH2)2-cyclopentanol, CH2-cyclohexanol), R8-(a substituted or unsubstituted saturated, unsaturated or aromatic monocyclic, fused ring or spiro ring 3- to 10-membered heterocyclic ring) (for example, (CH2)3-pyran, (CH2)2-pyrazole, (CH2)2-imidazole, CH2-tetrahydrofuran, CH2-dioxane, CH2-oxetane, CH2-piperidine, CH2-triazole, CH2-1-oxa-8-azaspiro[4.5]decane, (CH2)3-diazabicyclo[2.2.1]heptane, CH2-methyl-THF, CH2-ethyl-piperidine, CH2-oxa-azaspirodecan, (CH2)3-dimethylpyrazole, CH2-2-oxo-methylpyrrolidine, CH2-methyl-azetidine, CH2-azaspiroheptane), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R10 )(R 11 )(e.g., (CH2)3-4-fluoropiperidine, (CH2)3-N(CH2CH3)2, (CH2)3-N(CH(CH3)2)2, (CH2)3-piperidine, (CH2)4-NH(CH3), (CH2)3-NH-CH3, (CH2)3-NH-CH2CH3, (CH2)3-N(CCH2CH3)2, (CH2)3-NH2, (CH2)3-N(CH2CH3)(CH2CF3)), R8-C(O)N(R 10 )(R 11 )(e.g., (CH2)2-C(O)-piperidine), R9-R8-N(R 10 )(R 11 )(e.g., (CH2)2-C(O)-piperidine), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 、NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 、R8-C(O)-R 10 、C(O)H, C(O)-R 10 、a C1-C5 straight or branched chain C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10) C1-C5 linear or branched, substituted or unsubstituted alkyl (e.g., CH(CH3)CH2OCH3, CH(CH3)CH2NH2, CH(CH3)C(O)N(CH3)2, CH2-CH(OH)Ph, (CH2)3N(H)CH2CH3, CH(CH3)(CH2)2OH, CH(CH2OH)(CH2CH3), (CH2)3-OCH3, (CH2)2-OCH3, (CH2)2-OCH(CH3)2, CH(CH2OH)(CH2CH(CH3)2), CH2CH(CH3)(OCH3), CH2CH(N(CH3)2)(CH2CH3), benzyl, methyl, ethyl, CH2-CH2-CH2-O-CH3, CH(CH3)C(O)N(CH3)2), C1-C5 linear or branched, substituted or unsubstituted alkenyl, C1-C5 linear or branched or C3-C8 cyclic haloalkyl, C1-C5 linear or branched, substituted or unsubstituted or C3-C8 cyclic alkoxy (e.g., methoxy, O-(CH2)2-O-CH3) (optionally, at least one methylene group (CH2) in the alkoxy is replaced by an oxygen atom), C1-C5 linear or branched thioalkoxy, C1-C5 linear or branched haloalkoxy, C1-C5 linear or branched alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclohexyl, methoxycyclopropyl, methylcyclobutyl, aminomethyl-cyclobutyl, methoxycyclobutyl, 2,3-dihydro-1H-indenol), R8-(C3-C8 substituted or unsubstituted cycloalkyl), substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., piperidine, 1-methylpiperidine, 3-fluoro-1-methylpiperidine, azetidine, 1-methyl-azetidine, morpholine, pyrrolidine, pyrrolidinone, quinuclidine, tetrahydropyran, tetrahydrofuran, azaspiro[3.3]heptane, 8-methyl-8-azabicyclo[3.2.1) It is octane, 1,3 - dioxane, imidazole, trifluoromethyl - oxetane, hydroxy - tetrahydrofuran, azepan - 2 - one, azabicyclohexane), a substituted or unsubstituted aryl, a substituted or unsubstituted R8 - aryl (e.g., benzyl), or a substituted or unsubstituted benzyl;. Or, R6 and R5 are bonded to each other to form a substituted or unsubstituted 5 - to 8 - membered heterocyclic ring (e.g., azepane, piperazine, 2 - (piperazin - 1 - yl) acetamide); Or, R6 is represented by the following structural formula B or structural formula Bi:

[0046]

Chemical formula

[0047] In the formula, m is 0 or 1; R 12 is R 20 , or C1 - C5 C(O) - alkyl, and R 13 is R 30 ; Or, both R 12 and R 13 are H; Or, R 12 and R 13 are, independently of each other, H, or a substituted or unsubstituted C1 - C5 alkyl (e.g., ethyl, trifluoroethyl); Or, R 12 and C3 are bonded to each other to form ring A, and R 13 is R 30 ; Or, R 12 and R 13 are bonded to each other to form ring B; Or, R 12 and C1 are bonded to each other to form ring C, and R 13 is R 30 ; Or, C1 and C3 are bonded to each other to form ring D, and R 12 and R 13are independent of each other and are R 30 ; or, R 13 and C2 are bonded to each other to form an E ring, m is 1, and R 12 is R 30 ; or, R 12 and R 13 are bonded to each other to form a B ring, and C1 and C3 are bonded to each other to form a D ring; The A ring, C ring, and E ring are, independent of each other, a substituted or unsubstituted monocyclic, spiro, or fused 3- to 8-membered heterocyclic ring (e.g., A: pyrrolidine, methylpyrrolidine, ethylpyrrolidine; C: piperidine, pyrrolidine, methyl-2-oxopyrrolidine, pyran-pyrrolidine, methyl-azetidine, azabicyclooctane, 2-azabicyclo[2.1.1]hexane, 2-azaspiro[3.3]heptane; E: pyrrolidine, azetidine, ethylpyrrolidine, oxopyrrolidine, methylpiperidine); The B ring is a substituted or unsubstituted monocyclic, spiro, or fused 3- to 8-membered heterocyclic ring (B: piperidine, piperidin-2-one, 4-fluoropiperidin-2-one, piperidine-4-carbonitrile, 4-fluoropiperidine, 4-fluoro-2-methylpiperidine, methylpiperidine, fluoropiperidine, difluoropiperidine, pyrrolidine, piperazine, methylpyrrolidine, thiomorpholine 1,1-dioxide, 2-oxa-6-azaspiro[3.3]heptane, methylpiperazine, dimethylpyrazole, imidazole, 2-methyl-2,5-diazabicyclo[2.2.1]heptane, hydroxymethyl-pyrrolidine, 6-fluoro-3-azabicyclo[3.1.1]heptane); The D ring is a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclobutane, cyclohexane); R7 is H, F, Cl, Br, I, OH, O-R 20 ,SH,R8-OH,R8-SH,SR 10 ,-R8-O-R 10 ,-R8-S-R 10, R8-(C3-C8 cycloalkyl), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R 10 )(R 11 ), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 (COO-CH3), R8-C(O)-R 10 , C(O)H, C(O)-R 10 , C1-C5 straight-chain or branched C(O)-haloalkyl, -C(O)NH2, C(O)NHR (e.g., C(O)NH(CH3)), C(O)N(R 10 )(R 11 )(e.g., C(O)NH(CH3), C(O)NH(CH2CH2OCH3), C(O)NH(CH2CH2OH)), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10), C1-C5 linear or branched substituted or unsubstituted alkyl (e.g., methylimidazole, methyl, ethyl), C1-C5 linear or branched substituted or unsubstituted alkenyl, C1-C5 linear or branched or C3-C8 cyclic haloalkyl (e.g., CHF2), C1-C5 linear or branched thioalkyl, C1-C5 linear or branched thioalkoxy, C1-C5 linear or branched alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclopropanol, cyclohexyl, bicyclo[1.1.1]pentane), substituted or unsubstituted 4- to 7-membered heterocyclic ring (e.g., morpholine, tetrahydropyran, tetrahydropyran, oxetane, oxetan-3-ol, pyrrolidine, pyrrolidin-2-ol, pyrrolidin-3-ol, 1-methylpyrrolidine, pyrrolidin-2-one, pyrrolidin-3-one, 3-cyanopyrrolidine, pyrrolidinone, imidazole, pyrazole, isoxazolidine, piperazine, piperidine, piperidin-3-ol, piperidin-4-ol, piperidin-2-one, piperidine-4-carbonitrile, 4-fluoropiperidine, oxadiazole, triazole, pyrazole, 2-oxopyrrolidine, 4,7-diazaspiro[2.5]octane, 2,5-diazabicyclo[2.2.1]heptane, piperazin-2-one), R8-(substituted or unsubstituted monocyclic, fused-ring or spiro-ring 3- to 8-membered heterocyclic ring), substituted or unsubstituted aryl, or substituted or unsubstituted benzyl; Or, R7 is represented by the following structural formula A:

[0048]

Chemical formula

[0049] In the formula, X1 is N or O; R1 and R2 are, independently of one another, H, F, Cl, Br, I, OH, SH, CF3, a C1-C5 substituted or unsubstituted alkyl (e.g., CH2OH), a C1-C5 straight-chain or branched-chain, or a C3-C8 cyclic haloalkyl, a C1-C5 straight-chain or branched-chain substituted or unsubstituted or a C3-C8 cyclic alkoxy; or, R1 and R2 are bonded to each other to form =O, or a C3-C8 carbocyclic or heterocyclic ring (e.g., cyclopropyl); R3 and R4 are, independently of one another, H, Me, a C1-C5 substituted or unsubstituted alkyl (e.g., methoxyethylene, methylaminoethyl, aminoethyl), -R8-O-R 10 (e.g., (CH2)2-O-CH3), R8-N(R 10 )(R 11 (e.g., (CH2)2-NH(CH3)), a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl), a substituted or unsubstituted 5- to 7-membered heterocyclic ring (e.g., pyrrolidine, methylpyrrolidine, piperidine), or, R 20 ; or, R3 and R4 are bonded to each other to form a 3- to 8-membered heterocyclic ring (e.g., pyrrolidine, pyrrolidone, 2-oxopyrrolidine, piperidine, morpholine, piperazine, imidazole); or, R2 and R4 are bonded to each other to form a substituted or unsubstituted saturated or unsaturated 4- to 8-membered heterocyclic or carbocyclic ring (e.g., pyrrolidine, morpholine, 1-methylpyrrolidine, pyrrolidin-2-one, pyrrolidin-3-one, 3,3-difluoropyrrolidine, pyrrolidin-3-ol, 3-methoxypyrrolidine, 3-(difluoromethyl)pyrrolidine, pyrrolidine-3-carbonitrile, pyridine, piperidine, piperidin-2-one, imidazole, pyrimidine, triazole, oxadiazole, pyrazole). However, when the ring is an aromatic ring, R1 and / or R3 do not exist; however, when X1 is O, R4 does not exist; R7´ is H, F, Cl, Br, I, OH, O-R 20, SH, R8-OH, R8-SH, -R8-O-R 10 , R8-(C3-C8 cycloalkyl), R8-(3- to 8-membered heterocyclic ring), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R 10 )(R 11 ), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 , R8-C(O)-R 10 , C(O)H, C(O)-R 10 , C1-C5 linear or branched C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10) C1-C5 linear or branched substituted or unsubstituted alkyl (e.g., isopropyl, methyl, ethyl), C1-C5 linear or branched substituted or unsubstituted alkenyl, C1-C5 linear or branched or C3-C8 cyclic haloalkyl (e.g., CHF2), C1-C5 linear or branched or C3-C8 cyclic alkoxy (e.g., methoxy) (optionally, at least one methylene group (CH2) in the alkoxy is replaced by an oxygen atom), C1-C5 linear or branched thioalkoxy, C1-C5 linear or branched haloalkoxy, C1-C5 linear or branched alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclohexyl), substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., morpholine, pyran, oxetane, pyrrolidine, 3,3-difluoropyrrolidine, imidazole, pyrazole, triazole, piperazine, piperidine, piperidin-2-one, piperidin-4-ol, dioxazole, 2-oxopyrrolidine), substituted or unsubstituted aryl, or substituted or unsubstituted benzyl; However, R7 and R7' are different from each other; or, R7 and R7' are bonded to each other to form a substituted or unsubstituted saturated, unsaturated or aromatic 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); R 20 is represented by the following structural formula:

[0050]

Chemical formula

[0051] In the formula, R 30 is H, R 20 , F, Cl, Br, I, OH, SH, alkoxy, N(R)2, NH(R 10 ), N(R 10 )(R 11)、CF3, CN, NO2, a linear or branched, substituted or unsubstituted C1-C5 alkyl (e.g., methyl, ethyl, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a linear or branched C1-C5 alkoxy, a linear or branched C1-C5 haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , -R8-R 10 (e.g., (CH2)2-O-CH3), a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2-pyridine, 3-pyridine, or 4-pyridine)); R is H, F, Cl, Br, I, OH, SH, alkoxy, NH(R 10 ), NH-CH2-cyclopropyl, N(R 10 )(R 11 ), CF3, CN, NO2, COOH, CO(R 10 )(e.g., C(O)CH3), a linear or branched, substituted or unsubstituted C1-C5 alkyl (e.g., methyl, ethyl, CH2-OH, CH2-CH2-OH, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a substituted or unsubstituted C3-C8 cycloalkyl, cyclopropyl, a linear or branched C1-C5 alkoxy, isopropoxy, a linear or branched C1-C5 haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , -R8-R 10(For example, (CH2)2-O-CH3), a substituted or unsubstituted aryl (for example, phenyl), or a substituted or unsubstituted heteroaryl (for example, pyridine (2-pyridine, 3-pyridine, or 4-pyridine)); Each R8 is independently of one another, [CH2] p and p is from 1 to 10; R9 is [CH] q or [C] q and q is from 2 to 10; R 10 and R 11 are independently of one another, H, a straight-chain or branched-chain substituted or unsubstituted alkyl having 1 to 5 carbon atoms (for example, methyl, ethyl, CH2-cyclopropyl, CH2-CH2-O-CH3), a straight-chain or branched-chain substituted or unsubstituted haloalkyl having 1 to 5 carbon atoms (for example, CH2CF3), a straight-chain or branched-chain alkoxy having 1 to 5 carbon atoms (for example, O-CH3), R 20 , C(O)R, or S(O)2R; or R 10 and R 11 are joined to each other to form a substituted or unsubstituted 3- to 8-membered heterocyclic ring (for example, piperazine, piperidine); n is an integer from 0 to 4 (for example, 1, 2).

[0052] In various embodiments, the present invention relates to a compound represented by the following structural formula I(d), or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, N-oxide, reverse amide analogue, prodrug, isotopic variant (for example, deuterated analogue), PROTAC, pharmaceutical, or any combination thereof.

[0053]

Chemical formula

[0054] In the formula, X2, X3, and X4 are independently of one another, nitrogen or CH; X5, X6, X7, X8, and X9 are, independently of one another, a nitrogen atom or a carbon atom; X 10 is N, CH, or C(R) (e.g., C(CH2)OH, C(CH2)2-OH, C(NH-CH2-cyclopropyl), C(CH3), C(cyclopropyl), C(isopropoxy), C(COOH)); provided that at least one of X2, X3, X4, X5, X6, X7, X8, X9, and X 10 is N; R5 is H, or a C1-C5 straight-chain or branched-chain alkyl (e.g., methyl); R6 is H, F, Cl, Br, I, OH, SH, R8-OH, R8-SH, -R8-O-R 10 (e.g., CH2-O-CH3, (CH2)2-O-CH3, (CH2)3-O-CH3, (CH3)2-O-CH(CH3)2), R8-S-R 10 (e.g., (CH2)3-S-(CH2)2CH3), R8-NHC(O)-R 10 , -O-R8-R 10, R8-(C3-C8 substituted or unsubstituted cycloalkyl) (e.g., CH2-cyclopropyl, CH2-cyclobutanol, CH2-difluorocyclopropyl, CH2-methylcyclopropyl, CH2-dimethylamino-cyclohexyl, (CH2)2-cyclopentanol, CH2-cyclohexanol), R8-(substituted or unsubstituted saturated, unsaturated or aromatic monocyclic, fused ring or spiro ring 3- to 10-membered heterocyclic ring) (e.g., (CH2)3-pyran, (CH2)2-pyrazole, (CH2)2-imidazole, CH2-tetrahydrofuran, CH2-dioxane, CH2-oxetane, CH2-piperidine, CH2-triazole, CH2-1-oxa-8-azaspiro[4.5]decane, (CH2)3-diazabicyclo[2.2.1]heptane, CH2-methyl-THF, CH2-ethyl-piperidine, CH2-oxa-azaspirodecan, (CH2)3-dimethylpyrazole, CH2-2-oxo-methylpyrrolidine, CH2-methyl-azetidine, CH2-azaspiroheptane), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 )(e.g., (CH2)3-4-fluoropiperidine, (CH2)3-N(CH2CH3)2, (CH2)3-N(CH(CH3)2)2, (CH2)3-piperidine, (CH2)4-NH(CH3), (CH2)3-NH-CH3, (CH2)3-NH-CH2CH3, (CH2)3-N(CCH2CH3)2, (CH2)3-NH2, (CH2)3-N(CH2CH3)(CH2CF3)), R8-C(O)N(R 10 )(R 11 )(e.g., (CH2)2-C(O)-piperidine), R9-R8-N(R 10 )(R 11 )(e.g., (CH2)2-C(O)-piperidine), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R10 , R8-C(O)-R 10 , C(O)H, C(O)-R 10 , a straight-chain or branched-chain C(O)-haloalkyl having 1 to 5 carbon atoms, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10) C1-C5 linear or branched, substituted or unsubstituted alkyl (e.g., CH(CH3)CH2OCH3, CH(CH3)CH2NH2, CH(CH3)C(O)N(CH3)2, CH2-CH(OH)Ph, (CH2)3N(H)CH2CH3, CH(CH3)(CH2)2OH, CH(CH2OH)(CH2CH3), (CH2)3-OCH3, (CH2)2-OCH3, (CH2)2-OCH(CH3)2, CH(CH2OH)(CH2CH(CH3)2), CH2CH(CH3)(OCH3), CH2CH(N(CH3)2)(CH2CH3), benzyl, methyl, ethyl, CH2-CH2-CH2-O-CH3, CH(CH3)C(O)N(CH3)2), C1-C5 linear or branched, substituted or unsubstituted alkenyl, C1-C5 linear or branched or C3-C8 cyclic haloalkyl, C1-C5 linear or branched, substituted or unsubstituted or C3-C8 cyclic alkoxy (e.g., methoxy, O-(CH2)2-O-CH3) (optionally, at least one methylene group (CH2) in the alkoxy is replaced by an oxygen atom), C1-C5 linear or branched thioalkoxy, C1-C5 linear or branched haloalkoxy, C1-C5 linear or branched alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclohexyl, methoxycyclopropyl, methylcyclobutyl, aminomethyl-cyclobutyl, methoxycyclobutyl, 2,3-dihydro-1H-indenol), R8-(C3-C8 substituted or unsubstituted cycloalkyl), substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., piperidine, 1-methylpiperidine, 3-fluoro-1-methylpiperidine, azetidine, 1-methyl-azetidine, morpholine, pyrrolidine, pyrrolidinone, quinuclidine, tetrahydropyran, tetrahydrofuran, azaspiro[3.3]heptane, 8-methyl-8-azabicyclo[3.2.1) It is octane, 1,3 - dioxane, imidazole, trifluoromethyl - oxetane, hydroxy - tetrahydrofuran, azepan - 2 - one, azabicyclohexane), substituted or unsubstituted aryl, substituted or unsubstituted R8 - aryl (e.g., benzyl), or substituted or unsubstituted benzyl;. Or, R6 and R5 are bonded to each other to form a substituted or unsubstituted 5 - to 8 - membered heterocyclic ring (e.g., azepane, piperazine, 2 - (piperazin - 1 - yl) acetamide); Or, R6 is represented by the following structural formula B or structural formula Bi:

[0055]

Chemical formula

[0056] In the formula, m is 0 or 1; R 12 is R 20 , or C1 - C5 C(O) - alkyl, and R 13 is R 30 ; Or, both R 12 and R 13 are H; Or, R 12 and R 13 are, independently of each other, H, or C1 - C5 substituted or unsubstituted alkyl (e.g., ethyl, trifluoroethyl); Or, R 12 and C3 are bonded to each other to form ring A, and R 13 is R 30 ; Or, R 12 and R 13 are bonded to each other to form ring B; Or, R 12 and C1 are bonded to each other to form ring C, and R 13 is R 30 ; Or, C1 and C3 are bonded to each other to form ring D, and R 12 and R 13are each independently R 30 ; or, R 13 and C2 are bonded to each other to form an E ring, m is 1, and R 12 is R 30 ; or, R 12 and R 13 are bonded to each other to form a B ring, and C1 and C3 are bonded to each other to form a D ring; The A ring, C ring, and E ring are each independently a substituted or unsubstituted monocyclic, spiro, or fused ring 3- to 8-membered heterocyclic ring (e.g., A: pyrrolidine, methylpyrrolidine, ethylpyrrolidine; C: piperidine, pyrrolidine, methyl-2-oxopyrrolidine, pyran-pyrrolidine, methyl-azetidine, azabicyclooctane, 2-azabicyclo[2.1.1]hexane, 2-azaspiro[3.3]heptane; E: pyrrolidine, azetidine, ethylpyrrolidine, oxopyrrolidine, methylpiperidine); The B ring is a substituted or unsubstituted monocyclic, spiro, or fused ring 3- to 8-membered heterocyclic ring (B: piperidine, piperidin-2-one, 4-fluoropiperidin-2-one, piperidine-4-carbonitrile, 4-fluoropiperidine, 4-fluoro-2-methylpiperidine, methylpiperidine, fluoropiperidine, difluoropiperidine, pyrrolidine, piperazine, methylpyrrolidine, thiomorpholine 1,1-dioxide, 2-oxa-6-azaspiro[3.3]heptane, methylpiperazine, dimethylpyrazole, imidazole, 2-methyl-2,5-diazabicyclo[2.2.1]heptane, hydroxymethyl-pyrrolidine, 6-fluoro-3-azabicyclo[3.1.1]heptane); The D ring is a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclobutane, cyclohexane); R7 is Br, I, OH, O-R 20 SH, R8-OH, R8-SH, SR 10 -R8-O-R 10 -R8-S-R 10, R8-(C3-C8 cycloalkyl), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R 10 )(R 11 ), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 (COO-CH3), R8-C(O)-R 10 , C(O)H, C(O)-R 10 , C1-C5 linear or branched C(O)-haloalkyl, -C(O)NH2, C(O)NHR (e.g., C(O)NH(CH3)), C(O)N(R 10 )(R 11 )(e.g., C(O)NH(CH3), C(O)NH(CH2CH2OCH3), C(O)NH(CH2CH2OH)), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10) C1-C5 linear or branched, substituted or unsubstituted alkyl (e.g., methylimidazole, methyl, ethyl), C1-C5 linear or branched, substituted or unsubstituted alkenyl, C1-C5 linear or branched or C3-C8 cyclic haloalkyl (e.g., CHF2), C1-C5 linear or branched or C3-C8 cyclic alkoxy (e.g., methoxy, ethoxy) (optionally, at least one methylene group (CH2) in the alkoxy is replaced by an oxygen atom), C1-C5 linear or branched thioalkyl, C1-C5 linear or branched thioalkoxy, C1-C5 linear or branched haloalkoxy, C1-C5 linear or branched alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclopropanol, cyclohexyl, bicyclo[1.1.1]pentane), substituted or unsubstituted 4- to 7-membered heterocyclic ring (e.g., morpholine, tetrahydropyran, tetrahydropyran, oxetane, oxetan-3-ol, pyrrolidine, pyrrolidin-2-ol, pyrrolidin-3-ol, 1-methylpyrrolidine, pyrrolidin-2-one, pyrrolidin-3-one, 3-cyanopyrrolidine, pyrrolidinone, imidazole, pyrazole, isoxazolidine, piperazine, piperidine, piperidin-3-ol, piperidin-4-ol, piperidin-2-one, piperidine-4-carbonitrile, 4-fluoropiperidine, oxadiazole, triazole, pyrazole, 2-oxopyrrolidine, 4,7-diazaspiro[2.5]octane, 2,5-diazabicyclo[2.2.1]heptane, piperazin-2-one), R8-(substituted or unsubstituted monocyclic, fused ring or spiro ring 3- to 8-membered heterocyclic ring), substituted or unsubstituted aryl, or substituted or unsubstituted benzyl; or, R7 is represented by the following structural formula A:

[0057]

Chemical formula

[0058] In the formula, X1 is N or O; R1 and R2 are, independently of each other, H, F, Cl, Br, I, OH, SH, CF3, C1-C5 substituted or unsubstituted alkyl (e.g., CH2OH), C1-C5 linear or branched, or C3-C8 cyclic haloalkyl, C1-C5 linear or branched substituted or unsubstituted or C3-C8 cyclic alkoxy; or, R1 and R2 are bonded to each other to form =O, or a C3-C8 carbocyclic or heterocyclic ring (e.g., cyclopropyl); R3 and R4 are, independently of each other, H, Me, C1-C5 substituted or unsubstituted alkyl (e.g., methoxyethylene, methylaminoethyl, aminoethyl), -R8-O-R 10 (e.g., (CH2)2-O-CH3), R8-N(R 10 )(R 11 (e.g., (CH2)2-NH(CH3)), C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl), substituted or unsubstituted 5- to 7-membered heterocyclic ring (e.g., pyrrolidine, methylpyrrolidine, piperidine), or, R 20 ; or, R3 and R4 are bonded to each other to form a 3- to 8-membered heterocyclic ring (e.g., pyrrolidine, pyrrolidone, 2-oxopyrrolidine, piperidine, morpholine, piperazine, imidazole); or, R2 and R4 are bonded to each other to form a substituted or unsubstituted saturated or unsaturated 4- to 8-membered heterocyclic or carbocyclic ring (e.g., pyrrolidine, morpholine, 1-methylpyrrolidine, pyrrolidin-2-one, pyrrolidin-3-one, 3,3-difluoropyrrolidine, pyrrolidin-3-ol, 3-methoxypyrrolidine, 3-(difluoromethyl)pyrrolidine, pyrrolidine-3-carbonitrile, pyridine, piperidine, piperidin-2-one, imidazole, pyrimidine, triazole, oxadiazole, pyrazole). However, when the ring is an aromatic ring, R1 and / or R3 do not exist; however, when X1 is O, R4 does not exist; R7´ is H, F, Cl, Br, I, OH, O-R20 , SH, R8-OH, R8-SH, -R8-O-R 10 , R8-(C3-C8 cycloalkyl), R8-(3-8 membered heterocyclic ring), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R 10 )(R 11 ), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 , R8-C(O)-R 10 , C(O)H, C(O)-R 10 , C1-C5 linear or branched C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10) C1-C5 linear or branched substituted or unsubstituted alkyl (e.g., isopropyl, methyl, ethyl), C1-C5 linear or branched substituted or unsubstituted alkenyl, C1-C5 linear or branched or C3-C8 cyclic haloalkyl (e.g., CHF2), C1-C5 linear or branched or C3-C8 cyclic alkoxy (e.g., methoxy) (optionally, at least one methylene group (CH2) in the alkoxy is replaced by an oxygen atom), C1-C5 linear or branched thioalkoxy, C1-C5 linear or branched haloalkoxy, C1-C5 linear or branched alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclohexyl), substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., morpholine, pyran, oxetane, pyrrolidine, 3,3-difluoropyrrolidine, imidazole, pyrazole, triazole, piperazine, piperidine, piperidin-2-one, piperidin-4-ol, dioxazole, 2-oxopyrrolidine), substituted or unsubstituted aryl, or substituted or unsubstituted benzyl; or, R7 and R7´ are bonded to each other to form a substituted or unsubstituted saturated, unsaturated or aromatic 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); R 20 is represented by the following structural formula:

[0059] [Chemical formula]

[0060] In the formula, R 30 is H, R 20 , F, Cl, Br, I, OH, SH, alkoxy, N(R)2, NH(R 10 ), N(R 10 )(R 11)、CF3, CN, NO2, a linear or branched, substituted or unsubstituted C1-C5 alkyl (e.g., methyl, ethyl, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a linear or branched C1-C5 alkoxy, a linear or branched C1-C5 haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , -R8-R 10 (e.g., (CH2)2-O-CH3), a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2-pyridine, 3-pyridine, or 4-pyridine)); R is H, F, Cl, Br, I, OH, SH, alkoxy, NH(R 10 ), NH-CH2-cyclopropyl, N(R 10 )(R 11 ), CF3, CN, NO2, COOH, CO(R 10 )(e.g., C(O)CH3), a linear or branched, substituted or unsubstituted C1-C5 alkyl (e.g., methyl, ethyl, CH2-OH, CH2-CH2-OH, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a substituted or unsubstituted C3-C8 cycloalkyl, cyclopropyl, a linear or branched C1-C5 alkoxy, isopropoxy, a linear or branched C1-C5 haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , -R8-R 10(For example, (CH2)2-O-CH3), a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2-pyridine, 3-pyridine, or 4-pyridine)); Each R8 is independently of one another, [CH2] p and p is from 1 to 10; R9 is [CH] q or [C] q and q is from 2 to 10; R 10 and R 11 are independently of one another, H, a straight-chain or branched-chain substituted or unsubstituted alkyl having 1 to 5 carbon atoms (e.g., methyl, ethyl, CH2-cyclopropyl, CH2-CH2-O-CH3), a straight-chain or branched-chain substituted or unsubstituted haloalkyl having 1 to 5 carbon atoms (e.g., CH2CF3), a straight-chain or branched-chain alkoxy having 1 to 5 carbon atoms (e.g., O-CH3), R 20 , C(O)R, or S(O)2R; or R 10 and R 11 are joined to each other to form a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., piperazine, piperidine); n is an integer from 0 to 4 (e.g., 1, 2).

[0061] In various embodiments, the present invention relates to a compound represented by the following structural formula I(e), or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, N-oxide, reverse amide analogue, prodrug, isotopic variant (e.g., deuterated analogue), PROTAC, pharmaceutical, or any combination thereof.

[0062]

Chemical formula

[0063] Wherein, X2, X3, and X4 are independently of one another, nitrogen or CH; X5, X6, X7, X8, and X9 are, independently of each other, a nitrogen atom or a carbon atom; X 10 is N, CH, or C(R) (e.g., C(CH2)OH, C(CH2)2-OH, C(NH-CH2-cyclopropyl), C(CH3), C(cyclopropyl), C(isopropoxy), C(COOH)); R6 and R5 are bonded to each other to form a substituted or unsubstituted 5- to 8-membered heterocyclic ring (e.g., azepane, piperazine, 2-(piperazin-1-yl)acetamide); R7 is Br, I, OH, O-R 20 , SH, R8-OH, R8-SH, SR 10 , -R8-O-R 10 , -R8-S-R 10 , R8-(C3-C8 cycloalkyl), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R 10 )(R 11 ), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 (COO-CH3), R8-C(O)-R 10 , C(O)H, C(O)-R 10 , a C1-C5 straight-chain or branched-chain C(O)-haloalkyl, -C(O)NH2, C(O)NHR (e.g., C(O)NH(CH3)), C(O)N(R 10 )(R 11 ) (e.g., C(O)NH(CH3), C(O)NH(CH2CH2OCH3), C(O)NH(CH2CH2OH)), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10) C1-C5 linear or branched substituted or unsubstituted alkyl (e.g., methylimidazole, methyl, ethyl), C1-C5 linear or branched substituted or unsubstituted alkenyl, C1-C5 linear or branched or C3-C8 cyclic haloalkyl (e.g., CHF2), C1-C5 linear or branched or C3-C8 cyclic alkoxy (e.g., methoxy, ethoxy) (optionally, at least one methylene group (CH2) in the alkoxy is replaced by an oxygen atom), C1-C5 linear or branched thioalkyl, C1-C5 linear or branched thioalkoxy, C1-C5 linear or branched haloalkoxy, C1-C5 linear or branched alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclopropanol, cyclohexyl, bicyclo[1.1.1]pentane), substituted or unsubstituted 4- to 7-membered heterocyclic ring (e.g., morpholine, tetrahydropyran, tetrahydropyran, oxetane, oxetan-3-ol, pyrrolidine, pyrrolidin-2-ol, pyrrolidin-3-ol, 1-methylpyrrolidine, pyrrolidin-2-one, pyrrolidin-3-one, 3-cyanopyrrolidine, pyrrolidinone, imidazole, pyrazole, isoxazolidine, piperazine, piperidine, piperidin-3-ol, piperidin-4-ol, piperidin-2-one, piperidin-4-carbonitrile, 4-fluoropiperidine, oxadiazole, triazole, pyrazole, 2-oxopyrrolidine, 4,7-diazaspiro[2.5]octane, 2,5-diazabicyclo[2.2.1]heptane, piperazin-2-one), R8-(substituted or unsubstituted monocyclic, fused ring or spiro ring 3- to 8-membered heterocyclic ring), substituted or unsubstituted aryl, or substituted or unsubstituted benzyl; or, R7 is represented by the following structural formula A:

[0064]

Chemical formula

[0065] In the formula, X1 is N or O; R1 and R2 are, independently of one another, H, F, Cl, Br, I, OH, SH, CF3, C1-C5 substituted or unsubstituted alkyl (e.g., CH2OH), C1-C5 straight-chain or branched-chain, or C3-C8 cyclic haloalkyl, C1-C5 straight-chain or branched-chain substituted or unsubstituted or C3-C8 cyclic alkoxy; or R1 and R2 are joined to one another to form =O, or a C3-C8 carbocyclic or heterocyclic ring (e.g., cyclopropyl); R3 and R4 are, independently of one another, H, Me, C1-C5 substituted or unsubstituted alkyl (e.g., methoxyethylene, methylaminoethyl, aminoethyl), -R8-O-R 10 (e.g., (CH2)2-O-CH3), R8-N(R 10 )(R 11 (e.g., (CH2)2-NH(CH3)), C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl), substituted or unsubstituted 5- to 7-membered heterocyclic ring (e.g., pyrrolidine, methylpyrrolidine, piperidine), or, R 20 ; or R3 and R4 are joined to one another to form a 3- to 8-membered heterocyclic ring (e.g., pyrrolidine, pyrrolidone, 2-oxopyrrolidine, piperidine, morpholine, piperazine, imidazole); or R2 and R4 are joined to one another to form a substituted or unsubstituted saturated or unsaturated 4- to 8-membered heterocyclic or carbocyclic ring (e.g., pyrrolidine, morpholine, 1-methylpyrrolidine, pyrrolidin-2-one, pyrrolidin-3-one, 3,3-difluoropyrrolidine, pyrrolidin-3-ol, 3-methoxypyrrolidine, 3-(difluoromethyl)pyrrolidine, pyrrolidine-3-carbonitrile, pyridine, piperidine, piperidin-2-one, imidazole, pyrimidine, triazole, oxadiazole, pyrazole). However, when the ring is an aromatic ring, R1 and / or R3 are absent; provided that when X1 is O, R4 is absent; R7´ is H, F, Cl, Br, I, OH, O-R20 、 SH, R8-OH, R8-SH, -R8-O-R 10 、 R8-(C3-C8 cycloalkyl), R8-(3- to 8-membered heterocyclic ring), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R 10 )(R 11 ), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 、 NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 、 R8-C(O)-R 10 、 C(O)H, C(O)-R 10 、 C1-C5 linear or branched C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10), C1-C5 linear or branched substituted or unsubstituted alkyl (e.g., isopropyl, methyl, ethyl), C1-C5 linear or branched substituted or unsubstituted alkenyl, C1-C5 linear or branched or C3-C8 cyclic haloalkyl (e.g., CHF2), C1-C5 linear or branched or C3-C8 cyclic alkoxy (e.g., methoxy) (optionally, at least one methylene group (CH2) in the alkoxy is replaced by an oxygen atom), C1-C5 linear or branched thioalkoxy, C1-C5 linear or branched haloalkoxy, C1-C5 linear or branched alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclohexyl), substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., morpholine, pyran, oxetane, pyrrolidine, 3,3-difluoropyrrolidine, imidazole, pyrazole, triazole, piperazine, piperidine, piperidin-2-one, piperidin-4-ol, dioxazole, 2-oxopyrrolidine), substituted or unsubstituted aryl, or substituted or unsubstituted benzyl; or, R7 and R7´ are bonded to each other to form a substituted or unsubstituted saturated, unsaturated or aromatic 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); R 20 is represented by the following structural formula:

[0066]

Chemical formula

[0067] In the formula, R 30 is H, R 20 , F, Cl, Br, I, OH, SH, alkoxy, N(R)2, NH(R 10 ), N(R 10 )(R 11)、CF3, CN, NO2, a C1-C5 straight or branched chain substituted or unsubstituted alkyl (e.g., methyl, ethyl, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a C1-C5 straight or branched chain alkoxy, a C1-C5 straight or branched chain haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , -R8-R 10 (e.g., (CH2)2-O-CH3), a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2-pyridine, 3-pyridine, or 4-pyridine)); R is H, F, Cl, Br, I, OH, SH, alkoxy, NH(R 10 ), NH-CH2-cyclopropyl, N(R 10 )(R 11 ), CF3, CN, NO2, COOH, CO(R 10 )(e.g., C(O)CH3), a C1-C5 straight or branched chain substituted or unsubstituted alkyl (e.g., methyl, ethyl, CH2-OH, CH2-CH2-OH, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a C3-C8 substituted or unsubstituted cycloalkyl, cyclopropyl, a C1-C5 straight or branched chain alkoxy, isopropoxy, a C1-C5 straight or branched chain haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , -R8-R 10(e.g., (CH2)2-O-CH3), a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2-pyridine, 3-pyridine, or 4-pyridine)); Each R8 is, independently of one another, [CH2] p and p is from 1 to 10; R9 is [CH] q or [C] q and q is from 2 to 10; R 10 and R 11 are, independently of one another, H, a C1-C5 straight-chain or branched-chain substituted or unsubstituted alkyl (e.g., methyl, ethyl, CH2-cyclopropyl, CH2-CH2-O-CH3), a C1-C5 straight-chain or branched-chain substituted or unsubstituted haloalkyl (e.g., CH2CF3), a C1-C5 straight-chain or branched-chain alkoxy (e.g., O-CH3), R 20 , C(O)R, or S(O)2R; or R 10 and R 11 are joined to one another to form a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., piperazine, piperidine); n is an integer from 0 to 4 (e.g., 1, 2).

[0068] In various embodiments, the present invention relates to a compound represented by the following structural formula I(f), or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, N-oxide, reverse amide analogue, prodrug, isotopic variant (e.g., deuterated analogue), PROTAC, pharmaceutical, or any combination thereof.

[0069]

Chemical formula

[0070] In the formula, A´ is a saturated, unsaturated or aromatic monocyclic, spiro or fused ring 3- to 8-membered carbocyclic or heterocyclic ring (e.g., pyrrolidine, piperidine, piperazine, isochroman, 1,2,3,4-tetrahydroisoquinoline, indoline, isoindoline, 1,3-dihydroisobenzofuran, 2,3-dihydro-1H-indene, 1,2,3,4-tetrahydronaphthalene); X2, X3, and X4 are, independently of one another, nitrogen or CH; X 10 is N, CH, or C(R) (e.g., C(CH2)OH, C(CH2)2-OH, C(NH-CH2-cyclopropyl), C(CH3), C(cyclopropyl), C(isopropoxy), C(COOH)); R5 is H, or a C1-C5 straight-chain or branched-chain alkyl (e.g., methyl); R6 is H, F, Cl, Br, I, OH, SH, R8-OH, R8-SH, -R8-O-R 10 (e.g., CH2-O-CH3, (CH2)2-O-CH3, (CH2)3-O-CH3, (CH3)2-O-CH(CH3)2), R8-S-R 10 (e.g., (CH2)3-S-(CH2)2CH3), R8-NHC(O)-R 10 , -O-R8-R 10, R8-(C3-C8 substituted or unsubstituted cycloalkyl) (e.g., CH2-cyclopropyl, CH2-cyclobutanol, CH2-difluorocyclopropyl, CH2-methylcyclopropyl, CH2-dimethylamino-cyclohexyl, (CH2)2-cyclopentanol, CH2-cyclohexanol), R8-(substituted or unsubstituted saturated, unsaturated or aromatic monocyclic, fused ring or spiro ring 3- to 10-membered heterocyclic ring) (e.g., (CH2)3-pyran, (CH2)2-pyrazole, (CH2)2-imidazole, CH2-tetrahydrofuran, CH2-dioxane, CH2-oxetane, CH2-piperidine, CH2-triazole, CH2-1-oxa-8-azaspiro[4.5]decane, (CH2)3-diazabicyclo[2.2.1]heptane, CH2-methyl-THF, CH2-ethyl-piperidine, CH2-oxa-azaspirodecan, (CH2)3-dimethylpyrazole, CH2-2-oxo-methylpyrrolidine, CH2-methyl-azetidine, CH2-azaspiroheptane), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 )(e.g., (CH2)3-4-fluoropiperidine, (CH2)3-N(CH2CH3)2, (CH2)3-N(CH(CH3)2)2, (CH2)3-piperidine, (CH2)4-NH(CH3), (CH2)3-NH-CH3, (CH2)3-NH-CH2CH3, (CH2)3-N(CCH2CH3)2, (CH2)3-NH2, (CH2)3-N(CH2CH3)(CH2CF3)), R8-C(O)N(R 10 )(R 11 )(e.g., (CH2)2-C(O)-piperidine), R9-R8-N(R 10 )(R 11 )(e.g., (CH2)2-C(O)-piperidine), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R10 , R8-C(O)-R 10 , C(O)H, C(O)-R 10 , a straight-chain or branched-chain C1-C5 C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10), a C1-C5 linear or branched substituted or unsubstituted alkyl (e.g., CH(CH3)CH2OCH3, CH(CH3)CH2NH2, CH(CH3)C(O)N(CH3)2, CH2-CH(OH)Ph, (CH2)3N(H)CH2CH3, CH(CH3)(CH2)2OH, CH(CH2OH)(CH2CH3), (CH2)3-OCH3, (CH2)2-OCH3, (CH2)2-OCH(CH3)2, CH(CH2OH)(CH2CH(CH3)2), CH2CH(CH3)(OCH3), CH2CH(N(CH3)2)(CH2CH3), benzyl, methyl, ethyl, CH2-CH2-CH2-O-CH3, CH(CH3)C(O)N(CH3)2), a C1-C5 linear or branched substituted or unsubstituted alkenyl, a C1-C5 linear or branched or C3-C8 cyclic haloalkyl, a C1-C5 linear or branched substituted or unsubstituted or C3-C8 cyclic alkoxy (e.g., methoxy, O-(CH2)2-O-CH3) (optionally, at least one methylene group (CH2) in the alkoxy is substituted with an oxygen atom), a C1-C5 linear or branched thioalkoxy, a C1-C5 linear or branched haloalkoxy, a C1-C5 linear or branched alkoxyalkyl, a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclohexyl, methoxycyclopropyl, methylcyclobutyl, aminomethyl-cyclobutyl, methoxycyclobutyl, 2,3-dihydro-1H-indenol), R8-(C3-C8 substituted or unsubstituted cycloalkyl), a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., piperidine, 1-methylpiperidine, 3-fluoro-1-methylpiperidine, azetidine, 1-methyl-azetidine, morpholine, pyrrolidine, pyrrolidinone, quinuclidine, tetrahydropyran, tetrahydrofuran, azaspiro[3.3]heptane, 8-methyl-8-azabicyclo[3.2.1) is octane, 1,3 - dioxane, imidazole, trifluoromethyl - oxetane, hydroxy - tetrahydrofuran, azepan - 2 - one, azabicyclohexane), substituted or unsubstituted aryl, substituted or unsubstituted R8 - aryl (e.g., benzyl), or substituted or unsubstituted benzyl;. Or, R6 and R5 are bonded to each other to form a substituted or unsubstituted 5 - to 8 - membered heterocyclic ring (e.g., azepane, piperazine, 2 - (piperazin - 1 - yl) acetamide); Or, R6 is represented by the following structural formula B or structural formula Bi:

[0071] [Chemical formula]

[0072] In the formula, m is 0 or 1; R 12 is R 20 , or C1 - C5 C(O) - alkyl, and R 13 is R 30 ; Or, both R 12 and R 13 are H; Or, R 12 and R 13 are, independently of each other, H, or C1 - C5 substituted or unsubstituted alkyl (e.g., ethyl, trifluoroethyl); Or, R 12 and C3 are bonded to each other to form ring A, and R 13 is R 30 ; Or, R 12 and R 13 are bonded to each other to form ring B; Or, R 12 and C1 are bonded to each other to form ring C, and R 13 is R 30 ; Or, C1 and C3 are bonded to each other to form ring D, and R 12 and R 13are independent of each other and are R 30 ; or, R 13 and C2 are bonded to each other to form an E ring, m is 1, and R 12 is R 30 ; or, R 12 and R 13 are bonded to each other to form a B ring, and C1 and C3 are bonded to each other to form a D ring; The A ring, C ring, and E ring are, independent of each other, a substituted or unsubstituted monocyclic, spiro, or fused 3- to 8-membered heterocyclic ring (for example, A: pyrrolidine, methylpyrrolidine, ethylpyrrolidine; C: piperidine, pyrrolidine, methyl-2-oxopyrrolidine, pyran-pyrrolidine, methyl-azetidine, azabicyclooctane, 2-azabicyclo[2.1.1]hexane, 2-azaspiro[3.3]heptane; E: pyrrolidine, azetidine, ethylpyrrolidine, oxopyrrolidine, methylpiperidine); The B ring is a substituted or unsubstituted monocyclic, spiro, or fused 3- to 8-membered heterocyclic ring (B: piperidine, piperidin-2-one, 4-fluoropiperidin-2-one, piperidine-4-carbonitrile, 4-fluoropiperidine, 4-fluoro-2-methylpiperidine, methylpiperidine, fluoropiperidine, difluoropiperidine, pyrrolidine, piperazine, methylpyrrolidine, thiomorpholine 1,1-dioxide, 2-oxa-6-azaspiro[3.3]heptane, methylpiperazine, dimethylpyrazole, imidazole, 2-methyl-2,5-diazabicyclo[2.2.1]heptane, hydroxymethyl-pyrrolidine, 6-fluoro-3-azabicyclo[3.1.1]heptane); The D ring is a C3-C8 substituted or unsubstituted cycloalkyl (for example, cyclobutane, cyclohexane); R7 is Br, I, OH, O-R 20 SH, R8-OH, R8-SH, SR 10 -R8-O-R 10 -R8-S-R 10, R8-(C3-C8 cycloalkyl), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R 10 )(R 11 ), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 (COO-CH3), R8-C(O)-R 10 , C(O)H, C(O)-R 10 , C1-C5 linear or branched C(O)-haloalkyl, -C(O)NH2, C(O)NHR (e.g., C(O)NH(CH3)), C(O)N(R 10 )(R 11 )(e.g., C(O)NH(CH3), C(O)NH(CH2CH2OCH3), C(O)NH(CH2CH2OH)), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10) C1-C5 linear or branched substituted or unsubstituted alkyl (e.g., methylimidazole, methyl, ethyl), C1-C5 linear or branched substituted or unsubstituted alkenyl, C1-C5 linear or branched or C3-C8 cyclic haloalkyl (e.g., CHF2), C1-C5 linear or branched or C3-C8 cyclic alkoxy (e.g., methoxy, ethoxy) (optionally, at least one methylene group (CH2) in the alkoxy is replaced by an oxygen atom), C1-C5 linear or branched thioalkyl, C1-C5 linear or branched thioalkoxy, C1-C5 linear or branched haloalkoxy, C1-C5 linear or branched alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclopropanol, cyclohexyl, bicyclo[1.1.1]pentane), substituted or unsubstituted 4- to 7-membered heterocyclic ring (e.g., morpholine, tetrahydropyran, tetrahydropyran, oxetane, oxetan-3-ol, pyrrolidine, pyrrolidin-2-ol, pyrrolidin-3-ol, 1-methylpyrrolidine, pyrrolidin-2-one, pyrrolidin-3-one, 3-cyanopyrrolidine, pyrrolidinone, imidazole, pyrazole, isoxazolidine, piperazine, piperidine, piperidin-3-ol, piperidin-4-ol, piperidin-2-one, piperidin-4-carbonitrile, 4-fluoropiperidine, oxadiazole, triazole, pyrazole, 2-oxopyrrolidine, 4,7-diazaspiro[2.5]octane, 2,5-diazabicyclo[2.2.1]heptane, piperazin-2-one), R8-(substituted or unsubstituted monocyclic, fused-ring or spiro-ring 3- to 8-membered heterocyclic ring), substituted or unsubstituted aryl, or substituted or unsubstituted benzyl; Or, R7 is represented by the following structural formula A:

[0073]

Chemical formula

[0074] In the formula, X1 is N or O; R1 and R2 are, independently of each other, H, F, Cl, Br, I, OH, SH, CF3, a substituted or unsubstituted C1-C5 alkyl (for example, CH2OH), a C1-C5 straight-chain or branched-chain, or a C3-C8 cyclic haloalkyl, a C1-C5 straight-chain or branched-chain substituted or unsubstituted or a C3-C8 cyclic alkoxy; or, R1 and R2 are bonded to each other to form =O, or a C3-C8 carbocyclic or heterocyclic ring (for example, cyclopropyl); R3 and R4 are, independently of each other, H, Me, a substituted or unsubstituted C1-C5 alkyl (for example, methoxyethylene, methylaminoethyl, aminoethyl), -R8-O-R 10 (for example, (CH2)2-O-CH3), R8-N(R 10 )(R 11 (for example, (CH2)2-NH(CH3)), a substituted or unsubstituted C3-C8 cycloalkyl (for example, cyclopropyl), a substituted or unsubstituted 5- to 7-membered heterocyclic ring (for example, pyrrolidine, methylpyrrolidine, piperidine), or, R 20 ; or, R3 and R4 are bonded to each other to form a 3- to 8-membered heterocyclic ring (for example, pyrrolidine, pyrrolidone, 2-oxopyrrolidine, piperidine, morpholine, piperazine, imidazole); or, R2 and R4 are bonded to each other to form a substituted or unsubstituted saturated or unsaturated 4- to 8-membered heterocyclic or carbocyclic ring (for example, pyrrolidine, morpholine, 1-methylpyrrolidine, pyrrolidin-2-one, pyrrolidin-3-one, 3,3-difluoropyrrolidine, pyrrolidin-3-ol, 3-methoxypyrrolidine, 3-(difluoromethyl)pyrrolidine, pyrrolidine-3-carbonitrile, pyridine, piperidine, piperidin-2-one, imidazole, pyrimidine, triazole, oxadiazole, pyrazole). However, when the ring is an aromatic ring, R1 and / or R3 do not exist; however, when X1 is O, R4 does not exist; R7´ is H, F, Cl, Br, I, OH, O-R20 , SH, R8-OH, R8-SH, -R8-O-R 10 , R8-(C3-C8 cycloalkyl), R8-(3- to 8-membered heterocyclic ring), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R 10 )(R 11 ), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 , R8-C(O)-R 10 , C(O)H, C(O)-R 10 , C1-C5 linear or branched C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10), C1-C5 linear or branched substituted or unsubstituted alkyl (e.g., isopropyl, methyl, ethyl), C1-C5 linear or branched substituted or unsubstituted alkenyl, C1-C5 linear or branched or C3-C8 cyclic haloalkyl (e.g., CHF2), C1-C5 linear or branched or C3-C8 cyclic alkoxy (e.g., methoxy) (optionally, at least one methylene group (CH2) in the alkoxy is replaced by an oxygen atom), C1-C5 linear or branched thioalkoxy, C1-C5 linear or branched haloalkoxy, C1-C5 linear or branched alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclohexyl), substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., morpholine, pyran, oxetane, pyrrolidine, 3,3-difluoropyrrolidine, imidazole, pyrazole, triazole, piperazine, piperidine, piperidin-2-one, piperidin-4-ol, dioxazole, 2-oxopyrrolidine), substituted or unsubstituted aryl, or substituted or unsubstituted benzyl; or, R7 and R7´ are bonded to each other to form a substituted or unsubstituted saturated, unsaturated or aromatic 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); R 20 is represented by the following structural formula:

[0075] [Chemical formula]

[0076] In the formula, R 30 is H, R 20 , F, Cl, Br, I, OH, SH, alkoxy, N(R)2, NH(R 10 ), N(R 10 )(R 11)、CF3, CN, NO2, a linear or branched, substituted or unsubstituted C1-C5 alkyl (e.g., methyl, ethyl, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a linear or branched C1-C5 alkoxy, a linear or branched C1-C5 haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , -R8-R 10 (e.g., (CH2)2-O-CH3), a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2-pyridine, 3-pyridine, or 4-pyridine)); R is H, F, Cl, Br, I, OH, SH, alkoxy, NH(R 10 ), NH-CH2-cyclopropyl, N(R 10 )(R 11 ), CF3, CN, NO2, COOH, CO(R 10 )(e.g., C(O)CH3), a linear or branched, substituted or unsubstituted C1-C5 alkyl (e.g., methyl, ethyl, CH2-OH, CH2-CH2-OH, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a substituted or unsubstituted C3-C8 cycloalkyl, cyclopropyl, a linear or branched C1-C5 alkoxy, isopropoxy, a linear or branched C1-C5 haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , -R8-R 10(For example, (CH2)2-O-CH3), a substituted or unsubstituted aryl (for example, phenyl), or a substituted or unsubstituted heteroaryl (for example, pyridine (2-pyridine, 3-pyridine, or 4-pyridine)); Each R8 is, independently of one another, [CH2] p and p is from 1 to 10; R9 is [CH] q or [C] q and q is from 2 to 10; R 10 and R 11 are, independently of one another, H, a straight-chain or branched-chain substituted or unsubstituted alkyl having 1 to 5 carbon atoms (for example, methyl, ethyl, CH2-cyclopropyl, CH2-CH2-O-CH3), a straight-chain or branched-chain substituted or unsubstituted haloalkyl having 1 to 5 carbon atoms (for example, CH2CF3), a straight-chain or branched-chain alkoxy having 1 to 5 carbon atoms (for example, O-CH3), R 20 , C(O)R, or S(O)2R; or R 10 and R 11 are joined to each other to form a substituted or unsubstituted 3- to 8-membered heterocyclic ring (for example, piperazine, piperidine); n is an integer from 0 to 4 (for example, 1, 2).

[0077] In various embodiments, the present invention relates to a compound represented by the following structural formula I(g), or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, N-oxide, reverse amide analog, prodrug, isotopic variant (for example, deuterated analog), PROTAC, pharmaceutical, or any combination thereof.

[0078]

Chemical formula

[0079] In the formula, X2, X3, and X4 are, independently of one another, nitrogen or CH; X5, X6, X7, X8, and X9 are, independently of one another, a nitrogen atom or a carbon atom; X 10 is N, CH, or C(R) (for example, C(CH2)OH, C(CH2)2-OH, C(NH-CH2-cyclopropyl), C(CH3), C(cyclopropyl), C(isopropoxy), C(COOH)); R 100 is a C1-C5 straight-chain or branched-chain substituted or unsubstituted alkyl (for example, methyl), R8-OH (for example, (CH2)2-OH), -R8-O-R 10 (for example, (CH2)2-O-CH3), R8-N(R 10 )(R 11 )(for example, (CH2)2-NH(CH3), (CH2)2-NH2), R 20 or a substituted or unsubstituted 3- to 8-membered heterocyclic ring (for example, pyrrolidine, piperidine); R5 is H or a C1-C5 straight-chain or branched-chain alkyl (for example, methyl); R6 is H, F, Cl, Br, I, OH, SH, R8-OH, R8-SH, -R8-O-R 10 (for example, CH2-O-CH3, (CH2)2-O-CH3, (CH2)3-O-CH3, (CH3)2-O-CH(CH3)2), R8-S-R 10 (for example, (CH2)3-S-(CH2)2CH3), R8-NHC(O)-R 10 , -O-R8-R 10, R8-(C3-C8 substituted or unsubstituted cycloalkyl) (e.g., CH2-cyclopropyl, CH2-cyclobutanol, CH2-difluorocyclopropyl, CH2-methylcyclopropyl, CH2-dimethylamino-cyclohexyl, (CH2)2-cyclopentanol, CH2-cyclohexanol), R8-(substituted or unsubstituted saturated, unsaturated or aromatic monocyclic, fused ring or spiro ring 3- to 10-membered heterocyclic ring) (e.g., (CH2)3-pyran, (CH2)2-pyrazole, (CH2)2-imidazole, CH2-tetrahydrofuran, CH2-dioxane, CH2-oxetane, CH2-piperidine, CH2-triazole, CH2-1-oxa-8-azaspiro[4.5]decane, (CH2)3-diazabicyclo[2.2.1]heptane, CH2-methyl-THF, CH2-ethyl-piperidine, CH2-oxa-azaspirodecan, (CH2)3-dimethylpyrazole, CH2-2-oxo-methylpyrrolidine, CH2-methyl-azetidine, CH2-azaspiroheptane), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 )(e.g., (CH2)3-4-fluoropiperidine, (CH2)3-N(CH2CH3)2, (CH2)3-N(CH(CH3)2)2, (CH2)3-piperidine, (CH2)4-NH(CH3), (CH2)3-NH-CH3, (CH2)3-NH-CH2CH3, (CH2)3-N(CCH2CH3)2, (CH2)3-NH2, (CH2)3-N(CH2CH3)(CH2CF3)), R8-C(O)N(R 10 )(R 11 )(e.g., (CH2)2-C(O)-piperidine), R9-R8-N(R 10 )(R 11 )(e.g., (CH2)2-C(O)-piperidine), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R10 , R8-C(O)-R 10 , C(O)H, C(O)-R 10 , a linear or branched C1-C5 C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10)、C1-C5 linear or branched substituted or unsubstituted alkyl (e.g., CH(CH3)CH2OCH3, CH(CH3)CH2NH2, CH(CH3)C(O)N(CH3)2, CH2-CH(OH)Ph, (CH2)3N(H)CH2CH3, CH(CH3)(CH2)2OH, CH(CH2OH)(CH2CH3), (CH2)3-OCH3, (CH2)2-OCH3, (CH2)2-OCH(CH3)2, CH(CH2OH)(CH2CH(CH3)2), CH2CH(CH3)(OCH3), CH2CH(N(CH3)2)(CH2CH3), benzyl, methyl, ethyl, CH2-CH2-CH2-O-CH3, CH(CH3)C(O)N(CH3)2), C1-C5 linear or branched substituted or unsubstituted alkenyl, C1-C5 linear or branched or C3-C8 cyclic haloalkyl, C1-C5 linear or branched substituted or unsubstituted or C3-C8 cyclic alkoxy (e.g., methoxy, O-(CH2)2-O-CH3) (optionally, at least one methylene group (CH2) in the alkoxy is replaced by an oxygen atom), C1-C5 linear or branched thioalkoxy, C1-C5 linear or branched haloalkoxy, C1-C5 linear or branched alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclohexyl, methoxycyclopropyl, methylcyclobutyl, aminomethyl-cyclobutyl, methoxycyclobutyl, 2,3-dihydro-1H-indenol), R8-(C3-C8 substituted or unsubstituted cycloalkyl), substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., piperidine, 1-methylpiperidine, 3-fluoro-1-methylpiperidine, azetidine, 1-methyl-azetidine, morpholine, pyrrolidine, pyrrolidinone, quinuclidine, tetrahydropyran, tetrahydrofuran, azaspiro[3.3]heptane, 8-methyl-8-azabicyclo[3.2.1) It is octane, 1,3 - dioxane, imidazole, trifluoromethyl - oxetane, hydroxy - tetrahydrofuran, azepan - 2 - one, azabicyclohexane), substituted or unsubstituted aryl, substituted or unsubstituted R8 - aryl (e.g., benzyl), or substituted or unsubstituted benzyl;. Or, R6 and R5 are bonded to each other to form a substituted or unsubstituted 5 - to 8 - membered heterocyclic ring (e.g., azepane, piperazine, 2 - (piperazin - 1 - yl) acetamide); Or, R6 is represented by the following structural formula C:

[0080]

Chemical formula

[0081] In the formula, k is an integer from 1 to 4; R 12 and R 13 are independently of each other H, a straight - chain or branched - chain substituted or unsubstituted alkyl having 1 - C5 (e.g., ethyl, isopropyl), or R 20 ; or, R 12 and R 13 are bonded to each other to form a substituted or unsubstituted 4 - to 7 - membered heterocyclic ring (e.g., piperidine, piperazine, pyrrolidine, oxa - 6 - azaspiro[3.3]heptane). Or, R6 is represented by the following structural formula Bi:

[0082]

Chemical formula

[0083] In the formula, m is 0 or 1; R 12 is R 20 , or C(O)-alkyl having 1 - C5, and R 13 is R 30 ; Or, R12 and R 13 are both H; or, R 12 and R 13 are, independently of each other, H, or C1-C5 substituted or unsubstituted alkyl (for example, ethyl, trifluoroethyl); or, R 12 and C3 are joined to each other to form an A ring, and R 13 is R 30 ; or, R 12 and R 13 are joined to each other to form a B ring; or, R 12 and C1 are joined to each other to form a C ring, and R 13 is R 30 ; or, C1 and C3 are joined to each other to form a D ring, and R 12 and R 13 are independently of each other R 30 ; or, R 13 and C2 are joined to each other to form an E ring, and m is 1, and R 12 is R 30 ; or, R 12 and R 13 are joined to each other to form a B ring, and C1 and C3 are joined to each other to form a D ring; The A ring, C ring, and E ring are, independently of each other, a substituted or unsubstituted monocyclic, spiro, or fused ring 3- to 8-membered heterocyclic ring (for example, A: pyrrolidine, methylpyrrolidine, ethylpyrrolidine; C: piperidine, pyrrolidine, methyl-2-oxopyrrolidine, pyran-pyrrolidine, methyl-azetidine, azabicyclooctane, 2-azabicyclo[2.1.1]hexane, 2-azaspiro[3.3]heptane; E: pyrrolidine, azetidine, ethylpyrrolidine, oxopyrrolidine, methylpiperidine); Ring B is a substituted or unsubstituted monocyclic, spiro or fused 3- to 8-membered heterocyclic ring (B: piperidine, piperidin-2-one, 4-fluoropiperidin-2-one, piperidine-4-carbonitrile, 4-fluoropiperidine, 4-fluoro-2-methylpiperidine, methylpiperidine, fluoropiperidine, difluoropiperidine, pyrrolidine, piperazine, methylpyrrolidine, thiomorpholine 1,1-dioxide, 2-oxa-6-azaspiro[3.3]heptane, methylpiperazine, dimethylpyrazole, imidazole, 2-methyl-2,5-diazabicyclo[2.2.1]heptane, hydroxymethyl-pyrrolidine, 6-fluoro-3-azabicyclo[3.1.1]heptane); Ring D is a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclobutane, cyclohexane); R7´ is H, F, Cl, Br, I, OH, O-R 20 , SH, R8-OH, R8-SH, -R8-O-R 10 , R8-(C3-C8 cycloalkyl), R8-(3- to 8-membered heterocyclic ring), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R 10 )(R 11 ), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 , R8-C(O)-R 10 , C(O)H, C(O)-R 10 , C1-C5 linear or branched C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10) C1-C5 linear or branched, substituted or unsubstituted alkyl (e.g., isopropyl, methyl, ethyl), C1-C5 linear or branched, substituted or unsubstituted alkenyl, C1-C5 linear or branched or C3-C8 cyclic haloalkyl (e.g., CHF2), C1-C5 linear or branched or C3-C8 cyclic alkoxy (e.g., methoxy) (optionally, at least one methylene group (CH2) in the alkoxy is substituted by an oxygen atom), C1-C5 linear or branched thioalkoxy, C1-C5 linear or branched haloalkoxy, C1-C5 linear or branched alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclohexyl), substituted or unsubstituted 3- to 8-membered heterocycle (e.g., morpholine, pyran, oxetane, pyrrolidine, 3,3-difluoropyrrolidine, imidazole, pyrazole, triazole, piperazine, piperidine, piperidin-2-one, piperidin-4-ol, dioxazole, 2-oxopyrrolidine), substituted or unsubstituted aryl, or substituted or unsubstituted benzyl; R 20 is represented by the following structural formula:

[0084]

Chemical formula

[0085] In the formula, R 30 is H, R 20 , F, Cl, Br, I, OH, SH, alkoxy, N(R)2, NH(R 10 ), N(R 10 )(R 11)、CF3, CN, NO2, a C1-C5 straight or branched chain substituted or unsubstituted alkyl (e.g., methyl, ethyl, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a C1-C5 straight or branched chain alkoxy, a C1-C5 straight or branched chain haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), an R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , -R8-R 10 (e.g., (CH2)2-O-CH3), a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2-pyridine, 3-pyridine, or 4-pyridine)); R is H, F, Cl, Br, I, OH, SH, alkoxy, NH(R 10 ), NH-CH2-cyclopropyl, N(R 10 )(R 11 ), CF3, CN, NO2, COOH, CO(R 10 )(e.g., C(O)CH3), a C1-C5 straight or branched chain substituted or unsubstituted alkyl (e.g., methyl, ethyl, CH2-OH, CH2-CH2-OH, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a C3-C8 substituted or unsubstituted cycloalkyl, cyclopropyl, a C1-C5 straight or branched chain alkoxy, isopropoxy, a C1-C5 straight or branched chain haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), an R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , -R8-R 10(e.g., (CH2)2-O-CH3), a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2-pyridine, 3-pyridine, or 4-pyridine)); Each R8 is, independently of one another, [CH2] p and p is from 1 to 10; R9 is [CH] q or [C] q and q is from 2 to 10; R 10 and R 11 are, independently of one another, H, a straight-chain or branched-chain substituted or unsubstituted alkyl having 1 to 5 carbon atoms (e.g., methyl, ethyl, CH2-cyclopropyl, CH2-CH2-O-CH3), a straight-chain or branched-chain substituted or unsubstituted haloalkyl having 1 to 5 carbon atoms (e.g., CH2CF3), a straight-chain or branched-chain alkoxy having 1 to 5 carbon atoms (e.g., O-CH3), R 20 , C(O)R, or S(O)2R; or R 10 and R 11 are joined to each other to form a substituted or unsubstituted heterocyclic ring having 3 to 8 members (e.g., piperazine, piperidine); n is an integer from 0 to 4 (e.g., 1, 2).

[0086] In some embodiments, when R 100 is methyl and R5 is H, R 12 and R 13 are not both alkyl. In some embodiments, when R 100 is methyl and R5 is H, R 12 and R 13 cannot be joined to each other to form piperidine.

[0087] In various embodiments, the present invention relates to a compound represented by the following structural formula I(h), or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, N-oxide, reverse amide analog, prodrug, isotopic variant (e.g., deuterated analog), PROTAC, pharmaceutical, or any combination thereof.

[0088]

Chemical formula

[0089] Wherein, X2, X3, and X4 are each independently nitrogen or CH; X5, X6, X7, X8, and X9 are each independently a nitrogen atom or a carbon atom; X 10 is N, CH, or C(R) (e.g., C(CH2)OH, C(CH2)2-OH, C(NH-CH2-cyclopropyl), C(CH3), C(cyclopropyl), C(isopropoxy), C(COOH)); Ring F is absent or is a substituted or unsubstituted saturated or unsaturated 4- to 8-membered heterocyclic ring (e.g., pyrrolidine, morpholine, 1-methylpyrrolidine, pyrrolidin-2-one, pyrrolidin-3-one, 3,3-difluoropyrrolidine, pyrrolidin-3-ol, 3-methoxypyrrolidine, 3-(difluoromethyl)pyrrolidine, pyrrolidine-3-carbonitrile, pyridine, piperidine, piperidin-2-one, imidazole, pyrimidine, triazole, oxadiazole, pyrazole); R1 and R2 are each independently H, F, Cl, Br, I, OH, SH, CF3, a substituted or unsubstituted C1-C5 alkyl (e.g., CH2OH), a straight-chain or branched C1-C5 or cyclic C3-C8 haloalkyl, or a substituted or unsubstituted straight-chain or branched C1-C5 or cyclic C3-C8 alkoxy; or R1 and R2 are bonded to each other to form a 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopropyl); Alternatively, R2 and R4 are bonded to each other to form the F ring defined above (e.g., pyrrolidine, morpholine, 1-methylpyrrolidine, pyrrolidin-2-one, pyrrolidin-3-one, 3,3-difluoropyrrolidine, pyrrolidin-3-ol, 3-methoxypyrrolidine, 3-(difluoromethyl)pyrrolidine, pyrrolidine-3-carbonitrile, pyridine, piperidine, piperidin-2-one, imidazole, pyrimidine, triazole, oxadiazole, pyrazole); Provided that when the ring F is aromatic, R1 and / or R3 do not exist; R3 and R4 are each independently H, Me, C1-C5 substituted or unsubstituted alkyl (e.g., methoxyethylene, methylaminoethyl, aminoethyl), -R8-O-R 10 (e.g., (CH2)2-O-CH3), R8-N(R 10 )(R 11 )(e.g., (CH2)2-NH(CH3)), C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl), substituted or unsubstituted 5- to 7-membered heterocyclic ring (e.g., pyrrolidine, methylpyrrolidine, piperidine), or R 20 ; Alternatively, R3 and R4 are bonded to each other to form a 3- to 8-membered heterocyclic ring (e.g., pyrrolidine, pyrrolidone, 2-oxopyrrolidine, piperidine, morpholine, piperazine, imidazole); R5 is H, or C1-C5 straight-chain or branched-chain alkyl (e.g., methyl); R6 is H, F, Cl, Br, I, OH, SH, R8-OH, R8-SH, -R8-O-R 10 (e.g., CH2-O-CH3, (CH2)2-O-CH3, (CH2)3-O-CH3, (CH3)2-O-CH(CH3)2), R8-S-R 10 (e.g., (CH2)3-S-(CH2)2CH3), R8-NHC(O)-R 10 , -O-R8-R 10, R8-(C3-C8 substituted or unsubstituted cycloalkyl) (e.g., CH2-cyclopropyl, CH2-cyclobutanol, CH2-difluorocyclopropyl, CH2-methylcyclopropyl, CH2-dimethylamino-cyclohexyl, (CH2)2-cyclopentanol, CH2-cyclohexanol), R8-(substituted or unsubstituted saturated, unsaturated or aromatic monocyclic, fused ring or spiro ring 3- to 10-membered heterocyclic ring) (e.g., (CH2)3-pyran, (CH2)2-pyrazole, (CH2)2-imidazole, CH2-tetrahydrofuran, CH2-dioxane, CH2-oxetane, CH2-piperidine, CH2-triazole, CH2-1-oxa-8-azaspiro[4.5]decane, (CH2)3-diazabicyclo[2.2.1]heptane, CH2-methyl-THF, CH2-ethyl-piperidine, CH2-oxa-azaspirodecan, (CH2)3-dimethylpyrazole, CH2-2-oxo-methylpyrrolidine, CH2-methyl-azetidine, CH2-azaspiroheptane), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ) (e.g., (CH2)3-4-fluoropiperidine, (CH2)3-N(CH2CH3)2, (CH2)3-N(CH(CH3)2)2, (CH2)3-piperidine, (CH2)4-NH(CH3), (CH2)3-NH-CH3, (CH2)3-NH-CH2CH3, (CH2)3-N(CCH2CH3)2, (CH2)3-NH2, (CH2)3-N(CH2CH3)(CH2CF3)), R8-C(O)N(R 10 )(R 11 ) (e.g., (CH2)2-C(O)-piperidine), R9-R8-N(R 10 )(R 11 ) (e.g., (CH2)2-C(O)-piperidine), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R10 , R8-C(O)-R 10 , C(O)H, C(O)-R 10 , a straight-chain or branched-chain C(O)-haloalkyl having 1 to 5 carbon atoms, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10) C1-C5 linear or branched substituted or unsubstituted alkyl (e.g., CH(CH3)CH2OCH3, CH(CH3)CH2NH2, CH(CH3)C(O)N(CH3)2, CH2-CH(OH)Ph, (CH2)3N(H)CH2CH3, CH(CH3)(CH2)2OH, CH(CH2OH)(CH2CH3), (CH2)3-OCH3, (CH2)2-OCH3, (CH2)2-OCH(CH3)2, CH(CH2OH)(CH2CH(CH3)2), CH2CH(CH3)(OCH3), CH2CH(N(CH3)2)(CH2CH3), benzyl, methyl, ethyl, CH2-CH2-CH2-O-CH3, CH(CH3)C(O)N(CH3)2), C1-C5 linear or branched substituted or unsubstituted alkenyl, C1-C5 linear or branched or C3-C8 cyclic haloalkyl, C1-C5 linear or branched substituted or unsubstituted or C3-C8 cyclic alkoxy (e.g., methoxy, O-(CH2)2-O-CH3) (optionally, at least one methylene group (CH2) in the alkoxy is substituted by an oxygen atom), C1-C5 linear or branched thioalkoxy, C1-C5 linear or branched haloalkoxy, C1-C5 linear or branched alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclohexyl, methoxycyclopropyl, methylcyclobutyl, aminomethyl-cyclobutyl, methoxycyclobutyl, 2,3-dihydro-1H-indenol), R8-(C3-C8 substituted or unsubstituted cycloalkyl), substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., piperidine, 1-methylpiperidine, 3-fluoro-1-methylpiperidine, azetidine, 1-methyl-azetidine, morpholine, pyrrolidine, pyrrolidinone, quinuclidine, tetrahydropyran, tetrahydrofuran, azaspiro[3.3]heptane, 8-methyl-8-azabicyclo[3.2.1) It is octane, 1,3-dioxane, imidazole, trifluoromethyl-oxetane, hydroxy-tetrahydrofuran, azepan-2-one, azabicyclohexane), a substituted or unsubstituted aryl, a substituted or unsubstituted R8-aryl (e.g., benzyl), or a substituted or unsubstituted benzyl;. Or, R6 and R5 are bonded to each other to form a substituted or unsubstituted 5- to 8-membered heterocyclic ring (e.g., azepane, piperazine, 2-(piperazin-1-yl)acetamide); Or, R6 is represented by the following structural formula B or structural formula Bi:

[0090]

Chemical formula

[0091] In the formula, m is 0 or 1; R 12 is R 20 , or C1-C5 C(O)-alkyl, and R 13 is R 30 ; Or, both R 12 and R 13 are H; Or, R 12 and R 13 are, independently of each other, H, or C1-C5 substituted or unsubstituted alkyl (e.g., ethyl, trifluoroethyl); Or, R 12 and C3 are bonded to each other to form ring A, and R 13 is R 30 ; Or, R 12 and R 13 are bonded to each other to form ring B; Or, R 12 and C1 are bonded to each other to form ring C, and R 13 is R 30 ; Or, C1 and C3 are bonded to each other to form ring D, and R 12 and R 13are independently of each other R 30 ; or, R 13 and C2 are joined to each other to form an E ring, m is 1, and R 12 is R 30 ; or, R 12 and R 13 are joined to each other to form a B ring, and C1 and C3 are joined to each other to form a D ring; The A ring, C ring, and E ring are, independently of each other, a substituted or unsubstituted monocyclic, spiro or fused ring 3- to 8-membered heterocyclic ring (e.g., A: pyrrolidine, methylpyrrolidine, ethylpyrrolidine; C: piperidine, pyrrolidine, methyl-2-oxopyrrolidine, pyran-pyrrolidine, methyl-azetidine, azabicyclooctane, 2-azabicyclo[2.1.1]hexane, 2-azaspiro[3.3]heptane; E: pyrrolidine, azetidine, ethylpyrrolidine, oxopyrrolidine, methylpiperidine); The B ring is a substituted or unsubstituted monocyclic, spiro or fused ring 3- to 8-membered heterocyclic ring (B: piperidine, piperidin-2-one, 4-fluoropiperidin-2-one, piperidine-4-carbonitrile, 4-fluoropiperidine, 4-fluoro-2-methylpiperidine, methylpiperidine, fluoropiperidine, difluoropiperidine, pyrrolidine, piperazine, methylpyrrolidine, thiomorpholine 1,1-dioxide, 2-oxa-6-azaspiro[3.3]heptane, methylpiperazine, dimethylpyrazole, imidazole, 2-methyl-2,5-diazabicyclo[2.2.1]heptane, hydroxymethyl-pyrrolidine, 6-fluoro-3-azabicyclo[3.1.1]heptane); The D ring is a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclobutane, cyclohexane); R7´ and R7´´ are, independently of each other, Br, I, OH, O-R 20 , SH, R8-OH, R8-SH, SR 10 , -R8-O-R 10 , -R8-S-R 10, R8-(C3-C8 cycloalkyl), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R 10 )(R 11 ), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 (COO-CH3), R8-C(O)-R 10 , C(O)H, C(O)-R 10 , C1-C5 straight-chain or branched C(O)-haloalkyl, -C(O)NH2, C(O)NHR (e.g., C(O)NH(CH3)), C(O)N(R 10 )(R 11 )(e.g., C(O)NH(CH3), C(O)NH(CH2CH2OCH3), C(O)NH(CH2CH2OH)), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10), C1-C5 linear or branched substituted or unsubstituted alkyl (e.g., methylimidazole, methyl, ethyl), C1-C5 linear or branched substituted or unsubstituted alkenyl, C1-C5 linear or branched or C3-C8 cyclic haloalkyl (e.g., CHF2), C1-C5 linear or branched or C3-C8 cyclic alkoxy (e.g., methoxy, ethoxy) (optionally, at least one methylene group (CH2) in the alkoxy is replaced by an oxygen atom), C1-C5 linear or branched thioalkyl, C1-C5 linear or branched thioalkoxy, C1-C5 linear or branched haloalkoxy, C1-C5 linear or branched alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclopropanol, cyclohexyl, bicyclo[1.1.1]pentane), substituted or unsubstituted 4- to 7-membered heterocyclic ring (e.g., morpholine, tetrahydropyran, tetrahydropyran, oxetane, oxetan-3-ol, pyrrolidine, pyrrolidin-2-ol, pyrrolidin-3-ol, 1-methylpyrrolidine, pyrrolidin-2-one, pyrrolidin-3-one, 3-cyanopyrrolidine, pyrrolidinone, imidazole, pyrazole, isoxazolidine, piperazine, piperidine, piperidin-3-ol, piperidin-4-ol, piperidin-2-one, piperidin-4-carbonitrile, 4-fluoropiperidine, oxadiazole, triazole, pyrazole, 2-oxopyrrolidine, 4,7-diazaspiro[2.5]octane, 2,5-diazabicyclo[2.2.1]heptane, piperazin-2-one), R8-(substituted or unsubstituted monocyclic, fused ring or spiro ring 3- to 8-membered heterocyclic ring), substituted or unsubstituted aryl, or substituted or unsubstituted benzyl; or, R7′ and R7″ are bonded to each other to form a substituted or unsubstituted saturated, unsaturated or aromatic 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); R 20 is represented by the following structural formula:

[0092]

Chem.

[0093] In the formula, R is H, F, Cl, Br, I, OH, SH, alkoxy, NH(R 10 ), NH-CH2-cyclopropyl, N(R 10 )(R 11 ), CF3, CN, NO2, COOH, CO(R 10 )(e.g., C(O)CH3), a straight-chain or branched-chain substituted or unsubstituted alkyl having 1 to 5 carbon atoms (e.g., methyl, ethyl, CH2-OH, CH2-CH2-OH, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a substituted or unsubstituted cycloalkyl having 3 to 8 carbon atoms, cyclopropyl, a straight-chain or branched-chain alkoxy having 1 to 5 carbon atoms, isopropoxy, a straight-chain or branched-chain haloalkyl having 1 to 5 carbon atoms (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , -R8-R 10 (e.g., (CH2)2-O-CH3), a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2-pyridine, 3-pyridine, or 4-pyridine)); R 30 is H, R 20 , F, Cl, Br, I, OH, SH, alkoxy, N(R)2, NH(R 10 ), N(R 10 )(R 11)、CF3, CN, NO2, a linear or branched, substituted or unsubstituted C1-C5 alkyl (e.g., methyl, ethyl, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a linear or branched C1-C5 alkoxy, a linear or branched C1-C5 haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , -R8-R 10 (e.g., (CH2)2-O-CH3), a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2-pyridine, 3-pyridine, or 4-pyridine)); Each R8 is, independently of one another, [CH2] p and p is from 1 to 10; R9 is [CH] q or [C] q and q is from 2 to 10; R 10 and R 11 are, independently of one another, H, a linear or branched, substituted or unsubstituted C1-C5 alkyl (e.g., methyl, ethyl, CH2-cyclopropyl, CH2-CH2-O-CH3), a linear or branched, substituted or unsubstituted C1-C5 haloalkyl (e.g., CH2CF3), a linear or branched C1-C5 alkoxy (e.g., O-CH3), R 20 , C(O)R, or S(O)2R; or R 10 and R 11 are joined to each other to form a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., piperazine, piperidine); n is an integer from 0 to 4 (e.g., 1, 2).

[0094] In various embodiments, the present invention relates to a compound represented by the following structural formula I(i), or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, N-oxide, reverse amide analog, prodrug, isotopic variant (e.g., deuterated analog), PROTAC, pharmaceutical, or any combination thereof.

[0095] [Chemical formula]

[0096] Wherein, X2, X3, and X4 are each independently nitrogen or CH; X5, X6, X7, X8, and X9 are each independently a nitrogen atom or a carbon atom; X 10 is N, CH, or C(R) (e.g., C(CH2)OH, C(CH2)2-OH, C(NH-CH2-cyclopropyl), C(CH3), C(cyclopropyl), C(isopropoxy), C(COOH)); R5 is H, or a straight-chain or branched-chain alkyl of C1-C5 (e.g., methyl); R6 is H, F, Cl, Br, I, OH, SH, R8-OH, R8-SH, -R8-O-R 10 (e.g., CH2-O-CH3, (CH2)2-O-CH3, (CH2)3-O-CH3, (CH3)2-O-CH(CH3)2), R8-S-R 10 (e.g., (CH2)3-S-(CH2)2CH3), R8-NHC(O)-R 10 , -O-R8-R 10, R8-(C3-C8 substituted or unsubstituted cycloalkyl) (e.g., CH2-cyclopropyl, CH2-cyclobutanol, CH2-difluorocyclopropyl, CH2-methylcyclopropyl, CH2-dimethylamino-cyclohexyl, (CH2)2-cyclopentanol, CH2-cyclohexanol), R8-(substituted or unsubstituted saturated, unsaturated or aromatic monocyclic, fused ring or spiro ring 3- to 10-membered heterocyclic ring) (e.g., (CH2)3-pyran, (CH2)2-pyrazole, (CH2)2-imidazole, CH2-tetrahydrofuran, CH2-dioxane, CH2-oxetane, CH2-piperidine, CH2-triazole, CH2-1-oxa-8-azaspiro[4.5]decane, (CH2)3-diazabicyclo[2.2.1]heptane, CH2-methyl-THF, CH2-ethyl-piperidine, CH2-oxa-azaspirodecan, (CH2)3-dimethylpyrazole, CH2-2-oxo-methylpyrrolidine, CH2-methyl-azetidine, CH2-azaspiroheptane), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ) (e.g., (CH2)3-4-fluoropiperidine, (CH2)3-N(CH2CH3)2, (CH2)3-N(CH(CH3)2)2, (CH2)3-piperidine, (CH2)4-NH(CH3), (CH2)3-NH-CH3, (CH2)3-NH-CH2CH3, (CH2)3-N(CCH2CH3)2, (CH2)3-NH2, (CH2)3-N(CH2CH3)(CH2CF3)), R8-C(O)N(R 10 )(R 11 ) (e.g., (CH2)2-C(O)-piperidine), R9-R8-N(R 10 )(R 11 ) (e.g., (CH2)2-C(O)-piperidine), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R10 , R8-C(O)-R 10 , C(O)H, C(O)-R 10 , a straight-chain or branched-chain C(O)-haloalkyl having 1 to 5 carbon atoms, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10) C1-C5 linear or branched, substituted or unsubstituted alkyl (e.g., CH(CH3)CH2OCH3, CH(CH3)CH2NH2, CH(CH3)C(O)N(CH3)2, CH2-CH(OH)Ph, (CH2)3N(H)CH2CH3, CH(CH3)(CH2)2OH, CH(CH2OH)(CH2CH3), (CH2)3-OCH3, (CH2)2-OCH3, (CH2)2-OCH(CH3)2, CH(CH2OH)(CH2CH(CH3)2), CH2CH(CH3)(OCH3), CH2CH(N(CH3)2)(CH2CH3), benzyl, methyl, ethyl, CH2-CH2-CH2-O-CH3, CH(CH3)C(O)N(CH3)2), C1-C5 linear or branched, substituted or unsubstituted alkenyl, C1-C5 linear or branched or C3-C8 cyclic haloalkyl, C1-C5 linear or branched, substituted or unsubstituted or C3-C8 cyclic alkoxy (e.g., methoxy, O-(CH2)2-O-CH3) (optionally, at least one methylene group (CH2) in the alkoxy is replaced by an oxygen atom), C1-C5 linear or branched thioalkoxy, C1-C5 linear or branched haloalkoxy, C1-C5 linear or branched alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclohexyl, methoxycyclopropyl, methylcyclobutyl, aminomethyl-cyclobutyl, methoxycyclobutyl, 2,3-dihydro-1H-indenol), R8-(C3-C8 substituted or unsubstituted cycloalkyl), substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., piperidine, 1-methylpiperidine, 3-fluoro-1-methylpiperidine, azetidine, 1-methyl-azetidine, morpholine, pyrrolidine, pyrrolidinone, quinuclidine, tetrahydropyran, tetrahydrofuran, azaspiro[3.3]heptane, 8-methyl-8-azabicyclo[3.2.1) is octane, 1,3-dioxane, imidazole, trifluoromethyl-oxetane, hydroxy-tetrahydrofuran, azepan-2-one, azabicyclohexane), substituted or unsubstituted aryl, substituted or unsubstituted R8-aryl (e.g., benzyl), or substituted or unsubstituted benzyl;. or, R6 and R5 are bonded to each other to form a substituted or unsubstituted 5- to 8-membered heterocyclic ring (e.g., azepane, piperazine, 2-(piperazin-1-yl)acetamide); or, R6 is represented by the following structural formula B or structural formula Bi:

[0097] [Chemical formula]

[0098] In the formula, m is 0 or 1; R 12 is R 20 , or C1-C5 C(O)-alkyl, and R 13 is R 30 ; or, R 12 and R 13 are both H; or, R 12 and R 13 are, independently of each other, H, or C1-C5 substituted or unsubstituted alkyl (e.g., ethyl, trifluoroethyl); or, R 12 and C3 are bonded to each other to form ring A, and R 13 is R 30 ; or, R 12 and R 13 are bonded to each other to form ring B; or, R 12 and C1 are bonded to each other to form ring C, and R 13 is R 30 ; or, C1 and C3 are bonded to each other to form ring D, and R 12 and R 13are independently of each other R 30 ; or, R 13 and C2 are bonded to each other to form an E ring, m is 1, and R 12 is R 30 ; or, R 12 and R 13 are bonded to each other to form a B ring, and C1 and C3 are bonded to each other to form a D ring; The A ring, C ring, and E ring are, independently of each other, a substituted or unsubstituted monocyclic, spiro, or fused 3- to 8-membered heterocyclic ring (e.g., A: pyrrolidine, methylpyrrolidine, ethylpyrrolidine; C: piperidine, pyrrolidine, methyl-2-oxopyrrolidine, pyran-pyrrolidine, methyl-azetidine, azabicyclooctane, 2-azabicyclo[2.1.1]hexane, 2-azaspiro[3.3]heptane; E: pyrrolidine, azetidine, ethylpyrrolidine, oxopyrrolidine, methylpiperidine); The B ring is a substituted or unsubstituted monocyclic, spiro, or fused 3- to 8-membered heterocyclic ring (B: piperidine, piperidin-2-one, 4-fluoropiperidin-2-one, piperidine-4-carbonitrile, 4-fluoropiperidine, 4-fluoro-2-methylpiperidine, methylpiperidine, fluoropiperidine, difluoropiperidine, pyrrolidine, piperazine, methylpyrrolidine, thiomorpholine 1,1-dioxide, 2-oxa-6-azaspiro[3.3]heptane, methylpiperazine, dimethylpyrazole, imidazole, 2-methyl-2,5-diazabicyclo[2.2.1]heptane, hydroxymethyl-pyrrolidine, 6-fluoro-3-azabicyclo[3.1.1]heptane); The D ring is a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclobutane, cyclohexane); R7, R7´, R7´´, R7´´´, and R7´´´´ are, independently of each other, H, F, Cl, Br, I, OH, O-R 20 , SH, R8-OH, R8-SH, -R8-O-R 10, R8-(C3-C8 cycloalkyl), R8-(3- to 8-membered heterocyclic ring), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R 10 )(R 11 ), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 , R8-C(O)-R 10 , C(O)H, C(O)-R 10 , C1-C5 linear or branched C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10), a straight-chain or branched-chain, substituted or unsubstituted alkyl having 1 to 5 carbon atoms (e.g., isopropyl, methyl, ethyl), a straight-chain or branched-chain, substituted or unsubstituted alkenyl having 1 to 5 carbon atoms, a straight-chain or branched-chain or cyclic haloalkyl having 1 to 5 carbon atoms or 3 to 8 carbon atoms (e.g., CHF2), a straight-chain or branched-chain or cyclic alkoxy having 1 to 5 carbon atoms or 3 to 8 carbon atoms (e.g., methoxy) (optionally, at least one methylene group (CH2) in the alkoxy is substituted with an oxygen atom), a straight-chain or branched-chain thioalkoxy having 1 to 5 carbon atoms, a straight-chain or branched-chain haloalkoxy having 1 to 5 carbon atoms, a straight-chain or branched-chain alkoxyalkyl having 1 to 5 carbon atoms, a substituted or unsubstituted cycloalkyl having 3 to 8 carbon atoms (e.g., cyclopropyl, cyclohexyl), a substituted or unsubstituted heterocyclic ring having 3 to 8 members (e.g., morpholine, pyran, oxetane, pyrrolidine, 3,3-difluoropyrrolidine, imidazole, pyrazole, triazole, piperazine, piperidine, piperidin-2-one, piperidin-4-ol, dioxazole, 2-oxopyrrolidine), a substituted or unsubstituted aryl, or a substituted or unsubstituted benzyl; However, at least two of R7, R7', R7'', R7''', and R7'''' are H; Or, R7' and R7'' are bonded to each other to form a substituted or unsubstituted saturated, unsaturated or aromatic carbocyclic or heterocyclic ring having 3 to 8 members (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); Or, R7'' and R7 are bonded to each other to form a substituted or unsubstituted carbocyclic or carbocyclic or heterocyclic ring having 3 to 8 members (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); Or, R7 and R7''' are bonded to each other to form a substituted or unsubstituted carbocyclic or carbocyclic or heterocyclic ring having 3 to 8 members (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); Or, R7''' and R7'''' are bonded to each other to form a substituted or unsubstituted 3- to 8-membered carbocyclic or carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); R 20 is represented by the following structural formula:

[0099] [Chemical formula]

[0100] In the formula, R is H, F, Cl, Br, I, OH, SH, alkoxy, NH(R 10 ), NH-CH2-cyclopropyl, N(R 10 )(R 11 ), CF3, CN, NO2, COOH, CO(R 10 )(e.g., C(O)CH3), a linear or branched C1-C5 substituted or unsubstituted alkyl (e.g., methyl, ethyl, CH2-OH, CH2-CH2-OH, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a C3-C8 substituted or unsubstituted cycloalkyl, cyclopropyl, a linear or branched C1-C5 alkoxy, isopropoxy, a linear or branched C1-C5 haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , -R8-R 10 (e.g., (CH2)2-O-CH3), a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2-pyridine, 3-pyridine, or 4-pyridine)); R 30 is H, R 20, F, Cl, Br, I, OH, SH, alkoxy, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), CF3, CN, NO2, a linear or branched, substituted or unsubstituted C1-C5 alkyl (e.g., methyl, ethyl, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a linear or branched C1-C5 alkoxy, a linear or branched C1-C5 haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , -R8-R 10 (e.g., (CH2)2-O-CH3), a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2-pyridine, 3-pyridine, or 4-pyridine)); each R8 is, independently of one another, [CH2] p and p is from 1 to 10; R9 is [CH] q , or [C] q and q is from 2 to 10; R 10 and R 11 are, independently of one another, H, a linear or branched, substituted or unsubstituted C1-C5 alkyl (e.g., methyl, ethyl, CH2-cyclopropyl, CH2-CH2-O-CH3), a linear or branched, substituted or unsubstituted C1-C5 haloalkyl (e.g., CH2CF3), a linear or branched C1-C5 alkoxy (e.g., O-CH3), R 20 , C(O)R, or S(O)2R; or R 10 and R 11 are joined to each other to form a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., piperazine, piperidine); n is an integer from 0 to 4 (for example, 1, 2).

[0101] In various embodiments, the present invention relates to a compound represented by the following structural formula I(j), or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, N-oxide, reverse amide analog, prodrug, isotope variant (e.g., deuterated analog), PROTAC, pharmaceutical, or any combination thereof.

[0102]

Chemical formula

[0103] Wherein, X2, X3, and X4 are each independently nitrogen or CH; X 10 is N, CH, or C(R) (e.g., C(CH2)OH, C(CH2)2-OH, C(NH-CH2-cyclopropyl), C(CH3), C(cyclopropyl), C(isopropoxy), C(COOH)); Ring W is a saturated, unsaturated or aromatic monocyclic, fused ring, bridged ring or spiro ring of 3- to 10-membered carbocyclic or heterocyclic ring (e.g., morpholine, tetrahydrofuran, tetrahydropyran, oxetane, oxetan-3-ol, pyrrolidine, pyrrolidin-2-ol, pyrrolidin-3-ol, 3-methoxypyrrolidine, 3-cyanopyrrolidine, 1-methylpyrrolidine, 3-(difluoromethyl)pyrrolidine, 3,3-difluoropyrrolidine, pyrrolidin-2-one, pyrrolidin-3-one, pyrrolidinone, imidazole, pyrazole, isoxazolidine, piperazine, piperidine, piperidin-3-ol, piperidin-4-ol, piperidin-2-one, piperidine-4-carbonitrile, 4-fluoropiperidine, oxadiazole, triazole, 2-oxopyrrolidine, cyclopropyl, 2,2-dimethylpyrrolidine, 4-azaspiro[2.4]heptane, pyrrolidin-3-one-O-methyloxime, 2-oxa-5-azaspiro[3.4]octane, 1,4-dioxa-6-azaspiro[4.4]nonane, 3,3-dimethylmorpholine, 1-methylpiperazine, 4,7-diazaspiro[2.5]octane, bicyclo[1.1.1]pentane, 2,5-diazabicyclo[2.2.1]heptane, piperazine, piperazin-2-one); W1 is CH2, C=O, or CH(R 10 )(e.g., CHCH3); R7´ and R7´´ are, independently of each other, H, F, Cl, Br, I, OH, O-R 20 , SH, R8-OH, R8-SH, -R8-O-R 10 , R8-(C3-C8 cycloalkyl), R8-(3- to 8-membered heterocyclic ring), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R 10 )(R 11 ), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R10 )(R 11 )、COOH, -C(O)Ph, C(O)O-R 10 、R8-C(O)-R 10 、C(O)H, C(O)-R 10 、a C1-C5 straight or branched chain C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 )、SO2R、SO2N(R 10 )(R 11 )、CH(CF3)(NH-R 10 )、a C1-C5 straight or branched chain substituted or unsubstituted alkyl (e.g., isopropyl, methyl, ethyl), a C1-C5 straight or branched chain substituted or unsubstituted alkenyl, a C1-C5 straight or branched chain or C3-C8 cyclic haloalkyl (e.g., CHF2), a C1-C5 straight or branched chain or C3-C8 cyclic alkoxy (e.g., methoxy) (optionally, at least one methylene group (CH2) in the alkoxy is substituted by an oxygen atom), a C1-C5 straight or branched chain thioalkoxy, a C1-C5 straight or branched chain haloalkoxy, a C1-C5 straight or branched chain alkoxyalkyl, a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclohexyl), a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., morpholine, pyran, oxetane, pyrrolidine, 3,3-difluoropyrrolidine, imidazole, pyrazole, triazole, piperazine, piperidine, piperidin-2-one, piperidin-4-ol, dioxazole, 2-oxopyrrolidine), a substituted or unsubstituted aryl, or a substituted or unsubstituted benzyl; or, R7´ and R7´´ are bonded to each other to form a substituted or unsubstituted saturated, unsaturated or aromatic 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); R 20 is represented by the following structural formula:

[0104] [Chemical]

[0105] In the formula, R is H, F, Cl, Br, I, OH, SH, alkoxy, NH(R 10 ), NH-CH2-cyclopropyl, N(R 10 )(R 11 ), CF3, CN, NO2, COOH, CO(R 10 )(e.g., C(O)CH3), a linear or branched substituted or unsubstituted C1-C5 alkyl (e.g., methyl, ethyl, CH2-OH, CH2-CH2-OH, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a substituted or unsubstituted C3-C8 cycloalkyl, cyclopropyl, a linear or branched C1-C5 alkoxy, isopropoxy, a linear or branched C1-C5 haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , -R8-R 10 (e.g., (CH2)2-O-CH3), a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2-pyridine, 3-pyridine, or 4-pyridine)); R 30 is H, R 20 , F, Cl, Br, I, OH, SH, alkoxy, N(R)2, NH(R 10 ), N(R 10 )(R 11)、CF3, CN, NO2, a linear or branched, substituted or unsubstituted C1-C5 alkyl (e.g., methyl, ethyl, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a linear or branched C1-C5 alkoxy, a linear or branched C1-C5 haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , -R8-R 10 (e.g., (CH2)2-O-CH3), a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2-pyridine, 3-pyridine, or 4-pyridine)); R 200 is H, R 20 , F, Cl, Br, I, OH, SH, alkoxy, NH2, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), CF3, CN, NO2, a linear or branched, substituted or unsubstituted C1-C5 alkyl (e.g., methyl, ethyl, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a linear or branched C1-C5 alkoxy (e.g., methoxy), a linear or branched C1-C5 haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , -R8-R 10For example, (CH2)2-O-CH3, a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2-pyridine, 3-pyridine, or 4-pyridine)); or R 200 and the carbon atom to which it is attached is C=O or CF2; Each R8, independently of one another, is [CH2] p and p is from 1 to 10; R9 is [CH] q or [C] q and q is from 2 to 10; R 10 and R 11 are, independently of one another, H, a linear or branched substituted or unsubstituted alkyl of C1-C5 (e.g., methyl, ethyl, CH2-cyclopropyl, CH2-CH2-O-CH3), a linear or branched substituted or unsubstituted haloalkyl of C1-C5 (e.g., CH2CF3), a linear or branched alkoxy of C1-C5 (e.g., O-CH3), R 20 C(O)R, or S(O)2R; or R 10 and R 11 are joined to each other to form a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., piperazine, piperidine); n is an integer from 0 to 4 (e.g., 1, 2).

[0106] In various embodiments, the compound is not (R)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-N-(3-(4-fluoropiperidin-1-yl)propyl)benzo[d]imidazo[2,1-b]thiazole-7-carboxamide. In various embodiments, the compound is not (S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-N-(3-(4-fluoropiperidin-1-yl)propyl)benzo[d]imidazo[2,1-b]thiazole-7-carboxamide. In various embodiments, the compound is not 2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-N-(3-(4-fluoropiperidin-1-yl)propyl)benzo[d]imidazo[2,1-b]thiazole-7-carboxamide.

[0107] In various embodiments, the present invention relates to a compound represented by the following structural formula I(k), or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, N-oxide, reverse amide analog, prodrug, isotope variant (e.g., deuterated analog), PROTAC, pharmaceutical, or any combination thereof.

[0108]

Chemical formula

[0109] Wherein, X2, X3, and X4 are, independently of one another, nitrogen or CH; X 10 is N, CH, or C(R) (e.g., C(CH2)OH, C(CH2)2-OH, C(NH-CH2-cyclopropyl), C(CH3), C(cyclopropyl), C(isopropoxy), C(COOH)); Q1 is O, NH, or CH2 Q2 is C=O, NH, or CH2; R7 and R7´ are, independently of one another, H, F, Cl, Br, I, OH, O-R 20 , SH, R8-OH, R8-SH, -R8-O-R 10, R8-(C3-C8 cycloalkyl), R8-(3- to 8-membered heterocyclic ring), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R 10 )(R 11 ), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 , R8-C(O)-R 10 , C(O)H, C(O)-R 10 , C1-C5 linear or branched C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10) C1-C5 linear or branched, substituted or unsubstituted alkyl (e.g., isopropyl, methyl, ethyl), C1-C5 linear or branched, substituted or unsubstituted alkenyl, C1-C5 linear or branched or C3-C8 cyclic haloalkyl (e.g., CHF2), C1-C5 linear or branched or C3-C8 cyclic alkoxy (e.g., methoxy) (optionally, at least one methylene group (CH2) in the alkoxy is replaced by an oxygen atom), C1-C5 linear or branched thioalkoxy, C1-C5 linear or branched haloalkoxy, C1-C5 linear or branched alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclohexyl), substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., morpholine, pyran, oxetane, pyrrolidine, 3,3-difluoropyrrolidine, imidazole, pyrazole, triazole, piperazine, piperidine, piperidin-2-one, piperidin-4-ol, dioxazole, 2-oxopyrrolidine), substituted or unsubstituted aryl, or substituted or unsubstituted benzyl; or, R7 and R7´ are bonded to each other to form a substituted or unsubstituted saturated, unsaturated or aromatic 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); R 20 is represented by the following structural formula:

[0110]

Chemical formula

[0111] In the formula, R is H, F, Cl, Br, I, OH, SH, alkoxy, NH(R 10 ), NH-CH2-cyclopropyl, N(R 10 )(R 11 ), CF3, CN, NO2, COOH, CO(R 10)(e.g., C(O)CH3), a C1-C5 straight-chain or branched-chain substituted or unsubstituted alkyl (e.g., methyl, ethyl, CH2-OH, CH2-CH2-OH, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a C3-C8 substituted or unsubstituted cycloalkyl, cyclopropyl, a C1-C5 straight-chain or branched-chain alkoxy, isopropoxy, a C1-C5 straight-chain or branched-chain haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , -R8-R 10 (e.g., (CH2)2-O-CH3), a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2-pyridine, 3-pyridine, or 4-pyridine)); R 30 is H, R 20 , F, Cl, Br, I, OH, SH, alkoxy, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), CF3, CN, NO2, a C1-C5 straight-chain or branched-chain substituted or unsubstituted alkyl (e.g., methyl, ethyl, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a C1-C5 straight-chain or branched-chain alkoxy, a C1-C5 straight-chain or branched-chain haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , -R8-R 10(e.g., (CH2)2 - O - CH3), a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2 - pyridine, 3 - pyridine, or 4 - pyridine)); R 200 is H, R 20 , F, Cl, Br, I, OH, SH, alkoxy, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), CF3, CN, NO2, a C1 - C5 straight - chain or branched - chain substituted or unsubstituted alkyl (e.g., methyl, ethyl, CH2 - CH2 - O - CH2 - CH2 - O - CH3, CH2 - O - CH2 - CH2 - O - CH3), a C1 - C5 straight - chain or branched - chain alkoxy (e.g., methoxy), a C1 - C5 straight - chain or branched - chain haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8 - aryl (e.g., CH2 - Ph), - R8 - O - R8 - O - R 10 (e.g., (CH2)2 - O - (CH2)2 - O - CH3), - R8 - O - R 10 , - R8 - R 10 (e.g., (CH2)2 - O - CH3), a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2 - pyridine, 3 - pyridine, or 4 - pyridine)); or, R 200 and the carbon atom to which it is attached is C = O or CF2; Each R8, independently of one another, is [CH2] p and p is from 1 to 10; R9 is [CH] q , or [C] q and q is from 2 to 10; R 10 and R 11are, independently of each other, H, a straight-chain or branched-chain, substituted or unsubstituted C1-C5 alkyl (e.g., methyl, ethyl, CH2-cyclopropyl, CH2-CH2-O-CH3), a straight-chain or branched-chain, substituted or unsubstituted C1-C5 haloalkyl (e.g., CH2CF3), a straight-chain or branched-chain C1-C5 alkoxy (e.g., O-CH3), R 20 , C(O)R, or S(O)2R; or R 10 and R 11 are joined to each other to form a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., piperazine, piperidine); n is an integer from 0 to 4 (e.g., 1, 2).

[0112] In various embodiments, the compound is not (R)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-N-(3-(4-fluoropiperidin-1-yl)propyl)benzo[d]imidazo[2,1-b]thiazole-7-carboxamide. In various embodiments, the compound is not (S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-N-(3-(4-fluoropiperidin-1-yl)propyl)benzo[d]imidazo[2,1-b]thiazole-7-carboxamide. In various embodiments, the compound is not 2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-N-(3-(4-fluoropiperidin-1-yl)propyl)benzo[d]imidazo[2,1-b]thiazole-7-carboxamide.

[0113] In various embodiments, the present invention relates to a compound represented by the following structural formula I(l), or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, N-oxide, reverse amide analog, prodrug, isotope variant (e.g., deuterated analog), PROTAC, pharmaceutical, or any combination thereof.

[0114]

Chemical formula

[0115] In the formula, X2, X3, and X4 are, independently of one another, nitrogen or CH; X 10 is N, CH, or C(R) (for example, C(CH2)OH, C(CH2)2-OH, C(NH-CH2-cyclopropyl), C(CH3), C(cyclopropyl), C(isopropoxy), C(COOH)); R5 is H, or a linear or branched alkyl of C1-C5 (for example, methyl); R6 is H, F, Cl, Br, I, OH, SH, R8-OH, R8-SH, -R8-O-R 10 (for example, CH2-O-CH3, (CH2)2-O-CH3, (CH2)3-O-CH3, (CH3)2-O-CH(CH3)2), R8-S-R 10 (for example, (CH2)3-S-(CH2)2CH3), R8-NHC(O)-R 10 , -O-R8-R 10 , R8-(a substituted or unsubstituted cycloalkyl of C3-C8) (for example, CH2-cyclopropyl, CH2-cyclobutanol, CH2-difluorocyclopropyl, CH2-methylcyclopropyl, CH2-dimethylamino-cyclohexyl, (CH2)2-cyclopentanol, CH2-cyclohexanol), R8-(a substituted or unsubstituted saturated, unsaturated or aromatic monocyclic, fused ring or spiro ring 3- to 10-membered heterocyclic ring) (for example, (CH2)3-pyran, (CH2)2-pyrazole, (CH2)2-imidazole, CH2-tetrahydrofuran, CH2-dioxane, CH2-oxetane, CH2-piperidine, CH2-triazole, CH2-1-oxa-8-azaspiro[4.5]decane, (CH2)3-diazabicyclo[2.2.1]heptane, CH2-methyl-THF, CH2-ethyl-piperidine, CH2-oxa-azaspirodecan, (CH2)3-dimethylpyrazole, CH2-2-oxo-methylpyrrolidine, CH2-methyl-azetidine, CH2-azaspiroheptane), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R10 )(R 11 )、R8-N(R 10 )(R 11 )(e.g., (CH2)3-4-fluoropiperidine, (CH2)3-N(CH2CH3)2, (CH2)3-N(CH(CH3)2)2, (CH2)3-piperidine, (CH2)4-NH(CH3), (CH2)3-NH-CH3, (CH2)3-NH-CH2CH3, (CH2)3-N(CCH2CH3)2, (CH2)3-NH2, (CH2)3-N(CH2CH3)(CH2CF3)), R8-C(O)N(R 10 )(R 11 )(e.g., (CH2)2-C(O)-piperidine), R9-R8-N(R 10 )(R 11 )(e.g., (CH2)2-C(O)-piperidine), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 、NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 、R8-C(O)-R 10 、C(O)H, C(O)-R 10 、C1-C5 linear or branched C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10), a straight-chain or branched-chain substituted or unsubstituted alkyl of C1-C5 (e.g., CH(CH3)CH2OCH3, CH(CH3)CH2NH2, CH(CH3)C(O)N(CH3)2, CH2-CH(OH)Ph, (CH2)3N(H)CH2CH3, CH(CH3)(CH2)2OH, CH(CH2OH)(CH2CH3), (CH2)3-OCH3, (CH2)2-OCH3, (CH2)2-OCH(CH3)2, CH(CH2OH)(CH2CH(CH3)2), CH2CH(CH3)(OCH3), CH2CH(N(CH3)2)(CH2CH3), benzyl, methyl, ethyl, CH2-CH2-CH2-O-CH3, CH(CH3)C(O)N(CH3)2), a straight-chain or branched-chain substituted or unsubstituted alkenyl of C1-C5, a straight-chain or branched-chain or cyclic haloalkyl of C1-C5 or C3-C8, a straight-chain or branched-chain substituted or unsubstituted or cyclic alkoxy of C1-C5 or C3-C8 (e.g., methoxy, O-(CH2)2-O-CH3) (optionally, at least one methylene group (CH2) in the alkoxy is substituted by an oxygen atom), a straight-chain or branched-chain thioalkoxy of C1-C5, a straight-chain or branched-chain haloalkoxy of C1-C5, a straight-chain or branched-chain alkoxyalkyl of C1-C5, a substituted or unsubstituted cycloalkyl of C3-C8 (e.g., cyclopropyl, cyclobutyl, cyclohexyl, methoxycyclopropyl, methylcyclobutyl, aminomethyl-cyclobutyl, methoxycyclobutyl, 2,3-dihydro-1H-indenol), R8-(substituted or unsubstituted cycloalkyl of C3-C8), a substituted or unsubstituted saturated, unsaturated or aromatic monocyclic, fused-ring, bridged-ring or spiro-ring heterocyclic ring of 3 to 10 members (e.g., piperidine, 1-methylpiperidine, 3-fluoro-1-methylpiperidine, azetidine, 1-methyl-azetidine, morpholine, pyrrolidine, pyrrolidinone, quinuclidine, tetrahydropyran, tetrahydrofuran, azaspiro[3.3]heptane, 8-methyl-8-azabicyclo[3.2.1) is octane, 1,3-dioxane, imidazole, trifluoromethyl-oxetane, hydroxy-tetrahydrofuran, azepan-2-one, azabicyclohexane), substituted or unsubstituted aryl, substituted or unsubstituted R8-aryl (e.g., benzyl), or substituted or unsubstituted benzyl;. Alternatively, R6 and R5 are bonded to each other to form a substituted or unsubstituted 5- to 8-membered heterocyclic ring (e.g., azepane, piperazine, 2-(piperazin-1-yl)acetamide); R7´ and R7´´ are each independently H, F, Cl, Br, I, OH, O-R 20 , SH, R8-OH, R8-SH, -R8-O-R 10 , R8-(C3-C8 cycloalkyl), R8-(3- to 8-membered heterocyclic ring), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R 10 )(R 11 ), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 , R8-C(O)-R 10 , C(O)H, C(O)-R 10 , a C1-C5 straight-chain or branched-chain C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10) C1-C5 linear or branched, substituted or unsubstituted alkyl (e.g., isopropyl, methyl, ethyl), C1-C5 linear or branched, substituted or unsubstituted alkenyl, C1-C5 linear or branched or C3-C8 cyclic haloalkyl (e.g., CHF2), C1-C5 linear or branched or C3-C8 cyclic alkoxy (e.g., methoxy) (optionally, at least one methylene group (CH2) in the alkoxy is replaced by an oxygen atom), C1-C5 linear or branched thioalkoxy, C1-C5 linear or branched haloalkoxy, C1-C5 linear or branched alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclohexyl), substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., morpholine, pyran, oxetane, pyrrolidine, 3,3-difluoropyrrolidine, imidazole, pyrazole, triazole, piperazine, piperidine, piperidin-2-one, piperidin-4-ol, dioxazole, 2-oxopyrrolidine), substituted or unsubstituted aryl, or substituted or unsubstituted benzyl; or, R7´ and R7´´ are bonded to each other to form a substituted or unsubstituted saturated, unsaturated or aromatic 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); R 20 is represented by the following structural formula:

[0116]

Chemical formula

[0117] In the formula, R is H, F, Cl, Br, I, OH, SH, alkoxy, NH(R 10 ), NH-CH2-cyclopropyl, N(R 10 )(R 11 ), CF3, CN, NO2, COOH, CO(R 10)(e.g., C(O)CH3), a C1-C5 straight-chain or branched-chain substituted or unsubstituted alkyl (e.g., methyl, ethyl, CH2-OH, CH2-CH2-OH, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a C3-C8 substituted or unsubstituted cycloalkyl, cyclopropyl, a C1-C5 straight-chain or branched-chain alkoxy, isopropoxy, a C1-C5 straight-chain or branched-chain haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , -R8-R 10 (e.g., (CH2)2-O-CH3), a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2-pyridine, 3-pyridine, or 4-pyridine)); R 30 is H, R 20 , F, Cl, Br, I, OH, SH, alkoxy, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), CF3, CN, NO2, a C1-C5 straight-chain or branched-chain substituted or unsubstituted alkyl (e.g., methyl, ethyl, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a C1-C5 straight-chain or branched-chain alkoxy, a C1-C5 straight-chain or branched-chain haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , -R8-R 10(For example, (CH2)2-O-CH3), a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2-pyridine, 3-pyridine, or 4-pyridine)); R 200 is H, R 20 , F, Cl, Br, I, OH, SH, alkoxy, NH2, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), CF3, CN, NO2, a straight-chain or branched-chain substituted or unsubstituted C1-C5 alkyl (e.g., methyl, ethyl, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a straight-chain or branched-chain C1-C5 alkoxy (e.g., methoxy), a straight-chain or branched-chain C1-C5 haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , -R8-R 10 (e.g., (CH2)2-O-CH3), a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2-pyridine, 3-pyridine, or 4-pyridine)); or, R 200 and the carbon atom to which it is attached is C=O or CF2; Each R8, independently of one another, is [CH2] p and p is from 1 to 10; R9 is [CH] q , or [C] q and q is from 2 to 10; R 10 and R 11are, independently of each other, H, a linear or branched, substituted or unsubstituted C1-C5 alkyl (e.g., methyl, ethyl, CH2-cyclopropyl, CH2-CH2-O-CH3), a linear or branched, substituted or unsubstituted C1-C5 haloalkyl (e.g., CH2CF3), a linear or branched C1-C5 alkoxy (e.g., O-CH3), R 20 , C(O)R, or S(O)2R; or R 10 and R 11 are joined to each other to form a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., piperazine, piperidine); n is an integer from 0 to 4 (e.g., 1, 2).

[0118] In various embodiments, R6 of the compound of Structural Formula I(l) is H, a straight-chain or branched-chain substituted or unsubstituted C1-C5 alkyl (e.g., methyl), a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., piperidine, 1-methylpiperidine, 3-fluoro-1-methylpiperidine, azetidine, 1-methyl-azetidine, morpholine, pyrrolidine, pyrrolidinone, quinuclidine, tetrahydropyran, tetrahydrofuran, azaspiro[3.3]heptane, 8-methyl-8-azabicyclo[3.2.1]octane, dioxane, 1,3-dioxane). Each corresponds to a separate embodiment of the present invention. In various embodiments, R6 is H. In various embodiments, R6 is a straight-chain or branched-chain substituted or unsubstituted C1-C5 alkyl. In various embodiments, R6 is methyl. In various embodiments, R6 is a substituted or unsubstituted 3- to 8-membered heterocyclic ring. In various embodiments, R6 is piperidine. In various embodiments, R6 is 1-methylpiperidine. In various embodiments, R6 is 3-fluoro-1-methylpiperidine. In various embodiments, R6 is azetidine. In various embodiments, R6 is 1-methyl-azetidine. In various embodiments, R6 is morpholine. In various embodiments, R6 is tetrahydropyran. In various embodiments, R6 is tetrahydrofuran. In various embodiments, R6 is 8-methyl-8-azabicyclo[3.2.1]octane. In various embodiments, R6 is dioxane. In various embodiments, R6 is 1,3-dioxane.

[0119] In various embodiments, the present invention relates to a compound represented by the following Structural Formula I(m), or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, N-oxide, reverse amide analog, prodrug, isotopic variant (e.g., deuterated analog), PROTAC, pharmaceutical, or any combination thereof.

[0120]

Chemical Formula

[0121] In the formula, X2, X3, and X4 are, independently of one another, nitrogen or CH; X5, X6, X7, X8, and X9 are, independently of one another, a nitrogen atom or a carbon atom; X 10 is N, CH, or C(R) (for example, C(CH2)OH, C(CH2)2-OH, C(NH-CH2-cyclopropyl), C(CH3), C(cyclopropyl), C(isopropoxy), C(COOH)); W1 is CH2, C=O, or CH(R 10 )(for example, CHCH3); Ring F is absent or is a substituted or unsubstituted saturated or unsaturated 4- to 8-membered heterocyclic ring (for example, pyrrolidine, morpholine, 1-methylpyrrolidine, pyrrolidin-2-one, pyrrolidin-3-one, 3,3-difluoropyrrolidine, pyrrolidin-3-ol, 3-methoxypyrrolidine, 3-(difluoromethyl)pyrrolidine, pyrrolidine-3-carbonitrile, pyridine, piperidine, piperidin-2-one, imidazole, pyrimidine, triazole, oxadiazole, pyrazole); R1 and R2 are, independently of one another, H, F, Cl, Br, I, OH, SH, CF3, a substituted or unsubstituted C1-C5 alkyl (for example, CH2OH), a linear or branched C1-C5 or cyclic C3-C8 haloalkyl, or a substituted or unsubstituted linear or branched C1-C5 or cyclic C3-C8 alkoxy; or R1 and R2 are bonded to each other to form a 3- to 8-membered carbocyclic or heterocyclic ring (for example, cyclopropyl); Alternatively, R2 and R4 are joined to each other to form the F ring defined above (e.g., pyrrolidine, morpholine, 1-methylpyrrolidine, pyrrolidin-2-one, pyrrolidin-3-one, 3,3-difluoropyrrolidine, pyrrolidin-3-ol, 3-methoxypyrrolidine, 3-(difluoromethyl)pyrrolidine, pyrrolidine-3-carbonitrile, pyridine, piperidine, piperidin-2-one, imidazole, pyrimidine, triazole, oxadiazole, pyrazole); However, when the ring F is aromatic, R1 and / or R3 do not exist; R3 and R4 are, independently of each other, H, Me, C1-C5 substituted or unsubstituted alkyl (e.g., methoxyethylene, methylaminoethyl, aminoethyl), -R8-O-R 10 (e.g., (CH2)2-O-CH3), R8-N(R 10 )(R 11 )(e.g., (CH2)2-NH(CH3)), C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl), substituted or unsubstituted 5- to 7-membered heterocyclic ring (e.g., pyrrolidine, methylpyrrolidine, piperidine), or R 20 ; Alternatively, R3 and R4 are joined to each other to form a 3- to 8-membered heterocyclic ring (e.g., pyrrolidine, pyrrolidone, 2-oxopyrrolidine, piperidine, morpholine, piperazine, imidazole); R7´ and R7´´ are, independently of each other, Br, I, OH, O-R 20 , SH, R8-OH, R8-SH, SR 10 , -R8-O-R 10 , -R8-S-R 10 , R8-(C3-C8 cycloalkyl), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R 10 )(R 11)、B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 (COO-CH3), R8-C(O)-R 10 , C(O)H, C(O)-R 10 , a straight-chain or branched C1-C5 C(O)-haloalkyl, -C(O)NH2, C(O)NHR (e.g., C(O)NH(CH3)), C(O)N(R 10 )(R 11 )(e.g., C(O)NH(CH3), C(O)NH(CH2CH2OCH3), C(O)NH(CH2CH2OH)), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10), C1-C5 linear or branched substituted or unsubstituted alkyl (e.g., methylimidazole, methyl, ethyl), C1-C5 linear or branched substituted or unsubstituted alkenyl, C1-C5 linear or branched or C3-C8 cyclic haloalkyl (e.g., CHF2), C1-C5 linear or branched or C3-C8 cyclic alkoxy (e.g., methoxy, ethoxy) (optionally, at least one methylene group (CH2) in the alkoxy is substituted by an oxygen atom), C1-C5 linear or branched thioalkyl, C1-C5 linear or branched thioalkoxy, C1-C5 linear or branched haloalkoxy, C1-C5 linear or branched alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclopropanol, cyclohexyl, bicyclo[1.1.1]pentane), substituted or unsubstituted 4- to 7-membered heterocyclic ring (e.g., morpholine, tetrahydropyran, tetrahydropyran, oxetane, oxetan-3-ol, pyrrolidine, pyrrolidin-2-ol, pyrrolidin-3-ol, 1-methylpyrrolidine, pyrrolidin-2-one, pyrrolidin-3-one, 3-cyanopyrrolidine, pyrrolidinone, imidazole, pyrazole, isoxazolidine, piperazine, piperidine, piperidin-3-ol, piperidin-4-ol, piperidin-2-one, piperidin-4-carbonitrile, 4-fluoropiperidine, oxadiazole, triazole, pyrazole, 2-oxopyrrolidine, 4,7-diazaspiro[2.5]octane, 2,5-diazabicyclo[2.2.1]heptane, piperazin-2-one), R8-(substituted or unsubstituted monocyclic, fused-ring or spiro-ring 3- to 8-membered heterocyclic ring), substituted or unsubstituted aryl, or substituted or unsubstituted benzyl; or, R7′ and R7″ are bonded to each other to form a substituted or unsubstituted saturated, unsaturated or aromatic 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); R 20 is represented by the following structural formula:

[0122] [Chemical formula]

[0123] In the formula, R is H, F, Cl, Br, I, OH, SH, alkoxy, NH(R 10 ), NH-CH2-cyclopropyl, N(R 10 )(R 11 ), CF3, CN, NO2, COOH, CO(R 10 )(for example, C(O)CH3), a linear or branched substituted or unsubstituted alkyl having 1 to 5 carbon atoms (for example, methyl, ethyl, CH2-OH, CH2-CH2-OH, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a substituted or unsubstituted cycloalkyl having 3 to 8 carbon atoms, cyclopropyl, a linear or branched alkoxy having 1 to 5 carbon atoms, isopropoxy, a linear or branched haloalkyl having 1 to 5 carbon atoms (for example, CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (for example, CH2-Ph), -R8-O-R8-O-R 10 (for example, (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , -R8-R 10 (for example, (CH2)2-O-CH3), a substituted or unsubstituted aryl (for example, phenyl), or a substituted or unsubstituted heteroaryl (for example, pyridine (2-pyridine, 3-pyridine, or 4-pyridine)); R 30 is H, R 20 , F, Cl, Br, I, OH, SH, alkoxy, N(R)2, NH(R 10 ), N(R 10 )(R 11)、CF3, CN, NO2, a linear or branched, substituted or unsubstituted C1-C5 alkyl (e.g., methyl, ethyl, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a linear or branched C1-C5 alkoxy, a linear or branched C1-C5 haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , -R8-R 10 (e.g., (CH2)2-O-CH3), a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2-pyridine, 3-pyridine, or 4-pyridine)); Each R8 is, independently of one another, [CH2] p and p is from 1 to 10; R9 is [CH] q or [C] q and q is from 2 to 10; R 10 and R 11 are, independently of one another, H, a linear or branched, substituted or unsubstituted C1-C5 alkyl (e.g., methyl, ethyl, CH2-cyclopropyl, CH2-CH2-O-CH3), a linear or branched, substituted or unsubstituted C1-C5 haloalkyl (e.g., CH2CF3), a linear or branched C1-C5 alkoxy (e.g., O-CH3), R 20 , C(O)R, or S(O)2R; or R 10 and R 11 are joined to each other to form a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., piperazine, piperidine); n is an integer from 0 to 4 (e.g., 1, 2).

[0124] In various embodiments, the present invention relates to a compound represented by the following structural formula I(n), or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, N-oxide, reverse amide analog, prodrug, isotopic variant (e.g., deuterated analog), PROTAC, pharmaceutical, or any combination thereof.

[0125]

Chemical formula

[0126] Wherein, X2, X3, and X4 are each independently nitrogen or CH; X 10 is N, CH, or C(R) (e.g., C(CH2)OH, C(CH2)2-OH, C(NH-CH2-cyclopropyl), C(CH3), C(cyclopropyl), C(isopropoxy), C(COOH)); Ring W is a saturated, unsaturated or aromatic monocyclic, fused ring, bridged ring or spiro ring of 3- to 10-membered carbocyclic or heterocyclic ring (e.g., morpholine, tetrahydrofuran, tetrahydropyran, oxetane, oxetan-3-ol, pyrrolidine, pyrrolidin-2-ol, pyrrolidin-3-ol, 3-methoxypyrrolidine, 3-cyanopyrrolidine, 1-methylpyrrolidine, 3-(difluoromethyl)pyrrolidine, 3,3-difluoropyrrolidine, pyrrolidin-2-one, pyrrolidin-3-one, pyrrolidinone, imidazole, pyrazole, isoxazolidine, piperazine, piperidine, piperidin-3-ol, piperidin-4-ol, piperidin-2-one, piperidine-4-carbonitrile, 4-fluoropiperidine, oxadiazole, triazole, 2-oxopyrrolidine, cyclopropyl, 2,2-dimethylpyrrolidine, 4-azaspiro[2.4]heptane, pyrrolidin-3-one-O-methyloxime, 2-oxa-5-azaspiro[3.4]octane, 1,4-dioxa-6-azaspiro[4.4]nonane, 3,3-dimethylmorpholine, 1-methylpiperazine, 4,7-diazaspiro[2.5]octane, bicyclo[1.1.1]pentane, 2,5-diazabicyclo[2.2.1]heptane, piperazine, piperazin-2-one); W1 is CH2, C=O, or CH(R 10 )(e.g., CHCH3); R5 is H, or a linear or branched alkyl of C1-C5 (e.g., methyl); R6 is H, F, Cl, Br, I, OH, SH, R8-OH, R8-SH, -R8-O-R 10 (e.g., CH2-O-CH3, (CH2)2-O-CH3, (CH2)3-O-CH3, (CH3)2-O-CH(CH3)2), R8-S-R 10 (e.g., (CH2)3-S-(CH2)2CH3), R8-NHC(O)-R 10 , -O-R8-R 10, R8-(C3-C8 substituted or unsubstituted cycloalkyl) (e.g., CH2-cyclopropyl, CH2-cyclobutanol, CH2-difluorocyclopropyl, CH2-methylcyclopropyl, CH2-dimethylamino-cyclohexyl, (CH2)2-cyclopentanol, CH2-cyclohexanol), R8-(substituted or unsubstituted saturated, unsaturated or aromatic monocyclic, fused ring or spiro ring 3-10 membered heterocyclic ring) (e.g., (CH2)3-pyran, (CH2)2-pyrazole, (CH2)2-imidazole, CH2-tetrahydrofuran, CH2-dioxane, CH2-oxetane, CH2-piperidine, CH2-triazole, CH2-1-oxa-8-azaspiro[4.5]decane, (CH2)3-diazabicyclo[2.2.1]heptane, CH2-methyl-THF, CH2-ethyl-piperidine, CH2-oxa-azaspirodecan, (CH2)3-dimethylpyrazole, CH2-2-oxo-methylpyrrolidine, CH2-methyl-azetidine, CH2-azaspiroheptane), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ) (e.g., (CH2)3-4-fluoropiperidine, (CH2)3-N(CH2CH3)2, (CH2)3-N(CH(CH3)2)2, (CH2)3-piperidine, (CH2)4-NH(CH3), (CH2)3-NH-CH3, (CH2)3-NH-CH2CH3, (CH2)3-N(CCH2CH3)2, (CH2)3-NH2, (CH2)3-N(CH2CH3)(CH2CF3)), R8-C(O)N(R 10 )(R 11 ) (e.g., (CH2)2-C(O)-piperidine), R9-R8-N(R 10 )(R 11 ) (e.g., (CH2)2-C(O)-piperidine), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R10 , R8-C(O)-R 10 , C(O)H, C(O)-R 10 , a linear or branched C1-C5 C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10) C1-C5 linear or branched, substituted or unsubstituted alkyl (e.g., CH(CH3)CH2OCH3, CH(CH3)CH2NH2, CH(CH3)C(O)N(CH3)2, CH2-CH(OH)Ph, (CH2)3N(H)CH2CH3, CH(CH3)(CH2)2OH, CH(CH2OH)(CH2CH3), (CH2)3-OCH3, (CH2)2-OCH3, (CH2)2-OCH(CH3)2, CH(CH2OH)(CH2CH(CH3)2), CH2CH(CH3)(OCH3), CH2CH(N(CH3)2)(CH2CH3), benzyl, methyl, ethyl, CH2-CH2-CH2-O-CH3, CH(CH3)C(O)N(CH3)2), C1-C5 linear or branched, substituted or unsubstituted alkenyl, C1-C5 linear or branched or C3-C8 cyclic haloalkyl, C1-C5 linear or branched, substituted or unsubstituted or C3-C8 cyclic alkoxy (e.g., methoxy, O-(CH2)2-O-CH3) (optionally, at least one methylene group (CH2) in the alkoxy is replaced by an oxygen atom), C1-C5 linear or branched thioalkoxy, C1-C5 linear or branched haloalkoxy, C1-C5 linear or branched alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclohexyl, methoxycyclopropyl, methylcyclobutyl, aminomethyl-cyclobutyl, methoxycyclobutyl, 2,3-dihydro-1H-indenol), R8-(C3-C8 substituted or unsubstituted cycloalkyl), substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., piperidine, 1-methylpiperidine, 3-fluoro-1-methylpiperidine, azetidine, 1-methyl-azetidine, morpholine, pyrrolidine, pyrrolidinone, quinuclidine, tetrahydropyran, tetrahydrofuran, azaspiro[3.3]heptane, 8-methyl-8-azabicyclo[3.2.1) is octane, 1,3 - dioxane, imidazole, trifluoromethyl - oxetane, hydroxy - tetrahydrofuran, azepan - 2 - one, azabicyclohexane), substituted or unsubstituted aryl, substituted or unsubstituted R8 - aryl (e.g., benzyl), or substituted or unsubstituted benzyl;. Or, R6 and R5 are bonded to each other to form a substituted or unsubstituted 5 - to 8 - membered heterocyclic ring (e.g., azepane, piperazine, 2 - (piperazin - 1 - yl) acetamide); R7´ and R7´´ are, independently of each other, H, F, Cl, Br, I, OH, O - R 20 , SH, R8 - OH, R8 - SH, - R8 - O - R 10 , R8 - (C3 - C8 cycloalkyl), R8 - (3 - to 8 - membered heterocyclic ring), CF3, CD3, OCD3, CN, NO2, - CH2CN, - R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8 - N(R 10 )(R 11 ), R9 - R8 - N(R 10 )(R 11 ), B(OH)2, - OC(O)CF3, - OCH2Ph, NHC(O) - R 10 , NHCO - N(R 10 )(R 11 ), COOH, - C(O)Ph, C(O)O - R 10 , R8 - C(O) - R 10 , C(O)H, C(O) - R 10 , C1 - C5 straight - chain or branched - chain C(O) - haloalkyl, - C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH - R 10) C1-C5 straight-chain or branched-chain substituted or unsubstituted alkyl (e.g., isopropyl, methyl, ethyl), C1-C5 straight-chain or branched-chain substituted or unsubstituted alkenyl, C1-C5 straight-chain or branched-chain or C3-C8 cyclic haloalkyl (e.g., CHF2), C1-C5 straight-chain or branched-chain or C3-C8 cyclic alkoxy (e.g., methoxy) (optionally, at least one methylene group (CH2) in the alkoxy is substituted by an oxygen atom), C1-C5 straight-chain or branched-chain thioalkoxy, C1-C5 straight-chain or branched-chain haloalkoxy, C1-C5 straight-chain or branched-chain alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclohexyl), substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., morpholine, pyran, oxetane, pyrrolidine, 3,3-difluoropyrrolidine, imidazole, pyrazole, triazole, piperazine, piperidine, piperidin-2-one, piperidin-4-ol, dioxazole, 2-oxopyrrolidine), substituted or unsubstituted aryl, or substituted or unsubstituted benzyl; Or, R7´ and R7´´ are bonded to each other to form a substituted or unsubstituted saturated, unsaturated or aromatic 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); R 20 Is represented by the following structural formula:

[0127]

Chemical formula

[0128] In the formula, R is H, F, Cl, Br, I, OH, SH, alkoxy, NH(R 10 )、NH-CH2-cyclopropyl, N(R 10 )(R 11 )、CF3、CN、NO2、COOH、CO(R 10)(e.g., C(O)CH3), a C1-C5 straight-chain or branched-chain substituted or unsubstituted alkyl (e.g., methyl, ethyl, CH2-OH, CH2-CH2-OH, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a C3-C8 substituted or unsubstituted cycloalkyl, cyclopropyl, a C1-C5 straight-chain or branched-chain alkoxy, isopropoxy, a C1-C5 straight-chain or branched-chain haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , -R8-R 10 (e.g., (CH2)2-O-CH3), a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2-pyridine, 3-pyridine, or 4-pyridine)); R 30 is H, R 20 , F, Cl, Br, I, OH, SH, alkoxy, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), CF3, CN, NO2, a C1-C5 straight-chain or branched-chain substituted or unsubstituted alkyl (e.g., methyl, ethyl, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a C1-C5 straight-chain or branched-chain alkoxy, a C1-C5 straight-chain or branched-chain haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , -R8-R 10(e.g., (CH2)2 - O - CH3), a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2 - pyridine, 3 - pyridine, or 4 - pyridine)); R 200 is H, R 20 , F, Cl, Br, I, OH, SH, alkoxy, NH2, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), CF3, CN, NO2, a C1 - C5 straight - chain or branched - chain substituted or unsubstituted alkyl (e.g., methyl, ethyl, CH2 - CH2 - O - CH2 - CH2 - O - CH3, CH2 - O - CH2 - CH2 - O - CH3), a C1 - C5 straight - chain or branched - chain alkoxy (e.g., methoxy), a C1 - C5 straight - chain or branched - chain haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8 - aryl (e.g., CH2 - Ph), - R8 - O - R8 - O - R 10 (e.g., (CH2)2 - O - (CH2)2 - O - CH3), - R8 - O - R 10 , - R8 - R 10 (e.g., (CH2)2 - O - CH3), a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2 - pyridine, 3 - pyridine, or 4 - pyridine)); or, R 200 and the carbon atom to which it is attached is C = O or CF2; Each R8, independently of one another, is [CH2] p and p is from 1 to 10; R9 is [CH] q , or [C] q and q is from 2 to 10; R 10 and R 11are, independently of each other, H, a linear or branched, substituted or unsubstituted C1-C5 alkyl (e.g., methyl, ethyl, CH2-cyclopropyl, CH2-CH2-O-CH3), a linear or branched, substituted or unsubstituted haloalkyl of C1-C5 (e.g., CH2CF3), a linear or branched alkoxy of C1-C5 (e.g., O-CH3), R 20 , C(O)R, or S(O)2R; or R 10 and R 11 are joined to each other to form a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., piperazine, piperidine); n is an integer from 0 to 4 (e.g., 1, 2).

[0129] In various embodiments, the compound is not (R)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-N-(3-(4-fluoropiperidin-1-yl)propyl)benzo[d]imidazo[2,1-b]thiazole-7-carboxamide. In various embodiments, the compound is not (S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-N-(3-(4-fluoropiperidin-1-yl)propyl)benzo[d]imidazo[2,1-b]thiazole-7-carboxamide. In various embodiments, the compound is not 2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-N-(3-(4-fluoropiperidin-1-yl)propyl)benzo[d]imidazo[2,1-b]thiazole-7-carboxamide.

[0130] In various embodiments, the present invention relates to a compound represented by the following structural formula I(o), or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, N-oxide, reverse amide analogue, prodrug, isotope variant (e.g., deuterated analogue), PROTAC, pharmaceutical, or any combination thereof.

[0131]

Chemical formula

[0132] In the formula, X2, X3, and X4 are, independently of each other, nitrogen or CH; X5, X6, X7, X8, and X9 are, independently of each other, a nitrogen atom or a carbon atom; X 10 is N, CH, or C(R) (for example, C(CH2)OH, C(CH2)2-OH, C(NH-CH2-cyclopropyl), C(CH3), C(cyclopropyl), C(isopropoxy), C(COOH)); R1 is H, F, Cl, Br, I, OH, SH, CF3, a C1-C5 substituted or unsubstituted alkyl (for example, CH2OH), a C1-C5 straight-chain or branched-chain or C3-C8 cyclic haloalkyl, a substituted or unsubstituted C1-C5 straight-chain or branched-chain or C3-C8 cyclic alkoxy; R2 is a C1-C5 substituted or unsubstituted alkyl (for example, CH2OH, CH2OCH3), a 3- to 8-membered carbocyclic or heterocyclic ring (for example, oxetane); or, R1 and R2 are bonded to each other to form a 3- to 8-membered carbocyclic or heterocyclic ring (for example, cyclopropyl, oxetane); R3 and R4 are, independently of each other, H, Me, a C1-C5 substituted or unsubstituted alkyl (for example, methoxyethylene, methylaminoethyl, aminoethyl), -R8-O-R 10 (for example, (CH2)2-O-CH3), R8-N(R 10 )(R 11 )(for example, (CH2)2-NH(CH3)), a C3-C8 substituted or unsubstituted cycloalkyl (for example, cyclopropyl), a substituted or unsubstituted 5- to 7-membered heterocyclic ring (for example, pyrrolidine, methylpyrrolidine, piperidine), or, R 20 is; Alternatively, R3 and R4 are bonded to each other to form a 3- to 8-membered heterocyclic ring (e.g., pyrrolidine, pyrrolidone, 2-oxopyrrolidine, piperidine, morpholine, piperazine, imidazole); R5 is H or a linear or branched alkyl of C1-C5 (e.g., methyl); R6 is H, F, Cl, Br, I, OH, SH, R8-OH, R8-SH, -R8-O-R 10 (e.g., CH2-O-CH3, (CH2)2-O-CH3, (CH2)3-O-CH3, (CH3)2-O-CH(CH3)2), R8-S-R 10 (e.g., (CH2)3-S-(CH2)2CH3), R8-NHC(O)-R 10 , -O-R8-R 10 , R8-(substituted or unsubstituted C3-C8 cycloalkyl) (e.g., CH2-cyclopropyl, CH2-cyclobutanol, CH2-difluorocyclopropyl, CH2-methylcyclopropyl, CH2-dimethylamino-cyclohexyl, (CH2)2-cyclopentanol, CH2-cyclohexanol), R8-(substituted or unsubstituted saturated, unsaturated or aromatic monocyclic, fused ring or spiro ring 3- to 10-membered heterocyclic ring) (e.g., (CH2)3-pyran, (CH2)2-pyrazole, (CH2)2-imidazole, CH2-tetrahydrofuran, CH2-dioxane, CH2-oxetane, CH2-piperidine, CH2-triazole, CH2-1-oxa-8-azaspiro[4.5]decane, (CH2)3-diazabicyclo[2.2.1]heptane, CH2-methyl-THF, CH2-ethyl-piperidine, CH2-oxa-azaspirodecan, (CH2)3-dimethylpyrazole, CH2-2-oxo-methylpyrrolidine, CH2-methyl-azetidine, CH2-azaspiroheptane), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11)(e.g., (CH2)3-4-fluoropiperidine, (CH2)3-N(CH2CH3)2, (CH2)3-N(CH(CH3)2)2, (CH2)3-piperidine, (CH2)4-NH(CH3), (CH2)3-NH-CH3, (CH2)3-NH-CH2CH3, (CH2)3-N(CCH2CH3)2, (CH2)3-NH2, (CH2)3-N(CH2CH3)(CH2CF3)), R8-C(O)N(R 10 )(R 11 )(e.g., (CH2)2-C(O)-piperidine), R9-R8-N(R 10 )(R 11 )(e.g., (CH2)2-C(O)-piperidine), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 , R8-C(O)-R 10 , C(O)H, C(O)-R 10 , C1-C5 linear or branched C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10) C1-C5 linear or branched substituted or unsubstituted alkyl (e.g., CH(CH3)CH2OCH3, CH(CH3)CH2NH2, CH(CH3)C(O)N(CH3)2, CH2-CH(OH)Ph, (CH2)3N(H)CH2CH3, CH(CH3)(CH2)2OH, CH(CH2OH)(CH2CH3), (CH2)3-OCH3, (CH2)2-OCH3, (CH2)2-OCH(CH3)2, CH(CH2OH)(CH2CH(CH3)2), CH2CH(CH3)(OCH3), CH2CH(N(CH3)2)(CH2CH3), benzyl, methyl, ethyl, CH2-CH2-CH2-O-CH3, CH(CH3)C(O)N(CH3)2), C1-C5 linear or branched substituted or unsubstituted alkenyl, C1-C5 linear or branched or C3-C8 cyclic haloalkyl, C1-C5 linear or branched substituted or unsubstituted or C3-C8 cyclic alkoxy (e.g., methoxy, O-(CH2)2-O-CH3) (optionally, at least one methylene group (CH2) in the alkoxy is substituted by an oxygen atom), C1-C5 linear or branched thioalkoxy, C1-C5 linear or branched haloalkoxy, C1-C5 linear or branched alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclohexyl, methoxycyclopropyl, methylcyclobutyl, aminomethyl-cyclobutyl, methoxycyclobutyl, 2,3-dihydro-1H-indenol), R8-(C3-C8 substituted or unsubstituted cycloalkyl), substituted or unsubstituted saturated, unsaturated or aromatic monocyclic, fused ring, bridged ring or spiro ring 3- to 10-membered heterocyclic ring (e.g., piperidine, 1-methylpiperidine, 3-fluoro-1-methylpiperidine, azetidine, 1-methyl-azetidine, morpholine, pyrrolidine, pyrrolidinone, quinuclidine, tetrahydropyran, tetrahydrofuran, azaspiro[3.3]heptane, 8-methyl-8-azabicyclo[3.2.1) is octane, 1,3 - dioxane, imidazole, trifluoromethyl - oxetane, hydroxy - tetrahydrofuran, azepan - 2 - one, azabicyclohexane), substituted or unsubstituted aryl, substituted or unsubstituted R8 - aryl (e.g., benzyl), or substituted or unsubstituted benzyl;. Or, R6 and R5 are bonded to each other to form a substituted or unsubstituted 5 - to 8 - membered heterocyclic ring (e.g., azepane, piperazine, 2 - (piperazin - 1 - yl) acetamide); R7´ and R7´´ are, independently of each other, Br, I, OH, O - R 20 , SH, R8 - OH, R8 - SH, SR 10 , - R8 - O - R 10 , - R8 - S - R 10 , R8 - (C3 - C8 cycloalkyl), CF3, CD3, OCD3, CN, NO2, - CH2CN, - R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8 - N(R 10 )(R 11 ), R9 - R8 - N(R 10 )(R 11 ), B(OH)2, - OC(O)CF3, - OCH2Ph, NHC(O) - R 10 , NHCO - N(R 10 )(R 11 ), COOH, - C(O)Ph, C(O)O - R 10 (COO - CH3), R8 - C(O) - R 10 , C(O)H, C(O) - R 10 , C1 - C5 straight - chain or branched - chain C(O) - haloalkyl, - C(O)NH2, C(O)NHR (e.g., C(O)NH(CH3)), C(O)N(R 10 )(R 11 )(e.g., C(O)NH(CH3), C(O)NH(CH2CH2OCH3), C(O)NH(CH2CH2OH)), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH - R 10) C1-C5 straight-chain or branched-chain substituted or unsubstituted alkyl (e.g., methylimidazole, methyl, ethyl), C1-C5 straight-chain or branched-chain substituted or unsubstituted alkenyl, C1-C5 straight-chain or branched-chain or C3-C8 cyclic haloalkyl (e.g., CHF2), C1-C5 straight-chain or branched-chain or C3-C8 cyclic alkoxy (e.g., methoxy, ethoxy) (optionally, at least one methylene group (CH2) in the alkoxy is substituted by an oxygen atom), C1-C5 straight-chain or branched-chain thioalkyl, C1-C5 straight-chain or branched-chain thioalkoxy, C1-C5 straight-chain or branched-chain haloalkoxy, C1-C5 straight-chain or branched-chain alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclopropanol, cyclohexyl, bicyclo[1.1.1]pentane), substituted or unsubstituted 4- to 7-membered heterocyclic ring (e.g., morpholine, tetrahydropyran, tetrahydropyran, oxetane, oxetan-3-ol, pyrrolidine, pyrrolidin-2-ol, pyrrolidin-3-ol, 1-methylpyrrolidine, pyrrolidin-2-one, pyrrolidin-3-one, 3-cyanopyrrolidine, pyrrolidinone, imidazole, pyrazole, isoxazolidine, piperazine, piperidine, piperidin-3-ol, piperidin-4-ol, piperidin-2-one, piperidin-4-carbonitrile, 4-fluoropiperidine, oxadiazole, triazole, pyrazole, 2-oxopyrrolidine, 4,7-diazaspiro[2.5]octane, 2,5-diazabicyclo[2.2.1]heptane, piperazin-2-one), R8-(substituted or unsubstituted monocyclic, fused-ring or spiro-ring 3- to 8-membered heterocyclic ring), substituted or unsubstituted aryl, or substituted or unsubstituted benzyl; Or, R7' and R7'' are bonded to each other to form a substituted or unsubstituted saturated, unsaturated or aromatic 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); R 20 is represented by the following structural formula:

[0133]

Chem.

[0134] In the formula, R is H, F, Cl, Br, I, OH, SH, alkoxy, NH(R 10 ), NH-CH2-cyclopropyl, N(R 10 )(R 11 ), CF3, CN, NO2, COOH, CO(R 10 )(e.g., C(O)CH3), a linear or branched substituted or unsubstituted C1-C5 alkyl (e.g., methyl, ethyl, CH2-OH, CH2-CH2-OH, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a substituted or unsubstituted C3-C8 cycloalkyl, cyclopropyl, a linear or branched C1-C5 alkoxy, isopropoxy, a linear or branched C1-C5 haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , -R8-R 10 (e.g., (CH2)2-O-CH3), a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2-pyridine, 3-pyridine, or 4-pyridine)); R 30 is H, R 20 , F, Cl, Br, I, OH, SH, alkoxy, N(R)2, NH(R 10 ), N(R 10 )(R 11)、CF3, CN, NO2, a straight-chain or branched-chain, substituted or unsubstituted alkyl having 1 to 5 carbon atoms (e.g., methyl, ethyl, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a straight-chain or branched-chain alkoxy having 1 to 5 carbon atoms, a straight-chain or branched-chain haloalkyl having 1 to 5 carbon atoms (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , -R8-R 10 (e.g., (CH2)2-O-CH3), substituted or unsubstituted aryl (e.g., phenyl), or substituted or unsubstituted heteroaryl (e.g., pyridine (2-pyridine, 3-pyridine, or 4-pyridine)); Each R8 is independently of one another, [CH2] p and p is from 1 to 10; R9 is [CH] q , or [C] q and q is from 2 to 10; R 10 and R 11 are independently of one another, H, a straight-chain or branched-chain, substituted or unsubstituted alkyl having 1 to 5 carbon atoms (e.g., methyl, ethyl, CH2-cyclopropyl, CH2-CH2-O-CH3), a straight-chain or branched-chain, substituted or unsubstituted haloalkyl having 1 to 5 carbon atoms (e.g., CH2CF3), a straight-chain or branched-chain alkoxy having 1 to 5 carbon atoms (e.g., O-CH3), R 20 , C(O)R, or S(O)2R; or R 10 and R 11 are joined to one another to form a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., piperazine, piperidine); n is an integer from 0 to 4 (e.g., 1, 2).

[0135] In various embodiments, R7´ is F. In various embodiments, R7´´ is H. In various embodiments, R1 is H. In various embodiments, R2 is a substituted C1-C5 alkyl. In various embodiments, R2 is CH2OH. In various embodiments, R2 is CH2OCH3. In various embodiments, R2 is a 3- to 8-membered heterocyclic ring. In various embodiments, R2 is oxetane. In various embodiments, R2 is 3-oxetane or 2-oxetane. Each corresponds to a separate embodiment of the invention. In various embodiments, R6 is H. In various embodiments, R6 is a straight-chain or branched-chain, substituted or unsubstituted C1-C5 alkyl. In various embodiments, R6 is methyl. In various embodiments, R6 is a substituted or unsubstituted saturated or unsaturated monocyclic, fused-ring, bridged-ring, or spiro-ring 3- to 10-membered heterocyclic ring. In various embodiments, R6 is a substituted or unsubstituted saturated monocyclic 3- to 8-membered heterocyclic ring. In various embodiments, the heterocyclic ring is tetrahydropyran. In various embodiments, R7´ is F, R1 is H, and R6 is an unsubstituted C1-C5 straight-chain or branched-chain alkyl, or a substituted or unsubstituted saturated monocyclic 3- to 8-membered heterocyclic ring. In various embodiments, R7´ is F, R1 is H, and R6 is methyl.

[0136] In various embodiments, the present invention relates to a compound represented by the following structural formula II, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, N-oxide, reverse amide analog, prodrug, isotopic variant (e.g., deuterated analog), PROTAC, pharmaceutical, or any combination thereof.

[0137] [Chemical formula] Wherein, X2, X3, and X4 are each independently CH; X5, X6, X7, X8, and X9 are each independently a nitrogen atom or a carbon atom; X 10is N, CH, or C(R) (for example, C(CH2)OH, C(CH2)2-OH, C(NH-CH2-cyclopropyl), C(CH3), C(cyclopropyl), C(isopropoxy), C(COOH)); R5 is H, or a straight-chain or branched-chain alkyl of C1-C5 (for example, methyl); R6 is H, F, Cl, Br, I, OH, SH, R8-OH, R8-SH, -R8-O-R 10 (for example, CH2-O-CH3, (CH2)2-O-CH3, (CH2)3-O-CH3, (CH3)2-O-CH(CH3)2), R8-S-R 10 (for example, (CH2)3-S-(CH2)2CH3), R8-NHC(O)-R 10 , -O-R8-R 10 , R8-(a substituted or unsubstituted C3-C8 cycloalkyl) (for example, CH2-cyclopropyl, CH2-cyclobutanol, CH2-difluorocyclopropyl, CH2-methylcyclopropyl, CH2-dimethylamino-cyclohexyl, (CH2)2-cyclopentanol, CH2-cyclohexanol), R8-(a substituted or unsubstituted saturated, unsaturated or aromatic monocyclic, fused-ring or spiro-ring 3- to 10-membered heterocyclic ring) (for example, (CH2)3-pyran, (CH2)2-pyrazole, (CH2)2-imidazole, CH2-tetrahydrofuran, CH2-dioxane, CH2-oxetane, CH2-piperidine, CH2-triazole, CH2-1-oxa-8-azaspiro[4.5]decane, (CH2)3-diazabicyclo[2.2.1]heptane, CH2-methyl-THF, CH2-ethyl-piperidine, CH2-oxa-azaspirodecane, (CH2)3-dimethylpyrazole, CH2-2-oxo-methylpyrrolidine, CH2-methyl-azetidine, CH2-azaspiroheptane), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11)(e.g., (CH2)3-4-fluoropiperidine, (CH2)3-N(CH2CH3)2, (CH2)3-N(CH(CH3)2)2, (CH2)3-piperidine, (CH2)4-NH(CH3), (CH2)3-NH-CH3, (CH2)3-NH-CH2CH3, (CH2)3-N(CCH2CH3)2, (CH2)3-NH2, (CH2)3-N(CH2CH3)(CH2CF3)), R8-C(O)N(R 10 )(R 11 )(e.g., (CH2)2-C(O)-piperidine), R9-R8-N(R 10 )(R 11 )(e.g., (CH2)2-C(O)-piperidine), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 、NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 、R8-C(O)-R 10 、C(O)H, C(O)-R 10 、a C1-C5 linear or branched C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10), a C1-C5 linear or branched substituted or unsubstituted alkyl (e.g., CH(CH3)CH2OCH3, CH(CH3)CH2NH2, CH(CH3)C(O)N(CH3)2, CH2-CH(OH)Ph, (CH2)3N(H)CH2CH3, CH(CH3)(CH2)2OH, CH(CH2OH)(CH2CH3), (CH2)3-OCH3, (CH2)2-OCH3, (CH2)2-OCH(CH3)2, CH(CH2OH)(CH2CH(CH3)2), CH2CH(CH3)(OCH3), CH2CH(N(CH3)2)(CH2CH3), benzyl, methyl, ethyl, CH2-CH2-CH2-O-CH3, CH(CH3)C(O)N(CH3)2), a C1-C5 linear or branched substituted or unsubstituted alkenyl, a C1-C5 linear or branched or C3-C8 cyclic haloalkyl, a C1-C5 linear or branched substituted or unsubstituted or C3-C8 cyclic alkoxy (e.g., methoxy, O-(CH2)2-O-CH3) (optionally, at least one methylene group (CH2) in the alkoxy is replaced by an oxygen atom), a C1-C5 linear or branched thioalkoxy, a C1-C5 linear or branched haloalkoxy, a C1-C5 linear or branched alkoxyalkyl, a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclohexyl, methoxycyclopropyl, methylcyclobutyl, aminomethyl-cyclobutyl, methoxycyclobutyl, 2,3-dihydro-1H-indenol), R8-(C3-C8 substituted or unsubstituted cycloalkyl), a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., piperidine, 1-methylpiperidine, 3-fluoro-1-methylpiperidine, azetidine, 1-methyl-azetidine, morpholine, pyrrolidine, pyrrolidinone, quinuclidine, tetrahydropyran, tetrahydrofuran, azaspiro[3.3]heptane, 8-methyl-8-azabicyclo[3.2.1) is octane, 1,3 - dioxane, imidazole, trifluoromethyl - oxetane, hydroxy - tetrahydrofuran, azepan - 2 - one, azabicyclohexane), a substituted or unsubstituted aryl, a substituted or unsubstituted R8 - aryl (e.g., benzyl), or a substituted or unsubstituted benzyl;. or, R6 and R5 are bonded to each other to form a substituted or unsubstituted 5 - to 8 - membered heterocyclic ring (e.g., azepane, piperazine, 2 - (piperazin - 1 - yl) acetamide); or, R6 is represented by the following structural formula B or structural formula Bi:

[0138]

Chemical formula

[0139] In the formula, m is 0 or 1; R 12 is R 20 , or C1 - C5 C(O) - alkyl, and R 13 is R 30 ; or, R 12 and R 13 are both H; or, R 12 and R 13 are, independently of each other, H, or C1 - C5 substituted or unsubstituted alkyl (e.g., ethyl, trifluoroethyl); or, R 12 and C3 are bonded to each other to form ring A, and R 13 is R 30 ; or, R 12 and R 13 are bonded to each other to form ring B; or, R 12 and C1 are bonded to each other to form ring C, and R 13 is R 30 ; or, C1 and C3 are bonded to each other to form ring D, and R 12 and R 13are independent of each other and are R 30 ; or, R 13 and C2 are bonded to each other to form an E ring, m is 1, and R 12 is R 30 ; or, R 12 and R 13 are bonded to each other to form a B ring, and C1 and C3 are bonded to each other to form a D ring; The A ring, C ring, and E ring are, independent of each other, a substituted or unsubstituted monocyclic, spiro, or fused 3- to 8-membered heterocyclic ring (e.g., A: pyrrolidine, methylpyrrolidine, ethylpyrrolidine; C: piperidine, pyrrolidine, methyl-2-oxopyrrolidine, pyran-pyrrolidine, methyl-azetidine, azabicyclooctane, 2-azabicyclo[2.1.1]hexane, 2-azaspiro[3.3]heptane; E: pyrrolidine, azetidine, ethylpyrrolidine, oxopyrrolidine, methylpiperidine); The B ring is a substituted or unsubstituted monocyclic, spiro, or fused 3- to 8-membered heterocyclic ring (B: piperidine, piperidin-2-one, 4-fluoropiperidin-2-one, piperidine-4-carbonitrile, 4-fluoropiperidine, 4-fluoro-2-methylpiperidine, methylpiperidine, fluoropiperidine, difluoropiperidine, pyrrolidine, piperazine, methylpyrrolidine, thiomorpholine 1,1-dioxide, 2-oxa-6-azaspiro[3.3]heptane, methylpiperazine, dimethylpyrazole, imidazole, 2-methyl-2,5-diazabicyclo[2.2.1]heptane, hydroxymethyl-pyrrolidine, 6-fluoro-3-azabicyclo[3.1.1]heptane); The D ring is a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclobutane, cyclohexane); R7 is Br, I, OH, O-R 20 , SH, R8-OH, R8-SH, SR 10 , -R8-O-R 10 , -R8-S-R 10, R8-(C3-C8 cycloalkyl), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R 10 )(R 11 ), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 (COO-CH3), R8-C(O)-R 10 , C(O)H, C(O)-R 10 , C1-C5 linear or branched C(O)-haloalkyl, -C(O)NH2, C(O)NHR (e.g., C(O)NH(CH3)), C(O)N(R 10 )(R 11 )(e.g., C(O)NH(CH3), C(O)NH(CH2CH2OCH3), C(O)NH(CH2CH2OH)), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10) C1-C5 linear or branched substituted or unsubstituted alkyl (e.g., methylimidazole, methyl, ethyl), C1-C5 linear or branched substituted or unsubstituted alkenyl, C1-C5 linear or branched or C3-C8 cyclic haloalkyl (e.g., CHF2), C1-C5 linear or branched or C3-C8 cyclic alkoxy (e.g., methoxy, ethoxy) (optionally, at least one methylene group (CH2) in the alkoxy is replaced by an oxygen atom), C1-C5 linear or branched thioalkyl, C1-C5 linear or branched thioalkoxy, C1-C5 linear or branched haloalkoxy, C1-C5 linear or branched alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclopropanol, cyclohexyl, bicyclo[1.1.1]pentane), substituted or unsubstituted 4- to 7-membered heterocyclic ring (e.g., morpholine, tetrahydropyran, tetrahydropyran, oxetane, oxetan-3-ol, pyrrolidine, pyrrolidin-2-ol, pyrrolidin-3-ol, 1-methylpyrrolidine, pyrrolidin-2-one, pyrrolidin-3-one, 3-cyanopyrrolidine, pyrrolidinone, imidazole, pyrazole, isoxazolidine, piperazine, piperidine, piperidin-3-ol, piperidin-4-ol, piperidin-2-one, piperidin-4-carbonitrile, 4-fluoropiperidine, oxadiazole, triazole, pyrazole, 2-oxopyrrolidine, 4,7-diazaspiro[2.5]octane, 2,5-diazabicyclo[2.2.1]heptane, piperazin-2-one), R8-(substituted or unsubstituted monocyclic, fused-ring or spiro-ring 3- to 8-membered heterocyclic ring), substituted or unsubstituted aryl, or substituted or unsubstituted benzyl; Or, R7 is represented by the following structural formula A:

[0140]

Chemical formula

[0141] In the formula, X1 is N or O; R1 and R2 are, independently of one another, H, F, Cl, Br, I, OH, SH, CF3, C1-C5 substituted or unsubstituted alkyl (e.g., CH2OH), C1-C5 straight-chain or branched-chain, or C3-C8 cyclic haloalkyl, C1-C5 straight-chain or branched-chain substituted or unsubstituted or C3-C8 cyclic alkoxy; or R1 and R2 are joined to one another to form a C3-C8 carbocyclic or heterocyclic ring (e.g., cyclopropyl); R3 and R4 are, independently of one another, H, Me, C1-C5 substituted or unsubstituted alkyl (e.g., methoxyethylene, methylaminoethyl, aminoethyl), -R8-O-R 10 (e.g., (CH2)2-O-CH3), R8-N(R 10 )(R 11 )(e.g., (CH2)2-NH(CH3)), C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl), substituted or unsubstituted 5- to 7-membered heterocyclic ring (e.g., pyrrolidine, methylpyrrolidine, piperidine), or, R 20 ; or R3 and R4 are joined to one another to form a 3- to 8-membered heterocyclic ring (e.g., pyrrolidine, pyrrolidone, 2-oxopyrrolidine, piperidine, morpholine, piperazine, imidazole); or R2 and R4 are joined to one another to form a substituted or unsubstituted saturated or unsaturated 4- to 8-membered heterocyclic or carbocyclic ring (e.g., pyrrolidine, morpholine, 1-methylpyrrolidine, pyrrolidin-2-one, pyrrolidin-3-one, 3,3-difluoropyrrolidine, pyrrolidin-3-ol, 3-methoxypyrrolidine, 3-(difluoromethyl)pyrrolidine, pyrrolidine-3-carbonitrile, pyridine, piperidine, piperidin-2-one, imidazole, pyrimidine, triazole, oxadiazole, pyrazole). However, when the ring is an aromatic ring, R1 and / or R3 do not exist; however, when X1 is O, R4 does not exist; R7´ is H, F, Cl, Br, I, OH, O-R 20, SH, R8-OH, R8-SH, -R8-O-R 10 , R8-(C3-C8 cycloalkyl), R8-(3- to 8-membered heterocyclic ring), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R 10 )(R 11 ), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 , R8-C(O)-R 10 , C(O)H, C(O)-R 10 , C1-C5 linear or branched C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10) C1-C5 straight-chain or branched-chain substituted or unsubstituted alkyl (e.g., isopropyl, methyl, ethyl), C1-C5 straight-chain or branched-chain substituted or unsubstituted alkenyl, C1-C5 straight-chain or branched-chain or C3-C8 cyclic haloalkyl (e.g., CHF2), C1-C5 straight-chain or branched-chain or C3-C8 cyclic alkoxy (e.g., methoxy) (optionally, at least one methylene group (CH2) in the alkoxy is substituted by an oxygen atom), C1-C5 straight-chain or branched-chain thioalkoxy, C1-C5 straight-chain or branched-chain haloalkoxy, C1-C5 straight-chain or branched-chain alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclohexyl), substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., morpholine, pyran, oxetane, pyrrolidine, 3,3-difluoropyrrolidine, imidazole, pyrazole, triazole, piperazine, piperidine, piperidin-2-one, piperidin-4-ol, dioxazole, 2-oxopyrrolidine), substituted or unsubstituted aryl, or substituted or unsubstituted benzyl; or, R7 and R7' are bonded to each other to form a substituted or unsubstituted saturated, unsaturated or aromatic 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); R 20 is represented by the following structural formula:

[0142]

Chemical formula

[0143] In the formula, R 30 is H, R 20 , F, Cl, Br, I, OH, SH, alkoxy, N(R)2, NH(R 10 ), N(R 10 )(R 11)、CF3, CN, NO2, a C1-C5 straight-chain or branched-chain substituted or unsubstituted alkyl (e.g., methyl, ethyl, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a C1-C5 straight-chain or branched-chain alkoxy, a C1-C5 straight-chain or branched-chain haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), an R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , -R8-R 10 (e.g., (CH2)2-O-CH3), a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2-pyridine, 3-pyridine, or 4-pyridine)); R is H, F, Cl, Br, I, OH, SH, an alkoxy, NH(R 10 ), NH-CH2-cyclopropyl, N(R 10 )(R 11 ), CF3, CN, NO2, COOH, CO(R 10 )(e.g., C(O)CH3), a C1-C5 straight-chain or branched-chain substituted or unsubstituted alkyl (e.g., methyl, ethyl, CH2-OH, CH2-CH2-OH, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a C3-C8 substituted or unsubstituted cycloalkyl, cyclopropyl, a C1-C5 straight-chain or branched-chain alkoxy, isopropoxy, a C1-C5 straight-chain or branched-chain haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), an R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , -R8-R 10(e.g., (CH2)2-O-CH3), a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2-pyridine, 3-pyridine, or 4-pyridine)); Each R8 is, independently of one another, [CH2] p and p is from 1 to 10; R9 is [CH] q or [C] q and q is from 2 to 10; R 10 and R 11 are, independently of one another, H, a straight-chain or branched-chain substituted or unsubstituted alkyl having 1 to 5 carbon atoms (e.g., methyl, ethyl, CH2-cyclopropyl, CH2-CH2-O-CH3), a straight-chain or branched-chain substituted or unsubstituted haloalkyl having 1 to 5 carbon atoms (e.g., CH2CF3), a straight-chain or branched-chain alkoxy having 1 to 5 carbon atoms (e.g., O-CH3), R 20 , C(O)R, or S(O)2R; or R 10 and R 11 are joined to each other to form a substituted or unsubstituted heterocyclic ring having 3 to 8 members (e.g., piperazine, piperidine); n is an integer from 0 to 4 (e.g., 1, 2).

[0144] In some embodiments, X2 of Structural Formulas I, II, and / or I(a) to I(o) is a nitrogen atom. In other embodiments, X2 is CH.

[0145] In some embodiments, X3 of Structural Formulas I, II, and / or I(a) to I(o) is a nitrogen atom. In other embodiments, X3 is CH.

[0146] In some embodiments, X4 of Structural Formulas I, II, and / or I(a) to I(o) is a nitrogen atom. In other embodiments, X4 is CH.

[0147] In some embodiments, X5 of Structural Formulas I, II, I(a) - I(i), I(m), and / or I(o) is a nitrogen atom. In other embodiments, X5 is a carbon atom.

[0148] In some embodiments, X6 of Structural Formulas I, II, I(a) - I(i), I(m), and / or I(o) is a nitrogen atom. In other embodiments, X6 is a carbon atom.

[0149] In some embodiments, X7 of Structural Formulas I, II, and / or I(a) - I(e) is a nitrogen atom. In other embodiments, X7 is a carbon atom.

[0150] In some embodiments, X8 of Structural Formulas I, II, I(a) - I(i), I(m), and / or I(o) is a nitrogen atom. In other embodiments, X8 is a carbon atom.

[0151] In some embodiments, X9 of Structural Formulas I, II, I(a) - I(i), I(m), and / or I(o) is a nitrogen atom. In other embodiments, X9 is a carbon atom.

[0152] In some embodiments, X of Structural Formulas I, II, and / or I(a) - I(o) 10 is a nitrogen atom. In other embodiments, X 10 is N. In other embodiments, X 10 is CH. In other embodiments, X 10 is C(R), where R is as defined below. In other embodiments, X 10 is C(R), where R is alkyl. In other embodiments, X 10 is C(R), where R is methyl. In other embodiments, X 10 is C(R), where R is cycloalkyl. In other embodiments, X 10 is C(R), where R is cyclopropyl. In other embodiments, X 10 is C(R), where R is COOH. In other embodiments, X 10is C(R), where R is NH(R 10 ), and R 10 is substituted alkyl. In other embodiments, R 10 is C(N(H)(CH2-cyclopropyl)). In other embodiments, X 10 is C(R), where R is substituted alkyl. In other embodiments, X 10 is C(R), where R is CH2-OH. In other embodiments, X 10 is C(R), where R is CH2-CH2-OH. In other embodiments, X 10 is C(R), where R is alkoxy. In other embodiments, X 10 is C(R), where R is isopropoxy.

[0153] In some embodiments, at least one of X2, X3, X4, X5, X6, X7, X8, and X9 in Structural Formulas I, II, and / or I(a) - I(e) is a nitrogen atom. In some embodiments, at least one of X2, X3, X4, X5, X6, X8, and X9 in Structural Formulas I, II, I(a) - I(e), I(g) - I(i), I(m), and / or I(o) is a nitrogen atom. In some embodiments, at least one of X2, X3, X4, X5, X6, X7, X8, and X9 in Structural Formula I(d) is a nitrogen atom. In some embodiments, at least one of X2, X3, X4, X5, X6, X7, X8, X9, and X 10 is a nitrogen atom.

[0154] In some embodiments, at least one of X2, X3, X4, and X 10 in Structural Formulas I, II, and / or I(a) - I(o) is a nitrogen atom. In some embodiments, at least one of X2, X3, X4, and X 10 in Structural Formula I(d) is a nitrogen atom. In some embodiments, at least one of X5, X6, X8, and X9 in Structural Formulas I, II, and / or I(a) - I(o) is a nitrogen atom.

[0155] In some embodiments, R5 of Structural Formulas I, II, I(a) - I(d), I(f) - I(i), I(l), I(n), and / or I(o) is H. In other embodiments, R5 is a straight-chain or branched-chain C1-C5 alkyl. In other embodiments, R5 is methyl. In other embodiments, R5 is methyl, ethyl, propyl, isopropyl, butyl, t-butyl, isobutyl, pentyl, neopentyl. Each corresponds to a separate embodiment of the present invention.

[0156] In some embodiments, R5 and R6 of Structural Formulas I, II, I(a) - I(i), and / or I(l) are bonded to each other to form a substituted or unsubstituted 5- to 8-membered heterocyclic ring. In some embodiments, R5 and R6 are bonded to each other to form a substituted 5- to 8-membered heterocyclic ring. In some embodiments, R5 and R6 are bonded to each other to form an unsubstituted 5- to 8-membered heterocyclic ring. In some embodiments, the heterocyclic ring is azepane, piperazine, or 2-(piperazin-1-yl)acetamide. Each corresponds to a separate embodiment of the present invention. In some embodiments, the heterocyclic ring is F, Cl, Br, I, CF3, R 20 , a straight-chain or branched-chain C1-C5 alkyl, a straight-chain or branched-chain C1-C5 haloalkyl, OH, alkoxy, R8-OH (e.g., CH2-OH), OMe, amide, C(O)N(R)2, C(O)N(R 10 )(R 11 ), R8-C(O)N(R 10 )(R 11 ), C(O)-pyrrolidine, C(O)-piperidine, N(R)2, NH(R 10 ), N(R 10 )(R 11)、N(CH3)2, NH2, CF3, aryl, phenyl, heteroaryl, a C3-C8 substituted or unsubstituted cycloalkyl, cyclobutanol, a substituted or unsubstituted saturated, unsaturated or aromatic monocyclic, fused-ring or spiro-ring 3- to 8-membered heterocyclic ring, pyran, oxetane, piperidine, pyrazole, methylpyrazole, triazole, imidazole, halophenyl, (benzyloxy)phenyl, CN, and NO2, and is substituted by at least one substituent selected therefrom. Each corresponds to a separate embodiment of the present invention. In some embodiments, the heterocyclic ring of Structural Formula I(e) is not substituted with CO2-R.

[0157] In some embodiments, R6 of Structural Formulas I, II, I(a) to I(d), I(f) to I(i), I(l), I(n), and / or I(o) is H. For example, R6 is H, F, Cl, Br, I, OH, SH, R8-OH, R8-SH, -R8-O-R 10 , CH2-O-CH3, (CH2)2-O-CH3, (CH2)3-O-CH3, (CH3)2-O-CH(CH3)2, R8-S-R 10 , (CH2)3-S-(CH2)2CH3, R8-NHC(O)-R 10 , -O-R8-R 10, R8-(C3-C8 substituted or unsubstituted cycloalkyl), CH2-cyclopropyl, CH2-cyclobutanol, CH2-difluorocyclopropyl, CH2-methylcyclopropyl, CH2-dimethylamino-cyclohexyl, (CH2)2-cyclopentanol, CH2-cyclohexanol, R8-(substituted or unsubstituted saturated, unsaturated or aromatic monocyclic, fused ring or spiro ring 3- to 10-membered heterocyclic ring), (CH2)3-pyran, (CH2)2-pyrazole, (CH2)2-imidazole, CH2-tetrahydrofuran, CH2-dioxane, CH2-oxetane, CH2-piperidine, CH2-triazole, CH2-1-oxa-8-azaspiro[4.5]decane, (CH2)3-diazabicyclo[2.2.1]heptane, CH2-methyl-THF, CH2-ethyl-piperidine, CH2-oxa-azaspirodecan, (CH2)3-dimethylpyrazole, CH2-2-oxo-methylpyrrolidine, CH2-methyl-azetidine, CH2-azaspiroheptane, CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), (CH2)3-N(CH2CH3)2, (CH2)3-N(CH(CH3)2)2, (CH2)3-piperidine, (CH2)3-4-fluoropiperidine, (CH2)3-piperidin-2-one, (CH2)3-4-cyano-piperidine, (CH2)3-4-trifluoromethylpiperidine, (CH2)4-NH(CH3), (CH2)3-NH-CH3, (CH2)3-NH-CH2CH3, (CH2)3-N(CCH2CH3)2, (CH2)3-NH2, (CH2)3-N(CH2CH3)(CH2CF3), R8-C(O)N(R 10 )(R 11 ), (CH2)2-C(O)-piperidine, R9-R8-N(R 10 )(R 11 ), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11)、COOH, -C(O)Ph, C(O)O-R 10 , R8-C(O)-R 10 , C(O)H, C(O)-R 10 , a C1-C5 straight-chain or branched C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10), C1-C5 linear or branched substituted or unsubstituted alkyl, CH(CH3)CH2OCH3, CH(CH3)CH2NH2, CH(CH3)C(O)N(CH3)2, CH2-CH(OH)Ph, (CH2)3N(H)CH2CH3, CH(CH3)(CH2)2OH, CH(CH2OH)(CH2CH3), (CH2)3-OCH3, (CH2)2-OCH3, (CH2)2-OCH(CH3)2, CH(CH2OH)(CH2CH(CH3)2), CH2CH(CH3)(OCH3), CH2CH(N(CH3)2)(CH2CH3), benzyl, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, CH2-CH2-CH2-O-CH3, CH(CH3)C(O)N(CH3)2, C1-C5 linear or branched substituted or unsubstituted alkenyl, C1-C5 linear or branched or C3-C8 cyclic haloalkyl, C1-C5 linear or branched substituted or unsubstituted or C3-C8 cyclic alkoxymethoxy (optionally, at least one methylene group (CH2) in the alkoxy is replaced by an oxygen atom), O-(CH2)2-O-CH3, C1-C5 linear or branched thioalkoxy, C1-C5 linear or branched haloalkoxy, C1-C5 linear or branched alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl, cyclopropyl, cyclobutyl, cyclohexyl, 4,4-difluorocyclohexane, methoxycyclopropyl, methylcyclobutyl, cyclopropyl, aminomethyl-cyclobutyl, methoxycyclobutyl, 2,3-dihydro-1H-indenol, R8-(C3-C8 substituted or unsubstituted cycloalkyl), substituted or unsubstituted saturated, unsaturated or aromatic monocyclic, fused ring, bridged ring or spiro ring 3- to 10-membered carbocyclic or heterocyclic ring, piperidine (2,3, or 4-piperidine), 1-methylpiperidine (e.g., 1-methyl-3-piperidine, 1-methyl-4-piperidine), 3-fluoro-1-methylpiperidine, 1-(2,2,(2-Trifluoroethyl)piperidine, azetidine, 1-methyl-azetidine (e.g., 1-methyl-3-azetidine), morpholine, pyrrolidine, pyrrolidinone, quinuclidine, tetrahydropyran (e.g., 4-tetrahydropyran, or 3-tetrahydropyran), tetrahydrofuran, azaspiro[3.3]heptane, 8-methyl-8-azabicyclo[3.2.1]octane, dioxane, 1,3-dioxane, imidazole, trifluoromethyl-oxetane, hydroxy-tetrahydrofuran, azepan-2-one, azabicyclohexane, 4,4-difluorocyclohexane, substituted or unsubstituted aryl, substituted or unsubstituted R8-aryl (e.g., benzyl), or substituted or unsubstituted benzyl; each corresponds to a separate embodiment of the present invention. In some embodiments, R6 is F, Cl, Br, I, a C1-C5 straight-chain or branched alkyl, OH, alkoxy (e.g., OMe), amide, C(O)N(R)2, C(O)-alkyl, C(O)-pyrrolidine, C(O)-piperidine, N(R)2, NH(R, 10 ), N(R 10 )(R 11 ), N(CH3)2, NH2, CF3, aryl, phenyl, heteroaryl, a C3-C8 substituted or unsubstituted cycloalkyl, cyclobutanol, a substituted or unsubstituted 3- to 8-membered heterocyclic ring, pyran, oxetane, piperidine, pyrazole, methylpyrazole, triazole, imidazole, a C1-C5 straight-chain or branched haloalkyl (e.g., CH2CF3, CHF2), halophenyl, (benzyloxy)phenyl, CN, and NO2 and may be further substituted with at least one substituent selected from. Each corresponds to a separate embodiment of the present invention. In some embodiments, R6 is H. In some embodiments, R6 is -R8-O-R 10 . In some embodiments, R6 is CH2-O-CH3. In some embodiments, R6 is R8-S-R 10 . In some embodiments, R6 is (CH2)3-S-(CH2)2CH3. In some embodiments, R6 is R8-NHC(O)-R 10is. In some embodiments, R6 is (CH2)3-NHC(O)-R 10 is. In some embodiments, R6 is (CH2)-NHC(O)-R 10 is. In some embodiments, R6 is R8-(substituted or unsubstituted cycloalkyl having 3 to 8 carbon atoms). Examples of R8-(substituted or unsubstituted cycloalkyl having 3 to 8 carbon atoms) include, but are not limited to, CH2-cyclobutanol, CH2-difluorocyclopropyl, CH2-methylcyclopropyl, CH2-dimethylamino-cyclohexyl, (CH2)2-cyclopentanol, and CH2-cyclohexanol. Each is another corresponds to individual embodiments. In some embodiments, R6 is R8-(a substituted or unsubstituted saturated, unsaturated or aromatic monocyclic, fused ring or spiro ring 3- to 8-membered heterocyclic ring). In some embodiments, R6 is R8-(a substituted or unsubstituted saturated monocyclic 3- to 8-membered heterocyclic ring). In some embodiments, R6 is R8-(a substituted or unsubstituted unsaturated monocyclic 3- to 8-membered heterocyclic ring). In some embodiments, R6 is (CH2)3-4-fluoropiperidine. In some embodiments, R6 is R8-(a substituted or unsubstituted aromatic 3- to 8-membered monocyclic ring). In some embodiments, R6 is R8-(a substituted or unsubstituted saturated fused ring 3- to 8-membered heterocyclic ring). In some embodiments, R6 is R8-(a substituted or unsubstituted unsaturated fused ring 3- to 8-membered heterocyclic ring). In some embodiments, R6 is R8-(a substituted or unsubstituted aromatic fused ring 3- to 8-membered heterocyclic ring). In some embodiments, R6 is R8-(a substituted or unsubstituted spiro ring 3- to 8-membered heterocyclic ring). Examples of R8-(a substituted or unsubstituted saturated, unsaturated or aromatic monocyclic, fused ring or spiro ring 3- to 8-membered heterocyclic ring) include, but are not limited to, (CH2)3-4-fluoropiperidine, (CH2)3-pyran, (CH2)2-pyrazole, (CH2)2-imidazole, CH2-tetrahydrofuran, CH2-dioxane, CH2-oxetane, CH2-piperidine, CH2-triazole, CH2-1-oxa-8-azaspiro[4.5]decane, (CH2)3-diazabicyclo[2.2.1]heptane, CH2-methyl-THF, CH2-ethyl-piperidine, CH2-oxa-azaspirodecan, (CH2)3-dimethylpyrazole, CH2-2-oxo-methylpyrrolidine, CH2-methyl-azetidine, and CH2-azaspiroheptane. In some embodiments, R6 is NH2. In some embodiments, R6 is NHR. In some embodiments, R6 is N(R)2. In some embodiments, R6 is NH(R 10 ). In some embodiments, R6 is N(R 10 )(R 11) is. In some embodiments, R6 is R8-N(R 10 )(R 11 ). In some embodiments, examples of R8-N(R 10 )(R 11 ) include, but are not limited to, (CH2)3-N(CH2CH3)2, (CH2)3-N(CH(CH3)2)2, (CH2)3-piperidine, (CH2)4-NH(CH3), (CH2)3-NH-CH3, (CH2)3-NH-CH2CH3, (CH2)3-N(CH2CH3)2, (CH2)3-NH2, and (CH2)3-N(CH2CH3)(CH2CF3). In some embodiments, R6 is R8-C(O)N(R 10 )(R 11) For example, it is (CH2)2-C(O)-piperidine, etc. In some embodiments, R6 is a linear or branched, substituted or unsubstituted C1-C5 alkyl. Examples of linear or branched, substituted or unsubstituted C1-C5 alkyl include, but are not limited to, CH(CH3)CH2OCH3, CH(CH3)CH2NH2, CH(CH3)C(O)N(CH3)2, CH2-CH(OH)Ph, (CH2)3N(H)CH2CH3, CH(CH3)(CH2)2OH, CH(CH2OH)(CH2CH3), (CH2)3-OCH3, (CH2)2-OCH3, (CH2)2-OCH(CH3)2, CH(CH2OH)(CH2CH(CH3)2), CH2CH(CH3)(OCH3), CH2CH(N(CH3)2)(CH2CH3), CH(CH3)C(O)N(CH3)2, benzyl, methyl, ethyl, and CH2-OCH2-CH2-O-CH3. In some embodiments, R6 is a substituted or unsubstituted C3-C8 cycloalkyl. In some embodiments, examples of substituted or unsubstituted C3-C8 cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclohexyl, methoxycyclopropyl, methylcyclobutyl, aminomethyl-cyclobutyl, methoxycyclobutyl, and 2,3-dihydro-1H-inden. In some embodiments, R6 is R8-(substituted or unsubstituted C3-C8 cycloalkyl). In some embodiments, R6 is a substituted or unsubstituted saturated or unsaturated monocyclic, fused-ring, or spiro-ring 3- to 10-membered heterocyclic ring. In some embodiments, this ring is F, Cl, Br, I, linear or branched C1-C5 alkyl, OH, alkoxy, OMe, amide, C(O)N(R)2, C(O)-alkyl, C(O)-pyrrolidine, C(O)-piperidine, N(R)2, NH(R 10 )、N(R 10 )(R 11)、N(CH3)2, NH2, CF3, aryl, phenyl, heteroaryl, a substituted or unsubstituted C3-C8 cycloalkyl, cyclobutanol, a substituted or unsubstituted 3- to 8-membered heterocyclic ring, pyran, oxetane, piperidine, pyrazole, methylpyrazole, triazole, imidazole, a linear or branched C1-C5 haloalkyl (e.g., CH2CF3, CHF2), halophenyl, (benzyloxy)phenyl, CN, and NO2, and can be further substituted with at least one substituent selected from the group consisting of. Each corresponds to a separate embodiment of the present invention. In some embodiments, R6 is a substituted or unsubstituted saturated or unsaturated monocyclic, fused ring, bridged ring or spiro ring 3- to 10-membered heterocyclic ring. In some embodiments, R6 is a substituted or unsubstituted saturated, unsaturated or aromatic monocyclic, fused ring or spiro ring 3- to 10-membered heterocyclic ring. In some embodiments, R6 is a substituted or unsubstituted saturated, unsaturated or aromatic monocyclic 3- to 10-membered heterocyclic ring. In some embodiments, R6 is a substituted or unsubstituted saturated monocyclic 3- to 10-membered heterocyclic ring. In some embodiments, this ring is piperidine, 1-methylpiperidine, 3-fluoro-1-methylpiperidine, 1-(2,2,2-trifluoroethyl)piperidine, azetidine, 1-methyl-azetidine, morpholine, pyrrolidine, pyrrolidinone, quinuclidine, tetrahydropyran, tetrahydrofuran, azaspiro[3.3]heptane, 8-methyl-8-azabicyclo[3.2.1]octane, dioxane, 1,3-dioxane, imidazole, trifluoromethyl-oxetane, hydroxy-tetrahydrofuran, azepan-2-one, azabicyclohexane. Each corresponds to a separate embodiment of the present invention. In some embodiments, R6 is a substituted or unsubstituted saturated or unsaturated monocyclic, fused ring, bridged ring or spiro ring 3- to 10-membered carbocyclic ring. In some embodiments, R6 is 4,4-difluorocyclohexane. In some embodiments, R6 is a substituted or unsubstituted R8-aryl, e.g., benzyl. In some embodiments, R6 is F, Cl, Br, I, CF3, R 20, a straight-chain or branched-chain alkyl of C1-C5, a straight-chain or branched-chain haloalkyl of C1-C5, OH, alkoxy, R8-OH (e.g., CH2-OH), OMe, amide, C(O)N(R)2, C(O)N(R 10 )(R 11 ), R8-C(O)N(R 10 )(R 11 ), C(O)-pyrrolidine, C(O)-piperidine, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), N(CH3)2, NH2, CF3, aryl, phenyl, heteroaryl, a substituted or unsubstituted cycloalkyl of C3-C8, cyclobutanol, a substituted or unsubstituted saturated, unsaturated or aromatic monocyclic, fused-ring or spiro-ring heterocyclic ring of 3 to 8 members, pyran, oxetane, piperidine, pyrazole, methylpyrazole, triazole, imidazole, a straight-chain or branched-chain haloalkyl of C1-C5 (CH2CF3, CHF2), halophenyl, (benzyloxy)phenyl, CN, and NO2, and is substituted by at least one substituent selected therefrom. Each corresponds to a separate embodiment of the present invention.

[0158] In some embodiments, R6 of Structural Formula I(n) and / or I(o) is H. In some embodiments, R6 is CD3. In some embodiments, R6 is a straight-chain or branched C1-C5 alkyl. In some embodiments, R6 is methyl. In some embodiments, R6 is ethyl. In some embodiments, R6 is isopropyl. In some embodiments, R6 is a substituted or unsubstituted saturated or unsaturated monocyclic, fused-ring, bridged-ring or spiro-ring 3- to 10-membered heterocyclic ring. In some embodiments, R6 is an unsubstituted monocyclic 3- to 8-membered heterocyclic ring. In some embodiments, R6 is piperidine. In some embodiments, R6 is 4-piperidine. In some embodiments, R6 is azetidine. In some embodiments, R6 is morpholine. In some embodiments, R6 is tetrahydropyran. In some embodiments, R6 is tetrahydrofuran. In some embodiments, R6 is dioxane. In some embodiments, R6 is 1,3-dioxane. In some embodiments, R6 is pyrrolidine. In some embodiments, R6 is a substituted single 3- to 8-membered heterocyclic ring. In some embodiments, R6 is 1-methylpiperidine. In some embodiments, R6 is 3-fluoro-1-methylpiperidine. In some embodiments, R6 is 1-methyl-azetidine. In some embodiments, R6 is trifluoromethyl-oxetane. In some embodiments, R6 is hydroxy-tetrahydrofuran. In some embodiments, R6 is 1-(2,2,2-trifluoroethyl)piperidine. In some embodiments, R6 is a substituted or unsubstituted unsaturated monocyclic 3- to 8-membered heterocyclic ring. In some embodiments, R6 is pyrrolidinone. In some embodiments, R6 is imidazole. In some embodiments, R6 is azepan-2-one. In some embodiments, R6 is a substituted or unsubstituted saturated bridged-ring 3- to 10-membered heterocyclic ring. In some embodiments, R6 is quinuclidine.In some embodiments, R6 is 8-methyl-8-azabicyclo[3.2.1]octane. In some embodiments, R6 is azabicyclohexane. In some embodiments, R6 is a 3- to 10-membered heterocyclic ring of a substituted or unsubstituted saturated spiro ring. In some embodiments, R6 is azaspiro[3.3]heptane. In some embodiments, R6 is a C3-C8 substituted or unsubstituted cycloalkyl. In some embodiments, R6 is cyclopropyl. In some embodiments, R6 is 4,4-difluorocyclohexane.

[0159] In some embodiments, R6 and R5 in Formulas I, II, I(a) - I(i), I(l), and / or I(n) are bonded to each other to form a 5- to 8-membered heterocyclic ring of a substituted or unsubstituted saturated, unsaturated or aromatic monocyclic, fused ring or spiro ring. In some embodiments, the 5- to 8-membered heterocyclic ring of a substituted or unsubstituted saturated, unsaturated or aromatic monocyclic, fused ring or spiro ring is azepane, piperazine, or 2-(piperazin-1-yl)acetamide. Each corresponds to a separate embodiment of the present invention. In some embodiments, this ring is further substituted by at least one substituent selected from F, Cl, Br, I, C1-C5 linear or branched alkyl, OH, alkoxy (e.g., OMe), amide (e.g., C(O)N(R)2), C(O)-pyrrolidine, C(O)-piperidine, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), (e.g., N(CH3)2, NH2), CF3, aryl, phenyl, heteroaryl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclobutanol), substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., pyran, oxetane, piperidine, pyrazole, methylpyrazole, triazole, imidazole), halophenyl, (benzyloxy)phenyl, CN, and NO2. Each corresponds to a separate embodiment of the present invention.

[0160] In some embodiments, R6 of Structural Formulas I, II, and / or I(a) - I(i) is represented by the following Structural Formula B.

[0161]

Chemical Formula

[0162] In some embodiments, Structural Formula B is represented by Structural Formula Bi.

[0163] In some embodiments, R6 of Structural Formulas I, II, and / or I(a) - I(i) is represented by the following Structural Formula Bi.

[0164]

Chemical Formula

[0165] Wherein, m is 0 or 1; and, R 12 is R 20 or C1-C5 C(O)-alkyl, and R 13 is R 30 ; or, R 12 and R 13 are both H; or, R 12 and R 13 are each independently H, or a C1-C5 substituted or unsubstituted alkyl (e.g., ethyl, trifluoroethyl); or, R 12 and C3 are bonded to each other to form Ring A, and R 13 is R 30 ; or, R 12 and R 13 are bonded to each other to form Ring B; or, R 12 and C1 are bonded to each other to form Ring C, and R 13 is R 30 ; or, C1 and C3 are bonded to each other to form a D ring, and R 12 and R 13 are independently of each other R 30 ; or, R 13 and C2 are bonded to each other to form an E ring, m is 1, and R 12 is R 30 ; or, R 12 and R 13 are bonded to each other to form a B ring, and C1 and C3 are bonded to each other to form a D ring; The A ring, C ring, and E ring are independently of each other a substituted or unsubstituted monocyclic, spiro, or fused 3- to 8-membered heterocyclic ring; The B ring is a substituted or unsubstituted monocyclic, spiro, or fused 3- to 8-membered heterocyclic ring; and, The D ring is a C3-C8 substituted or unsubstituted cycloalkyl.

[0166] In some embodiments, R 12 in Structural Formulas B and / or Bi is H. In some embodiments, R 12 is R 20 . In other embodiments, R 12 is R 30 . In some embodiments, R 12 is C1-C5 C(O)-alkyl. In some embodiments, R 12 is a C1-C5 substituted or unsubstituted alkyl. In some embodiments, R 12 is an unsubstituted C1-C5 alkyl. In some embodiments, the alkyl is ethyl. In some embodiments, R 12 is a substituted C1-C5 alkyl. In some embodiments, the alkyl is trifluoroethyl.

[0167] In some embodiments, R 13 in Structural Formulas B and / or Bi is H. In other embodiments, R 13 is R 30 . In some embodiments, R 13is a C1-C5 substituted or unsubstituted alkyl. In some embodiments, R 13 is an unsubstituted C1-C5 alkyl. In some embodiments, the alkyl is ethyl. In some embodiments, R 13 is a substituted C1-C5 alkyl. In some embodiments, the alkyl is trifluoroethyl.

[0168] In some embodiments, R6 of Structural Formulas I, II, and / or I(a)-I(i) is represented by Structural Formula B. In some embodiments, R 12 of Structural Formula B is R 20 , or C1-C5 C(O)-alkyl, and R 13 is R 30 . In some embodiments, R 12 and R 13 of Structural Formula B are both H. In some embodiments, R 12 and R 13 of Structural Formula B are independently of each other H, or a C1-C5 substituted or unsubstituted alkyl (e.g., ethyl, trifluoroethyl). In some embodiments, R 12 and R 13 of Structural Formula B are independently of each other H or trifluoroethyl. In some embodiments, R 12 and C3 of Structural Formula B are bonded to each other to form an A ring, and R 13 is R 30 . In some embodiments, R 12 and R 13 of Structural Formula B are bonded to each other to form a B ring. In some embodiments, R 12 and C1 of Structural Formula B are bonded to each other to form a C ring, and R 13 is R 30 . In some embodiments, C1 and C3 of Structural Formula B are bonded to each other to form a D ring, and R 12 and R 13 of Structural Formula B are independently of each other R 30 . In some embodiments, R 13 and C2 of Structural Formula B are bonded to each other to form an E ring, m is 1, and R of Structural Formula B12 is R 30 In some embodiments, R of Structural Formula B 12 and R 13 are bonded to each other to form a B ring, and C1 and C3 of Structural Formula B are bonded to each other to form a D ring.

[0169] In some embodiments, R6 of Structural Formulas I, II, and / or I(a) - I(h) is represented by Structural Formula Bi. In some embodiments, R 12 of Structural Formula Bi is R 20 , or C1 - C5 C(O)-alkyl, and R 13 is R 30 In some embodiments, R 12 and R 13 of Structural Formula Bi are both H. In some embodiments, R 12 and R 13 of Structural Formula Bi are each independently H, or C1 - C5 substituted or unsubstituted alkyl (e.g., ethyl, trifluoroethyl). In some embodiments, R 12 and R 13 of Structural Formula Bi are each independently H or trifluoroethyl. In some embodiments, R 12 and C3 of Structural Formula Bi are bonded to each other to form an A ring, and R 13 is R 30 In some embodiments, R 12 and R 13 of Structural Formula Bi are bonded to each other to form a B ring. In some embodiments, R 12 and C1 of Structural Formula Bi are bonded to each other to form a C ring, and R 13 is R 30 In some embodiments, C1 and C3 of Structural Formula Bi are bonded to each other to form a D ring, and R 12 and R 13 of Structural Formula Bi are each independently R 30 In some embodiments, R 13 and C2 of Structural Formula Bi are bonded to each other to form an E ring, m is 1, and R 12 of Structural Formula Bi is R 30In some embodiments, R of Structural Formula Bi 12 and R 13 are bonded to each other to form a B ring, and C1 and C3 of Structural Formula Bi are bonded to each other to form a D ring.

[0170] In some embodiments, R6 of Structural Formula I(g) is represented by Structural Formula C below:

[0171]

Chemical Formula

[0172] wherein k is an integer from 1 to 4; R 12 and R 13 are each independently H, a linear or branched substituted or unsubstituted alkyl having 1 to 5 carbon atoms (e.g., ethyl, isopropyl), or R 20 ; or R 12 and R 13 are bonded to each other to form a substituted or unsubstituted 4- to 7-membered heterocyclic ring (e.g., piperidine, piperazine, pyrrolidine, oxa-6-azaspiro[3.3]heptane).

[0173] In some embodiments, k of Structural Formula C is 1. In some embodiments, k is 2. In some embodiments, k is 3. In some embodiments, k is 4.

[0174] In some embodiments, R 12 and R 13 of Structural Formula C are each independently H, a linear or branched substituted or unsubstituted alkyl having 1 to 5 carbon atoms (e.g., ethyl, isopropyl), or R 20 ; each corresponding to a separate embodiment of the present invention. In some embodiments, R 12 and R 13 of Structural Formula C are both ethyl. In some embodiments, R 12 and R 13Both are isopropyl. In some embodiments, R of Structural Formula C 12 and R 13 are both alkyl.

[0175] In some embodiments, R of Structural Formula C 12 and R 13 are bonded to each other to form a substituted or unsubstituted 4- to 7-membered heterocyclic ring. In some embodiments, R of Structural Formula C 12 and R 13 are bonded to each other to form piperidine, piperazine, pyrrolidine, oxa-6-azaspiro[3.3]heptane. Each corresponds to a separate embodiment of the present invention. In some embodiments, the heterocyclic ring may be further substituted with at least one substitution as defined herein for the heterocyclic ring.

[0176] In some embodiments, R6 of Structural Formula I(b) is represented by Structural Formula Bi and / or B, R of Structural Formula Bi and / or B 12 is R 20 , or C1-C5 C(O)-alkyl, and R of Structural Formula Bi and / or B 13 is R 30 ; or, R 12 and R 13 are both H, or R 12 and R 13 are independently of each other H or trifluoroethyl; or, R 12 and C3 are bonded to each other to form Ring A, and R 13 is R 30 ; or, R 12 and R 13 are bonded to each other to form a substituted or unsubstituted pyrrolidine ring, piperazine, thiomorpholine 1,1-dioxide, 2-oxa-6-azaspiro[3.3]heptane, pyrazole, imidazole, 2,5-diazabicyclo[2.2.1]heptane, or diazabicyclo[2.2.1]heptane; or, R12 and C1 are bonded to each other to form a C ring, and R 13 is R 30 ; or, C1 and C3 are bonded to each other to form a D ring, and R 12 and R 13 are independently of each other R 30 ; or, R 13 and C2 are bonded to each other to form an E ring, m is 1, and R 12 is R 30 ; or, R 12 and R 13 are bonded to each other to form a B ring, and C1 and C3 are bonded to each other to form a D ring.

[0177] In some embodiments, R6 of formula I(b) is represented by formula Bi and / or B, R of formula Bi and / or B 12 is R 20 , or C1-C5 C(O)-alkyl, and R of formula Bi and / or B 13 is R 30 ; or, R 12 and C3 are bonded to each other to form an A ring, and R 13 is R 30 ; or, R 12 and R 13 are bonded to each other to form a substituted or unsubstituted pyrrolidine ring, piperazine, thiomorpholine 1,1-dioxide, 2-oxa-6-azaspiro[3.3]heptane, pyrazole, imidazole, 2,5-diazabicyclo[2.2.1]heptane, or diazabicyclo[2.2.1]heptane; or, R 12 and C1 are bonded to each other to form a C ring, and R 13 is R 30 ; or, C1 and C3 are bonded to each other to form a D ring, and R 12 and R 13 are independently of each other R 30 ; or, R13 and C2 are bonded to each other to form an E ring, m is 1, and R 12 is R 30 ; or, R 12 and R 13 are bonded to each other to form a B ring, and C1 and C3 are bonded to each other to form a D ring.

[0178] In some embodiments, the A ring of Structural Formula Bi is a substituted or unsubstituted monocyclic, spiro, or fused 3- to 8-membered heterocyclic ring. In some embodiments, the A ring is an unsubstituted monocyclic 3- to 8-membered heterocyclic ring. In some embodiments, the A ring is an unsubstituted spiro 3- to 8-membered heterocyclic ring. In some embodiments, the A ring is an unsubstituted fused 3- to 8-membered heterocyclic ring. In some embodiments, the A ring is a substituted monocyclic 3- to 8-membered heterocyclic ring. In some embodiments, the A ring is a substituted spiro 3- to 8-membered heterocyclic ring. In some embodiments, the A ring is a substituted fused 3- to 8-membered heterocyclic ring. In some embodiments, the A ring is pyrrolidine, methylpyrrolidine, ethylpyrrolidine, 2-oxopyrrolidine, piperidine, methylpiperidine, methyl-2-oxopyrrolidine, pyran-azetidine, methyl-azetidine, azabicyclooctane, 2-azabicyclo[2.1.1]hexane, or 2-azaspiro[3.3]heptane. Each corresponds to a separate embodiment of the present invention. In some embodiments, the A ring is pyrrolidine, methylpyrrolidine, or ethylpyrrolidine. Each corresponds to a separate embodiment of the present invention.

[0179] In some embodiments, the B ring of Structural Formula Bi is a substituted or unsubstituted monocyclic, spirocyclic or fused ring heterocyclic ring having 3 to 8 members. In some embodiments, the B ring is an unsubstituted monocyclic heterocyclic ring having 3 to 8 members. In some embodiments, the B ring is an unsubstituted spirocyclic heterocyclic ring having 3 to 8 members. In some embodiments, the B ring is an unsubstituted fused ring heterocyclic ring having 3 to 8 members. In some embodiments, the B ring is a substituted monocyclic heterocyclic ring having 3 to 8 members. In some embodiments, the B ring is a substituted spirocyclic heterocyclic ring having 3 to 8 members. In some embodiments, the B ring is a substituted fused ring heterocyclic ring having 3 to 8 members. In some embodiments, the B ring is pyrrolidine, methylpyrrolidine, ethylpyrrolidine, 2-oxopyrrolidine, hydroxymethyl-pyrrolidine, piperidine, piperidin-2-one, 4-fluoropiperidin 2-one, piperidine-4-carbonitrile, methylpiperidine, fluoropiperidine, 4-fluoropiperidine, 4-fluoro-2-methylpiperidine, difluoropiperidine, piperazine, methylpiperazine, dimethylpyrazole, methyl-2-oxopyrrolidine, pyran-, azetidine, methyl-azetidine, imidazole, azabicyclooctane, 2-azabicyclo[2.1.1]hexane, 2-azaspiro[3.3]heptane, diazabicyclo[2.2.1]heptane, 2-methyl-2,5-diazabicyclo[2.2.1]heptane, or thiomorpholine 1,1-dioxide-2-oxa-6-azaspiro[3.3]heptane. Each corresponds to a separate embodiment of the present invention. In some embodiments, the B ring is piperidine, methylpiperidine, fluoropiperidine, difluoropiperidine, pyrrolidine, piperazine, methylpyrrolidine, thiomorpholine, methylpiperazine, dimethylpyrazole, imidazole, 2-methyl-2,5-diazabicyclo[2.2.1]heptane, 1,1-dioxide-2-oxa-6-azaspiro[3.3]heptane, hydroxymethyl-pyrrolidine, diazabicyclo[2.2.1]heptane, or 6-fluoro-3-azabicyclo[3.1.1]heptane. Each corresponds to a separate embodiment of the present invention.

[0180] In some embodiments, the C-ring of Structural Formula Bi is a substituted or unsubstituted monocyclic, spiro, or fused 3- to 8-membered heterocyclic ring. In some embodiments, the C-ring is an unsubstituted monocyclic 3- to 8-membered heterocyclic ring. In some embodiments, the C-ring is an unsubstituted spiro 3- to 8-membered heterocyclic ring. In some embodiments, the C-ring is an unsubstituted fused 3- to 8-membered heterocyclic ring. In some embodiments, the C-ring is a substituted monocyclic 3- to 8-membered heterocyclic ring. In some embodiments, the C-ring is a substituted spiro 3- to 8-membered heterocyclic ring. In some embodiments, the C-ring is a substituted fused 3- to 8-membered heterocyclic ring. In some embodiments, the C-ring is pyrrolidine, methylpyrrolidine, ethylpyrrolidine, 2-oxopyrrolidine, piperidine, methylpiperidine, methyl-2-oxopyrrolidine, pyran-azetidine, methyl-azetidine, azabicyclooctane, 2-azabicyclo[2.1.1]hexane, or 2-azaspiro[3.3]heptane. Each corresponds to a separate embodiment of the present invention. In some embodiments, the C-ring is piperidine, pyrrolidine, methyl-2-oxopyrrolidine, pyran-pyrrolidine, methyl-azetidine, azabicyclooctane, 2-azabicyclo[2.1.1]hexane, or 2-azaspiro[3.3]heptane. Each corresponds to a separate embodiment of the present invention.

[0181] In some embodiments, the D-ring of Structural Formula Bi is a C3-C8 substituted or unsubstituted cycloalkyl. In some embodiments, the D-ring is a substituted C3-C8 cycloalkyl. In some embodiments, the D-ring is an unsubstituted C3-C8 cycloalkyl. In some embodiments, the D-ring is cyclopropane, cyclobutene, cyclopentane, cyclohexane, or cycloheptane. Each corresponds to a separate embodiment of the present invention.

[0182] In some embodiments, the E-ring of Structural Formula Bi is a substituted or unsubstituted monocyclic, spiro, or fused 3- to 8-membered heterocyclic ring. In some embodiments, the E-ring is an unsubstituted monocyclic 3- to 8-membered heterocyclic ring. In some embodiments, the E-ring is an unsubstituted spiro 3- to 8-membered heterocyclic ring. In some embodiments, the E-ring is an unsubstituted fused 3- to 8-membered heterocyclic ring. In some embodiments, the E-ring is a substituted monocyclic 3- to 8-membered heterocyclic ring. In some embodiments, the E-ring is a substituted spiro 3- to 8-membered heterocyclic ring. In some embodiments, the E-ring is a substituted fused 3- to 8-membered heterocyclic ring. In some embodiments, the E-ring is pyrrolidine, methylpyrrolidine, ethylpyrrolidine, 2-oxopyrrolidine, piperidine, methylpiperidine, methyl-2-oxopyrrolidine, pyran-azetidine, methyl-azetidine, azabicyclooctane, 2-azabicyclo[2.1.1]hexane, or 2-azaspiro[3.3]heptane. Each corresponds to a separate embodiment of the present invention. In some embodiments, the E-ring is pyrrolidine, azetidine, ethylpyrrolidine, oxopyrrolidine, or methylpiperidine. Each corresponds to a separate embodiment of the present invention.

[0183] In some embodiments, R6 of Structural Formula I(b) is F, Cl, Br, I, OH, SH, R8-OH, R8-SH, -R8-O-R 10 , CH2-O-CH3, R8-S-R 10 , (CH2)3-S-(CH2)2CH3, R8-NHC(O)-R 10 , -O-R8-R 10, R8-(substituted or unsubstituted C3-C8 cycloalkyl), CH2-cyclobutanol, CH2-difluorocyclopropyl, CH2-methylcyclopropyl, CH2-dimethylamino-cyclohexyl, (CH2)2-cyclopentanol, CH2-cyclohexanol, (CH2)3-pyran, CH2-tetrahydrofuran, CH2-dioxane, CH2-methyl-THF, CH2-oxa-azaspirodecan, CH2-azaspiroheptane, (CH2)3-dimethylpyrazole, CH2-methyl-azetidine, CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8-CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R9-R8-N(R 10 )(R 11 ), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 , R8-C(O)-R 10 , C(O)H, C(O)-R 10 , C1-C5 linear or branched C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10), a straight-chain or branched-chain, substituted or unsubstituted C1-C5 alkyl, CH(CH3)CH2OCH3, CH(CH3)CH2NH2, CH(CH3)C(O)N(CH3)2, CH2-CH(OH)Ph, (CH2)3N(H)CH2CH3, CH(CH3)(CH2)2OH, CH(CH2OH)(CH2CH3), (CH2)3-OCH3, (CH2)2-OCH3, (CH2)2-OCH(CH3)2, CH(CH2OH)(CH2CH(CH3)2), CH2CH(CH3)(OCH3), CH2CH(N(CH3)2)(CH2CH3), benzyl, methyl, ethyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, CH2-OCH2-CH2-O-CH3, a straight-chain or branched-chain, substituted or unsubstituted C1-C5 alkenyl, a straight-chain or branched-chain C1-C5 or cyclic C3-C8 haloalkyl, a straight-chain or branched-chain, substituted or unsubstituted C1-C5 or cyclic C3-C8 alkoxy, methoxy, O-(CH2)2-O-CH3, a straight-chain or branched-chain, substituted or unsubstituted C1-C5 or cyclic C3-C8 alkoxy (optionally, at least one methylene group (CH2) in the alkoxy is replaced by an oxygen atom), a straight-chain or branched-chain C1-C5 thioalkoxy, a straight-chain or branched-chain C1-C5 haloalkoxy, a straight-chain or branched-chain C1-C5 alkoxyalkyl, a substituted or unsubstituted C3-C8 cycloalkyl, methoxycyclopropyl, methylcyclobutyl, cyclopropyl, cyclobutyl, cyclohexyl, 4,4-difluorocyclohexane, aminomethyl-cyclobutyl, methoxycyclobutyl, 2,3-dihydro-1H-indenol, a substituted or unsubstituted saturated or unsaturated monocyclic, fused-ring, bridged-ring, or spiro-ring 3- to 10-membered carbocyclic or heterocyclic ring, piperidine, 1-methylpiperidine, 3-fluoro-1-methylpiperidine, 1-(2,2,2-trifluoroethyl)piperidine, azetidine, 1-methyl-azetidine, morpholine, pyrrolidine, pyrrolidinone, quinuclidine, tetrahydropyran, tetrahydrofuran, azaspiro[3.3]heptane, 8-methyl-8-azabicyclo[3.2.1] It is octane, dioxane, 1,3 - dioxane, imidazole, trifluoromethyl - oxetane, hydroxy - tetrahydrofuran, azepan - 2 - one, azabicyclohexane, 4,4 - difluorocyclohexane, a substituted or unsubstituted aryl, or a substituted or unsubstituted benzyl. Each corresponds to a separate embodiment of the present invention. In some embodiments, R6 is F, Cl, Br, I, a straight - chain or branched - chain C1 - C5 alkyl, OH, alkoxy (e.g., OMe), amide (e.g., C(O)N(R)2), C(O) - alkyl, C(O) - pyrrolidine, C(O) - piperidine, N(R)2 (e.g., N(CH3)2, NH2), NH(R. 10 )、N(R 10 )(R 11 )、CF3, aryl, phenyl, heteroaryl, a substituted or unsubstituted C3 - C8 cycloalkyl (e.g., cyclobutanol), a substituted or unsubstituted 3 - to 8 - membered heterocyclic ring (e.g., pyran, oxetane, piperidine, pyrazole, methylpyrazole, triazole, imidazole), halophenyl, (benzyloxy)phenyl, CN, and NO2 and can be further substituted with at least one substituent selected from them. Each corresponds to a separate embodiment of the present invention.

[0184] In some embodiments, R6 of structural formula I(b) and / or I(l) is -R8 - O - R 10 . In some embodiments, -R8 - O - R 10 is CH2 - O - CH3. In some embodiments, R6 is R8 - S - R 10 . In some embodiments, R8 - S - R 10 is (CH2)3 - S - (CH2)2CH3. In some embodiments, R6 is R8 - NHC(O) - R 10It is. In some embodiments, R6 is R8-(substituted or unsubstituted cycloalkyl of C3-C8). In some embodiments, R8-(substituted or unsubstituted cycloalkyl of C3-C8) is CH2-cyclobutanol, CH2-difluorocyclopropyl, CH2-methylcyclopropyl, CH2-dimethylamino-cyclohexyl, (CH2)2-cyclopentanol, CH2-cyclohexanol, (CH2)3-pyran, CH2-tetrahydrofuran, CH2-dioxane, CH2-methyl-THF, CH2-oxa-azaspirodecan, (CH2)3-dimethylpyrazole, CH2-methyl-azetidine, or CH2-azaspiroheptane. Each corresponds to a separate embodiment of the present invention. In some embodiments, R6 is a straight-chain or branched-chain substituted or unsubstituted alkyl of C1-C5. In some embodiments, R6 is a straight-chain or branched-chain substituted alkyl of C1-C5. In some embodiments, the substituted alkyl is CH(CH3)CH2OCH3, CH(CH3)CH2NH2, CH(CH3)C(O)N(CH3)2, CH2-CH(OH)Ph, (CH2)3N(H)CH2CH3, CH(CH3)(CH2)2OH, CH(CH2OH)(CH2CH3), (CH2)3-OCH3, (CH2)2-OCH3, (CH2)2-OCH(CH3)2, CH(CH2OH)(CH2CH(CH3)2), CH2CH(CH3)(OCH3), CH2CH(N(CH3)2)(CH2CH3), CH2-OCH2-CH2-O-CH3, or benzyl. Each corresponds to a separate embodiment of the present invention. In some embodiments, R6 is a straight-chain or branched-chain unsubstituted alkyl of C1-C5. In some embodiments, the unsubstituted alkyl is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, or neopentyl. Each corresponds to a separate embodiment of the present invention. In some embodiments, R6 is a substituted or unsubstituted cycloalkyl of C3-C8. In some embodiments, R6 is a substituted cycloalkyl of C3-C8.In some embodiments, the substituted cycloalkyl is methoxycyclopropyl, methylcyclobutyl, aminomethyl-cyclobutyl, methoxycyclobutyl, or 2,3-dihydro-1H-indenol. Each corresponds to a separate embodiment of the invention. In some embodiments, R6 is unsubstituted C3-C8 cycloalkyl. In some embodiments, the unsubstituted cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl. Each corresponds to a separate embodiment of the invention. In some embodiments, R6 is a substituted or unsubstituted saturated or unsaturated monocyclic, fused ring, bridged ring or spiro ring 3- to 10-membered ring carbocyclic or heterocyclic ring. In some embodiments, the carbocyclic or heterocyclic ring defined by R6 is F, Cl, Br, I, C1-C5 straight or branched chain alkyl, OH, alkoxy (e.g., OMe), amide, C(O)N(R)2, C(O)-alkyl, C(O)-pyrrolidine, C(O)-piperidine, N(R)2, NH(R. 10 )、N(R 10 )(R 11)、N(CH3)2, NH2, CF3, aryl, phenyl, heteroaryl, a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclobutanol), a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., pyran, oxetane, piperidine, pyrazole, triazole, imidazole), a C1-C5 linear or branched haloalkyl (e.g., CH2CF3, CHF2), halophenyl, (benzyloxy)phenyl, CN, and NO2. In some embodiments, R6 is a substituted or unsubstituted 3- to 10-membered heterocyclic ring. In some embodiments, the substituted heterocyclic ring is piperidine, 1-methylpiperidine, 3-fluoro-1-methylpiperidine, 1-(2,2,2-trifluoroethyl)piperidine, azetidine, 1-methyl-azetidine, morpholine, pyrrolidine, pyrrolidinone, quinuclidine, tetrahydropyran, tetrahydrofuran, azaspiro[3.3]heptane, 8-methyl-8-azabicyclo[3.2.1]octane, dioxane, 1,3-dioxane, imidazole, trifluoromethyl-oxetane, hydroxy-tetrahydrofuran, azepan-2-one, azabicyclohexane. Each corresponds to a separate embodiment of the present invention. In some embodiments, R6 is piperidine. In some embodiments, R6 is 1-methylpiperidine. In some embodiments, R6 is 3-fluoro-1-methylpiperidine. In some embodiments, R6 is 1-(2,2,2-trifluoroethyl)piperidine. In some embodiments, R6 is azetidine. In some embodiments, R6 is 1-methyl-azetidine. In some embodiments, R6 is morpholine. In some embodiments, R6 is pyrrolidine. In some embodiments, R6 is pyrrolidinone. In some embodiments, R6 is tetrahydropyran. In some embodiments, R6 is tetrahydrofuran. In some embodiments, R6 is 8-methyl-8-azabicyclo[3.2.1]octane. In some embodiments, R6 is dioxane. In some embodiments, R6 is 1,3-dioxane.In some embodiments, R6 is a substituted or unsubstituted saturated or unsaturated monocyclic, fused ring, bridged ring or spiro ring 3- to 10-membered carbocyclic ring. In some embodiments, R6 is 4,4-difluorocyclohexane.

[0185] In some embodiments, R7 in Structural Formulas I, II, I(a)-(f), and / or I(i) is H, F, Cl, Br, I, OH, O-R 20 , SH, R8-OH, R8-SH, SR 10 , -R8-O-R 10 , -R8-S-R 10 , R8-(C3-C8 cycloalkyl), R8-(3- to 8-membered heterocyclic ring), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8-CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R 10 )(R 11 ), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 , COO-CH3, R8-C(O)-R 10 , C(O)H, C(O)-R 10 , C1-C5 straight-chain or branched C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10) C1-C5 linear or branched substituted or unsubstituted alkyl, methylimidazole, methyl, ethyl, C1-C5 linear or branched substituted or unsubstituted alkenyl, C1-C5 linear or branched or C3-C8 cyclic haloalkyl, C1-C5 linear or branched or C3-C8 cyclic alkoxy (optionally, at least one methylene group (CH2) in the alkoxy is replaced by an oxygen atom), C1-C5 linear or branched thioalkyl, C1-C5 linear or branched thioalkoxy, C1-C5 linear or branched haloalkoxy, C1-C5 linear or branched alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl, cyclopropyl-1-ol, cyclopropylamine, oxetan-3-ol, bicyclo[1.1.1]pentane, substituted or unsubstituted 4- to 7-membered heterocyclic ring, morpholine, 3,3-dimethylmorpholine, tetrahydrofuran, tetrahydropyran, oxetane, oxetan-3-ol, pyrrolidine, pyrrolidin-2-ol, pyrrolidin-3-ol, 3-methoxypyrrolidine, pyrrolidine-3-carbonitrile, 3-cyanopyrrolidine, 1-methylpyrrolidine, 2,2-dimethylpyrrolidine, 3,3-difluoropyrrolidine, difluoromethylpyrrolidine, pyrrolidin-3-one - O-methyloxime, pyrrolidin-2-one, pyrrolidin-3-one, pyrrolidinone, imidazole, pyrazole, isoxazolidine, piperazine, piperazin-2-one, 1-methylpiperazine, piperidine, piperidin-3-ol, piperidin-4-ol, piperidin-2-one, piperidine-4-carbonitrile, 4-fluoropiperidine, oxadiazole, triazole, 2-oxopyrrolidine, isoxazolidine, piperazin-2-one, substituted or unsubstituted bridged ring, fused ring or spiro ring 3- to 10-membered heterocyclic ring, 4-azaspiro[2.4]heptane, 2-oxa-5-azaspiro[3.4]octane, 1,4-dioxa-6-azaspiro[4.4]nonane, 4,7-diazaspiro[2.5]octane, 2,5-diazabicyclo[2.2.1] It is heptane, R8-(a substituted or unsubstituted monocyclic, fused-ring or spiro-ring 3- to 8-membered heterocyclic ring), a substituted or unsubstituted aryl, or a substituted or unsubstituted benzyl. Each corresponds to a separate embodiment of the present invention. In some embodiments, R7 is F, Cl, Br, I, a linear or branched C1-C5 alkyl, OH, an alkoxy (e.g., OMe), an amide (e.g., C(O)N(R)2), C(O)-alkyl, C(O)-pyrrolidine, C(O)-piperidine, N(R)2, NH(R. 10 )、N(R 10 )(R 11 ), (e.g., N(CH3)2, NH2), CF3, aryl, phenyl, heteroaryl, a substituted or unsubstituted C3-C8 cycloalkyl (e.g., cyclobutanol), a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., pyran, oxetane, piperidine, pyrazole, methylpyrazole, triazole, imidazole), a halophenyl, (benzyloxy)phenyl, CN, and NO2, and is further substituted with at least one substituent selected from the group consisting of. Each corresponds to a separate embodiment of the present invention.

[0186] In some embodiments, R7 of Structural Formulas I, II, I(b), I(d)-I(f), and / or I(i) is H. In some embodiments, R7 is F. In some embodiments, R7 is Cl. In some embodiments, R7 is Br. In some embodiments, R7 is I. In some embodiments, R7 is OH. In some embodiments, R7 is O-R 20 . In some embodiments, R7 is CF3. In some embodiments, R7 is CN. In some embodiments, R7 is NH2. In some embodiments, R7 is NHR. In some embodiments, R7 is N(R)2. In some embodiments, R7 is NH(R 10 ). In some embodiments, R7 is N(R 10 )(R 11 ). In some embodiments, R7 is NHC(O)-R 10is. In some embodiments, R7 is COOH. In some embodiments, R7 is -C(O)Ph. In some embodiments, R7 is C(O)O-R 10 is. In some embodiments, R7 is COO-CH3. In some embodiments, R7 is C(O)H. In some embodiments, R7 is C(O)-R 10 is. In some embodiments, R7 is a C1-C5 linear or branched C(O)-haloalkyl. In some embodiments, R7 is -C(O)NH2. In some embodiments, R7 is C(O)NHR. In some embodiments, C(O)NHR is C(O)NH(CH3). In some embodiments, R7 is C(O)N(R 10 )(R 11 ) is. In some embodiments, C(O)N(R 10 )(R 11) is C(O)NH(CH3), C(O)NH(CH2CH2OCH3), or C(O)NH(CH2CH2OH). Each corresponds to a separate embodiment of the present invention. In some embodiments, R7 is SO2R. In some embodiments, R7 is a straight-chain or branched-chain, substituted or unsubstituted C1-C5 alkyl. In some embodiments, the alkyl is methylimidazole, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, neopentyl, or hexyl. Each corresponds to a separate embodiment of the present invention. In some embodiments, R7 is a straight-chain or branched-chain C1-C5 or cyclic C3-C8 haloalkyl. In some embodiments, R7 is a straight-chain C1-C5 haloalkyl. In some embodiments, the haloalkyl is CHF2. In some embodiments, R7 is a branched-chain C1-C5 haloalkyl. In some embodiments, R7 is a cyclic C3-C8 haloalkyl. In some embodiments, R7 is a straight-chain or branched-chain C1-C5 or cyclic C3-C8 alkoxy (optionally, at least one methylene group (CH2) in the alkoxy is replaced by an oxygen atom). In some embodiments, R7 is a straight-chain C1-C5 alkoxy. In some embodiments, the alkoxy is methoxy. In some embodiments, the alkoxy is ethoxy. In some embodiments, R7 is a branched-chain C1-C5 alkoxy. In some embodiments, R7 is a cyclic C3-C8 alkoxy. In some embodiments, R7 is a straight-chain or branched-chain C1-C5 thioalkyl. In some embodiments, R7 is a straight-chain or branched-chain C1-C5 haloalkoxy. In some embodiments, R7 is a straight-chain C1-C5 haloalkoxy. In some embodiments, R7 is a branched-chain C1-C5 haloalkoxy. In some embodiments, R7 is a straight-chain or branched-chain C1-C5 alkoxyalkyl. In some embodiments, R7 is a substituted or unsubstituted C3-C8 cycloalkyl.In some embodiments, the cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, bicyclo[1.1.1]pentane, cyclohexyl, cycloheptyl, or cyclooctyl. Each corresponds to a separate embodiment of the present invention. In some embodiments, R7 is a substituted or unsubstituted saturated, unsaturated or aromatic monocyclic, fused ring, bridged ring or spiro ring 3- to 10-membered ring carbocyclic or heterocyclic ring. In some embodiments, R7 is a substituted or unsubstituted saturated, unsaturated or aromatic monocyclic, fused ring, bridged ring or spiro ring 3- to 10-membered ring heterocyclic ring. In some embodiments, R7 is a substituted or unsubstituted 4- to 7-membered ring heterocyclic ring. In some embodiments, R7 is an unsubstituted 4- to 7-membered ring heterocyclic ring. In some embodiments, the heterocyclic ring is morpholine, tetrahydrofuran, tetrahydropyran, oxetane, pyrrolidine, pyrrolidin-3-one, pyrrolidin-2-one, pyrrolidinone, imidazole, pyrazole, isoxazolidine, piperazine, piperazin-2-one, piperidine, piperidin-2-one, oxadiazole, triazole, isoxazolidine, or 2-oxopyrrolidine. Each corresponds to a separate embodiment of the present invention. In some embodiments, R7 is a substituted 4- to 7-membered ring heterocyclic ring. In some embodiments, the heterocyclic ring is 3,3-dimethylmorpholine, oxetan-3-ol, pyrrolidin-2-ol, pyrrolidin-3-ol, 3-methoxypyrrolidine, pyrrolidine-3-carbonitrile, 3-cyanopyrrolidine, 1-methylpyrrolidine, 2,2-dimethylpyrrolidine, 3,3-difluoropyrrolidine, difluoromethylpyrrolidine, pyrrolidin-3-one-O-methyloxime, pyrrolidin-3-one-O-methyloxime, 1-methylpiperazine, piperidin-3-ol, piperidin-4-ol, piperidine-4-carbonitrile, 4-fluoropiperidine. Each corresponds to a separate embodiment of the present invention. In some embodiments, R7 is a substituted or unsubstituted bridged ring, fused ring or spiro ring 3- to 10-membered ring heterocyclic ring.In some embodiments, this ring is 4-azaspiro[2.4]heptane, 2-oxa-5-azaspiro[3.4]octane, 1,4-dioxa-6-azaspiro[4.4]nonane, 4,7-diazaspiro[2.5]octane, 2,5-diazabicyclo[2.2.1]heptane. Each corresponds to a separate embodiment of the invention. In some embodiments, R7 is R8-(a 3- to 8-membered heterocyclic ring of a substituted or unsubstituted monocyclic, fused-ring or spiro-ring). In some embodiments, R7 is R8-(an unsubstituted 3- to 8-membered heterocyclic ring of a monocyclic ring). In some embodiments, R7 is R8-(an unsubstituted 3- to 8-membered heterocyclic ring of a fused-ring). In some embodiments, R7 is R8-(an unsubstituted 3- to 8-membered heterocyclic ring of a spiro-ring). In some embodiments, R7 is R8-(a substituted 3- to 8-membered heterocyclic ring of a monocyclic ring). In some embodiments, R7 is R8-(a substituted 3- to 8-membered heterocyclic ring of a fused-ring). In some embodiments, R7 is R8-(a substituted 3- to 8-membered heterocyclic ring of a spiro-ring). In some embodiments, the heterocyclic ring can be saturated. In some embodiments, the heterocyclic ring can be unsaturated. In some embodiments, the heterocyclic ring can be aromatic. In some embodiments, R7 is a substituted or unsubstituted aryl. In some embodiments, R7 is phenyl. In some embodiments, R7 is F, Cl, Br, I, a straight-chain or branched-chain C1-C5 alkyl, OH, an alkoxy (e.g., OMe), an amide (e.g., C(O)N(R)2), C(O)-pyrrolidine, C(O)-piperidine, N(R)2, NH(R. 10 ), N(R 10 )(R 11) (e.g., N(CH3)2, NH2), CF3, aryl, phenyl, heteroaryl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclobutanol), C1-C5 linear or branched haloalkyl (e.g., CH2CF3, CHF2), substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., pyran, oxetane, piperidine, pyrazole, methylpyrazole, triazole, imidazole), halophenyl, (benzyloxy)phenyl, CN, and NO2, and may be further substituted with at least one substituent selected therefrom. Each corresponds to a separate embodiment of the present invention.

[0187] In some embodiments, R7 of Structural Formula I(a) is O-R 20In some embodiments, R7 is a substituted or unsubstituted 4- to 7-membered heterocyclic ring. In some embodiments, R7 is a substituted or unsubstituted saturated, unsaturated or aromatic monocyclic, fused ring, bridged ring or spiro ring 3- to 10-membered carbocyclic or heterocyclic ring. In some embodiments, R7 is a substituted or unsubstituted saturated, unsaturated or aromatic monocyclic, fused ring, bridged ring or spiro ring 3- to 10-membered heterocyclic ring. In some embodiments, R7 is a substituted or unsubstituted 4- to 7-membered heterocyclic ring. In some embodiments, R7 is an unsubstituted 4- to 7-membered heterocyclic ring. In some embodiments, the heterocyclic ring is morpholine, tetrahydrofuran, tetrahydropyran, oxetane, pyrrolidine, pyrrolidin-3-one, pyrrolidin-2-one, pyrrolidinone, imidazole, pyrazole, isoxazolidine, piperazine, piperidine, piperidin-2-one, oxadiazole, triazole, isoxazolidine, or 2-oxopyrrolidine. Each corresponds to a separate embodiment of the present invention. In some embodiments, R7 is a substituted 4- to 7-membered heterocyclic ring. In some embodiments, the heterocyclic ring is 3,3-dimethylmorpholine, oxetan-3-ol, pyrrolidin-2-ol, pyrrolidin-3-ol, 3-methoxypyrrolidine, pyrrolidine-3-carbonitrile, 3-cyanopyrrolidine, 1-methylpyrrolidine, 2,2-dimethylpyrrolidine, 3,3-difluoropyrrolidine, difluoromethylpyrrolidine, pyrrolidin-3-one-O-methyloxime, pyrrolidin-3-one-O-methyloxime, 1-methylpiperazine, piperidin-3-ol, piperidin-4-ol, piperidine-4-carbonitrile, 4-fluoropiperidine. Each corresponds to a separate embodiment of the present invention. In some embodiments, R7 is a substituted or unsubstituted bridged ring, fused ring or spiro ring 3- to 10-membered heterocyclic ring. In some embodiments, this ring is 4-azaspiro[2.4]heptane, 2-oxa-5-azaspiro[3.4]octane, 1,4-dioxa-6-azaspiro[4.4]nonane. Each corresponds to a separate embodiment of the present invention. In some embodiments, R7 is morpholine.In some embodiments, R7 is tetrahydrofuran. In some embodiments, R7 is tetrahydropyran. In some embodiments, R7 is oxetane. In some embodiments, R7 is oxetan-3-ol. In some embodiments, R7 is pyrrolidine. In some embodiments, R7 is pyrrolidin-2-ol. In some embodiments, R7 is pyrrolidin-3-ol. In some embodiments, R7 is 3-methoxypyrrolidine. In some embodiments, R7 is pyrrolidine-3-carbonitrile. In some embodiments, R7 is 1-methylpyrrolidine. In some embodiments, R7 is pyrrolidin-2-one. In some embodiments, R7 is pyrrolidin-3-one. In some embodiments, R7 is pyrrolidinone. In some embodiments, R7 is imidazole. In some embodiments, R7 is pyrazole. In some embodiments, R7 is isoxazolidine. In some embodiments, R7 is piperazine. In some embodiments, R7 is piperidine. In some embodiments, R7 is piperidin-3-ol. In some embodiments, R7 is piperidin-4-ol. In some embodiments, R7 is piperidin-2-one. In some embodiments, R7 is piperazin-2-one. In some embodiments, R7 is piperidine-4-carbonitrile. In some embodiments, R7 is 4-fluoropiperidine. In some embodiments, R7 is 2,2-dimethylpyrrolidine. In some embodiments, R7 is pyrrolidin-3-one-O-methyloxime. In some embodiments, R7 is a 3- to 10-membered heterocyclic ring of a substituted or unsubstituted bridged ring, fused ring or spiro ring. In some embodiments, R7 is 4-azaspiro[2.4]heptane. In some embodiments, R7 is 2-oxa-5-azaspiro[3.4]octane. In some embodiments, R7 is 1,4-dioxa-6-azaspiro[4.4]nonane. In some embodiments, R7 is 4,7-diazaspiro[2.5]octane.In some embodiments, R7 is 2,5-diazabicyclo[2.2.1]heptane. In some embodiments, R7 is 3,3-dimethylmorpholine. In some embodiments, R7 is 1-methylpiperazine. In some embodiments, R7 is oxadiazole. In some embodiments, R7 is triazole. In some embodiments, R7 is a substituted or unsubstituted aryl. In some embodiments, R7 is phenyl. In some embodiments, R7 is F, Cl, Br, I, a straight-chain or branched C1-C5 alkyl, OH, an alkoxy (e.g., OMe), an amide (e.g., C(O)N(R)2), C(O)-pyrrolidine, C(O)-piperidine, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), (e.g., N(CH3)2, NH2), CF3, aryl, phenyl, heteroaryl, a substituted or unsubstituted C3-C8 cycloalkyl (e.g., cyclobutanol), a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., pyran, oxetane, piperidine, pyrazole, methylpyrazole, triazole, imidazole), a straight-chain or branched C1-C5 haloalkyl (e.g., CH2CF3, CHF2), halophenyl, (benzyloxy)phenyl, CN, and NO2 and may be further substituted with at least one substituent selected from. Each corresponds to a separate embodiment of the present invention.

[0188] In some embodiments, R7 of structural formula I(c) is not H, F, Cl, a straight-chain or branched C1-C5 or cyclic C3-C8 alkoxy, a straight-chain or branched C1-C5 haloalkoxy, or a straight-chain or branched substituted or unsubstituted C1-C5 alkyl.

[0189] In some embodiments, R7 of structural formulas I, II, I(a) to I(f), and / or I(i) is represented by the following structural formula A.

[0190] [Chemical formula]

[0191] In the formula, X1 is N or O; R1 and R2 are each independently H, F, Cl, Br, I, OH, SH, CF3, a substituted or unsubstituted alkyl having 1 to 5 carbon atoms (for example, CH2OH, CH2OCH3), a linear or branched alkyl having 1 to 5 carbon atoms or a cyclic haloalkyl having 3 to 8 carbon atoms, a linear or branched substituted or unsubstituted alkoxy having 1 to 5 carbon atoms or a cyclic alkoxy having 3 to 8 carbon atoms (for example, oxetane); or, R1 and R2 are bonded to each other to form a carbocyclic or heterocyclic ring having 3 to 8 carbon atoms (for example, cyclopropyl); R3 and R4 are each independently H, Me, a substituted or unsubstituted alkyl having 1 to 5 carbon atoms (for example, methoxyethylene, methylaminoethyl, aminoethyl), -R8-O-R 10 (for example, (CH2)2-O-CH3), R8-N(R 10 )(R 11 )(for example, (CH2)2-NH(CH3)), a substituted or unsubstituted cycloalkyl having 3 to 8 carbon atoms (for example, cyclopropyl), a substituted or unsubstituted heterocyclic ring having 5 to 7 members (for example, pyrrolidine, methylpyrrolidine, piperidine), or, R 20 ; R3 and R4 are bonded to each other to form a heterocyclic ring having 3 to 8 members (for example, pyrrolidine, pyrrolidone, 2-oxopyrrolidine, piperidine, morpholine, piperazine, imidazole); or, R2 and R4 are bonded to each other to form a substituted or unsubstituted saturated or unsaturated heterocyclic ring having 4 to 8 members (for example, pyrrolidine, morpholine, 1-methylpyrrolidine, pyrrolidin-2-one, pyrrolidin-3-one, 3,3-difluoropyrrolidine, pyrrolidin-3-ol, 3-methoxypyrrolidine, 3-(difluoromethyl)pyrrolidine, pyrrolidine-3-carbonitrile, pyridine, piperidine, piperidin-2-one, imidazole, pyrimidine, triazole, oxadiazole, pyrazole). However, when X1 is O, R4 does not exist.

[0192] In some embodiments, X1 of Structural Formula A is N. In other embodiments, X1 is O.

[0193] In some embodiments, R1 of Structural Formula A, I(h), I(m), and / or I(o) is H. In other embodiments, R1 is F. In other embodiments, R1 is CF3. In other embodiments, R1 is Cl. In other embodiments, R1 is Br. In other embodiments, R1 is I. In other embodiments, R1 is OH. In other embodiments, R1 is SH. In other embodiments, R1 is a C1-C5 substituted or unsubstituted alkyl. In other embodiments, R1 is CH2OH. In other embodiments, R1 is CH2OCH3. In other embodiments, R1 is a C1-C5 straight-chain or branched-chain or C3-C8 cyclic haloalkyl. In other embodiments, R1 is a C1-C5 straight-chain or branched-chain substituted or unsubstituted or C3-C8 cyclic alkoxy. In other embodiments, R1 is a 3- to 8-membered carbocyclic or heterocyclic ring. In other embodiments, R1 is a 3- to 8-membered heterocyclic ring. In other embodiments, R1 is oxetane. In other embodiments, R1 is a 3- to 8-membered carbocyclic ring.

[0194] In some embodiments, R2 of Structural Formulas A, I(h), I(m), and / or I(o) is H. In other embodiments, R2 is F. In other embodiments, R2 is CF3. In other embodiments, R2 is Cl. In other embodiments, R2 is Br. In other embodiments, R2 is I. In other embodiments, R2 is OH. In other embodiments, R2 is SH. In other embodiments, R2 is a C1-C5 substituted or unsubstituted alkyl. In other embodiments, R2 is CH2OH. In other embodiments, R2 is CH2OCH3. In other embodiments, R2 is a C1-C5 straight-chain or branched-chain or C3-C8 cyclic haloalkyl. In other embodiments, R2 is a C1-C5 straight-chain or branched-chain substituted or unsubstituted or C3-C8 cyclic alkoxy. In other embodiments, R2 is a 3- to 8-membered carbocyclic or heterocyclic ring. In other embodiments, R2 is a 3- to 8-membered heterocyclic ring. In other embodiments, R2 is oxetane. In other embodiments, R2 is a 3- to 8-membered carbocyclic ring.

[0195] In some embodiments, R1 and R2 of Structural Formulas A, I(h), I(m), and / or I(o) are bonded to each other to form =O. In other embodiments, R1 and R2 are bonded to each other to form a 3- to 8-membered carbocyclic or heterocyclic ring. In other embodiments, R1 and R2 are bonded to each other to form a 3- to 8-membered carbocyclic ring. In some embodiments, the carbocyclic ring is cyclopropyl. In other embodiments, R1 and R2 are bonded to each other to form a 3- to 8-membered heterocyclic ring.

[0196] In some embodiments, R1 and R2 of Structural Formulas A, I(a), and / or I(h) are not bonded to each other to form =O.

[0197] In some embodiments, R3 of Structural Formulas A, I(h), I(m), and / or I(o) is H. In some embodiments, R3 is methyl. In some embodiments, R3 is a C1-C5 substituted or unsubstituted alkyl. In some embodiments, the alkyl is methoxyethylene, methylaminoethylene, or aminoethylene. Each corresponds to a separate embodiment of the present invention. In some embodiments, R3 is -R8-O-R 10 is. In some embodiments, R3 is (CH2)2-O-CH3. In some embodiments, R3 is R8-N(R 10 )(R 11 ) is. In some embodiments, R3 is (CH2)2-NH(CH3). In some embodiments, R3 is a C3-C8 substituted or unsubstituted cycloalkyl. In some embodiments, the cycloalkyl is cyclopropyl. In some embodiments, R3 is a substituted or unsubstituted 5- to 7-membered heterocyclic ring. In some embodiments, the heterocyclic ring is pyrrolidine, methylpyrrolidine, or piperidine. Each corresponds to a separate embodiment of the present invention. In some embodiments, R3 is pyrrolidine. In some embodiments, R3 is methylpyrrolidine. In some embodiments, R3 is piperidine. In some embodiments, R3 is R 20 as defined below.

[0198] In some embodiments, R4 of Structural Formulas A, I(h), I(m), and / or I(o) is H. In some embodiments, R4 is methyl. In some embodiments, R4 is a C1-C5 substituted or unsubstituted alkyl. In some embodiments, the alkyl is methoxyethylene, methylaminoethylene, or aminoethylene. Each corresponds to a separate embodiment of the present invention. In some embodiments, R4 is -R8-O-R 10 is. In some embodiments, R4 is (CH2)2-O-CH3. In some embodiments, R4 is R8-N(R 10 )(R 11) It is. In some embodiments, R4 is (CH2)2-NH(CH3). In some embodiments, R4 is a C3-C8 substituted or unsubstituted cycloalkyl. In some embodiments, the cycloalkyl is cyclopropyl. In some embodiments, R4 is a substituted or unsubstituted 5- to 7-membered heterocyclic ring. In some embodiments, the heterocyclic ring is pyrrolidine, methylpyrrolidine, or piperidine. Each corresponds to a separate embodiment of the present invention. In some embodiments, R4 is pyrrolidine. In some embodiments, R4 is methylpyrrolidine. In some embodiments, R4 is piperidine. In some embodiments, R4 is R as defined hereinbelow 20 It is.

[0199] In some embodiments, R3 and R4 of structural formulas A, I(h), I(m), and / or I(o) are bonded to each other to form a 3- to 8-membered heterocyclic ring. In some embodiments, the heterocyclic ring is imidazole, pyrrolidine, pyrrolidone, 2-oxopyrrolidine, piperidine, morpholine, or piperazine. Each corresponds to a separate embodiment of the present invention.

[0200] In some embodiments, R2 and R4 of Structural Formulas A, I(h), and / or I(m) are joined to each other to form an F ring. In some embodiments, the F ring is absent. In some embodiments, the F ring is a substituted or unsubstituted saturated or unsaturated 4- to 8-membered heterocyclic ring. In some embodiments, R2 and R4 are joined to each other to form pyrrolidine, 1-methylpyrrolidine, pyrrolidin-2-one, pyridine, piperidine, imidazole, pyrimidine, triazole, oxadiazole, pyrazole. Each corresponds to a separate embodiment of the present invention. In some embodiments, the F ring is an unsubstituted saturated 4- to 8-membered heterocyclic ring. In some embodiments, the F ring is pyrrolidine, morpholine, or piperidine. Each corresponds to a separate embodiment of the present invention. In some embodiments, the F ring is a substituted saturated 4- to 8-membered heterocyclic ring. In some embodiments, the F ring is 1-methylpyrrolidine, 3,3-difluoropyrrolidine, pyrrolidin-3-ol, 3-methoxypyrrolidine, 3-(difluoromethyl)pyrrolidine, or pyrrolidine-3-carbonitrile. Each corresponds to a separate embodiment of the present invention. In some embodiments, the F ring is a substituted or unsubstituted unsaturated 4- to 8-membered heterocyclic ring. In some embodiments, the F ring is pyrrolidin-2-one, pyrrolidin-3-one, pyridine, piperidin-2-one, imidazole, pyrimidine, triazole, oxadiazole, or pyrazole. Each corresponds to a separate embodiment of the present invention. In some embodiments, when the F ring is aromatic, R1 is absent. In some embodiments, when the F ring is aromatic, R3 is absent. In some embodiments, when the F ring is aromatic, R1 and / or R3 are absent.

[0201] In some embodiments, R2 and R4 of Structural Formulas A, I(h), and / or I(m) are joined to each other to form a substituted or unsubstituted saturated or unsaturated 4- to 8-membered heterocyclic ring. In some embodiments, the heterocyclic ring is pyrrolidine, morpholine, 1-methylpyrrolidine, pyrrolidin-2-one, pyrrolidin-3-one, 3,3-difluoropyrrolidine, pyrrolidin-3-ol, 3-methoxypyrrolidine, 3-(difluoromethyl)pyrrolidine, pyrrolidine-3-carbonitrile, pyridine, piperidine, piperidin-2-one, imidazole, pyrimidine, triazole, oxadiazole, or pyrazole. Each corresponds to a separate embodiment of the present invention.

[0202] In some embodiments, when X1 of Structural Formula A is O, R4 is absent.

[0203] In some embodiments, R2 and R4 of Structural Formulas I(h) and / or I(m) are joined to each other to form an F ring. In some embodiments, the F ring is absent. In some embodiments, the F ring is a substituted or unsubstituted saturated or unsaturated 4- to 8-membered heterocyclic ring. In some embodiments, the F ring is an unsubstituted saturated 4- to 8-membered heterocyclic ring. In some embodiments, the F ring is pyrrolidine, morpholine, or piperidine. Each corresponds to a separate embodiment of the present invention. In some embodiments, the F ring is a substituted saturated 4- to 8-membered heterocyclic ring. In some embodiments, the F ring is 1-methylpyrrolidine, 3,3-difluoropyrrolidine, pyrrolidin-3-ol, 3-methoxypyrrolidine, 3-(difluoromethyl)pyrrolidine, or pyrrolidine-3-carbonitrile. Each corresponds to a separate embodiment of the present invention. In some embodiments, the F ring is a substituted or unsubstituted unsaturated 4- to 8-membered heterocyclic ring. In some embodiments, the F ring is pyrrolidin-2-one, pyrrolidin-3-one, pyridine, piperidin-2-one, imidazole, pyrimidine, triazole, oxadiazole, or pyrazole. Each corresponds to a separate embodiment of the present invention.

[0204] In some embodiments, the F-ring of Structural Formula I(h) and / or I(m) is absent. In some embodiments, the F-ring is a substituted or unsubstituted saturated or unsaturated 4- to 8-membered heterocyclic ring. In some embodiments, the F-ring is a substituted saturated 4- to 8-membered heterocyclic ring. In some embodiments, the F-ring is a substituted unsaturated 4- to 8-membered heterocyclic ring. In some embodiments, the F-ring is an unsubstituted saturated 4- to 8-membered heterocyclic ring. In some embodiments, the F-ring is an unsubstituted unsaturated 4- to 8-membered heterocyclic ring. In some embodiments, the F-ring is pyrrolidine. In some embodiments, the F-ring is pyrrolidin-2-one. In some embodiments, the F-ring is piperidine. In some embodiments, the F-ring is piperazine. In some embodiments, the F-ring is morpholine. In some embodiments, the F-ring is pyridinyl. In other embodiments, the F-ring is 2-pyridinyl. In other embodiments, the F-ring is pyrimidine. In other embodiments, the F-ring is imidazole. In other embodiments, the F-ring is pyridazine. In other embodiments, the F-ring is pyrazine. In other embodiments, the F-ring is pyrazole. In other embodiments, the F-ring is thiazole. In other embodiments, the F-ring is isothiazolyl. In other embodiments, the F-ring is thiadiazolyl. In other embodiments, the F-ring is triazolyl. In other embodiments, the F-ring is thiazolyl. In other embodiments, the F-ring is oxazolyl. In other embodiments, the F-ring is isoxazolyl. In other embodiments, the F-ring is pyrrolyl. In other embodiments, the F-ring is oxadiazolyl. In other embodiments, the F-ring is 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, or 1,3,4-oxadiazolyl. Each corresponds to a separate embodiment of the present invention. In other embodiments, the F-ring is oxazolonyl. In other embodiments, the F-ring is oxazolidonyl. In other embodiments, the F-ring is thiazolonyl. In other embodiments, the F-ring is isothiazolinonyl. In other embodiments, the F-ring is isoxazolidinonyl. In other embodiments, the F-ring is imidazolidinonyl.In other embodiments, the F ring is pyrazolonyl. In other embodiments, the F ring is 2H-pyrrol-2-onyl. In other embodiments, the F ring is triazolopyrimidine. In other embodiments, the F ring is 3H-[1,2,3]triazolo[4,5-d]pyrimidine, 1H-[1,2,3]triazolo[4,5-d]pyrimidine, [1,2,4]triazolo[4,3-c]pyrimidine, [1,2,4]triazolo[4,3-a]pyrimidine, [1,2,3]triazolo[1,5-a]pyrimidine, [1,2,3]triazolo[1,5-c]pyrimidine, [1,2,4]triazolo[1,5-a]pyrimidine, or [1,2,4]triazolo[1,5-c]pyrimidine. Each corresponds to a separate embodiment of the present invention. In other embodiments, the F ring is 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine.

[0205] In some embodiments, R7 of Structural Formula I(a) is O-R 20 , a substituted or unsubstituted 4- to 7-membered heterocyclic ring (e.g., morpholine, tetrahydrofuran, tetrahydropyran, oxetane, oxetan-3-ol, pyrrolidine, pyrrolidin-2-ol, pyrrolidin-3-ol, 3-methoxypyrrolidine, 1-methylpyrrolidine, pyrrolidin-2-one, pyrrolidin-3-one, pyrrolidine-3-carbonitrile, 3-cyanopyrrolidine, pyrrolidinone, imidazole, pyrazole, isoxazolidine, piperazine, piperidine, piperidin-3-ol, piperidin-4-ol, piperidin-2-one, piperidine-4-carbonitrile, 4-fluoropiperidine, oxadiazole, triazole, pyrazole, 2-oxopyrrolidine), or a substituted or unsubstituted aryl. In some embodiments, R7 of Structural Formula I(a) is represented by Structural Formula A, where X1, R1, R2, R3, and R4 are as defined above, except that R1 and R2 cannot be bonded to each other to form =O.

[0206] In some embodiments, R7' of Structural Formula I(c) is not H.

[0207] In some embodiments, R7´ of Structural Formulas I, II, I(a) - I(b), and / or I(d) - I(o) is H. In some embodiments, R7´ of Structural Formulas I, II, and / or I(a) - I(o) is F, Cl, Br, I, OH, O-R 20 , SH, R8-OH, R8-SH, -R8-O-R 10 , R8-(C3-C8 cycloalkyl), R8-(3- to 8-membered heterocycle), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8-CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R 10 )(R 11 ), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 , R8-C(O)-R 10 , C(O)H, C(O)-R 10 , C1-C5 linear or branched C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10), a straight-chain or branched-chain, substituted or unsubstituted C1-C5 alkyl, a substituted or unsubstituted C1-C5 straight-chain or branched-chain alkenyl, a straight-chain or branched-chain C1-C5 or cyclic C3-C8 haloalkyl, a straight-chain or branched-chain C1-C5 or cyclic C3-C8 alkoxy (optionally, at least one methylene group (CH2) in the alkoxy is substituted by an oxygen atom), methoxy, a straight-chain or branched-chain C1-C5 thioalkoxy, a straight-chain or branched-chain C1-C5 haloalkoxy, a straight-chain or branched-chain C1-C5 alkoxyalkyl, a substituted or unsubstituted C3-C8 cycloalkyl, cyclopropyl, cyclohexyl, a substituted or unsubstituted 3- to 8-membered heterocyclic ring, morpholine, pyran, oxetane, pyrrolidine, 3,3-difluoropyrrolidine, imidazole, pyrazole, triazole, piperazine, piperidine, piperidin-2-one, piperidin-4-ol, dioxazole, 2-oxopyrrolidine, a substituted or unsubstituted aryl, a substituted or unsubstituted benzyl. Each corresponds to a separate embodiment of the present invention. In some embodiments, the heterocyclic ring is morpholine, pyran, oxetane, pyrrolidine, 3,3-difluoropyrrolidine, imidazole, pyrazole, triazole, piperazine, piperidine, piperidin-2-one, piperidin-4-ol, dioxazole, 2-oxopyrrolidine. Each corresponds to a separate embodiment of the present invention. In some embodiments, R7´ is morpholine, pyran, oxetane, pyrrolidine, 3,3-difluoropyrrolidine, imidazole, pyrazole, triazole, piperazine, piperidine, piperidin-2-one, piperidin-4-ol, dioxazole, 2-oxopyrrolidine. Each corresponds to a separate embodiment of the present invention. In some embodiments, R7´ is F, Cl, Br, I, a straight-chain or branched-chain C1-C5 alkyl, OH, alkoxy (e.g., OMe), amide (e.g., C(O)N(R)2), C(O)-pyrrolidine, C(O)-piperidine, N(R)2, NH(R 10 ), N(R 10 )(R 11) (e.g., N(CH3)2, NH2), CF3, aryl, phenyl, heteroaryl, a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclobutanol), a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., pyran, oxetane, piperidine, pyrazole, methylpyrazole, triazole, imidazole), halophenyl, (benzyloxy)phenyl, CN, and NO2, and is further substituted with at least one substituent selected therefrom. Each corresponds to a separate embodiment of the present invention.

[0208] In some embodiments, R7´ of Structural Formulas I, II, and / or I(a) - I(o) is H. In some embodiments, R7´ is F. In some embodiments, R7´ is Cl. In some embodiments, R7´ is Br. In some embodiments, R7´ is I. In some embodiments, R7´ is CF3. In some embodiments, R7´ is a linear or branched, substituted or unsubstituted C1 - C5 alkyl. In some embodiments, R7´ is a linear or branched, unsubstituted C1 - C5 alkyl. In some embodiments, the alkyl is isopropyl, methyl, or ethyl. Each corresponds to a separate embodiment of the present invention. In some embodiments, R7´ is a linear or branched, substituted C1 - C5 alkyl. In some embodiments, R7´ is isopropyl. In some embodiments, R7´ is methyl. In some embodiments, R7´ is ethyl. In some embodiments, R7´ is a linear or branched C1 - C5 or cyclic C3 - C8 haloalkyl. In some embodiments, R7´ is a linear or branched C1 - C5 haloalkyl. In some embodiments, the haloalkyl is CHF2. In some embodiments, R7´ is a cyclic C3 - C8 haloalkyl. In some embodiments, R7´ is a substituted or unsubstituted C3 - C8 cycloalkyl. In some embodiments, the cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl. Each corresponds to a separate embodiment of the present invention. In some embodiments, the cycloalkyl is cyclopropyl. In some embodiments, the cycloalkyl is cyclohexyl. In some embodiments, R7´ is morpholine. In some embodiments, R7´ is pyran. In some embodiments, R7´ is oxetane. In some embodiments, R7´ is pyrrolidine. In some embodiments, R7´ is 3,3 - difluoropyrrolidine. In some embodiments, R7´ is imidazole. In some embodiments, R7´ is pyrazole.In some embodiments, R7´ is triazole. In some embodiments, R7´ is piperazine. In some embodiments, R7´ is piperidine. In some embodiments, R7´ is piperidin-2-one. In some embodiments, R7´ is piperidin-4-ol. In some embodiments, R7´ is dioxazole. In some embodiments, R7´ is 2-oxopyrrolidine.

[0209] In some embodiments, R7 and R7' of Structural Formulas I, II, and / or I(a) - I(f) are joined to each other to form a substituted or unsubstituted saturated, unsaturated, or aromatic 3 - 8 - membered carbocyclic or heterocyclic ring (but not limited to, for example, cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine. Each corresponds to a separate embodiment of the present invention). In some embodiments, R7 and R7' are joined to each other to form a substituted or unsubstituted saturated, unsaturated, or aromatic 5 - or 6 - membered carbocyclic or heterocyclic ring. In some embodiments, R7 and R7' are joined to each other to form an unsubstituted saturated or unsaturated 5 - membered carbocyclic ring. In some embodiments, R7 and R7' are joined to each other to form an unsubstituted saturated or unsaturated 6 - membered carbocyclic ring. In some embodiments, R7 and R7' are joined to each other to form cyclohexyl. In some embodiments, R7 and R7' are joined to each other to form a substituted saturated or unsaturated 5 - membered carbocyclic ring. In some embodiments, R7 and R7' are joined to each other to form cyclohexyl. In some embodiments, R7 and R7' are joined to each other to form a substituted saturated or unsaturated 6 - membered carbocyclic ring. In some embodiments, R7 and R7' are joined to each other to form a substituted or unsubstituted aromatic 6 - membered carbocyclic ring. In some embodiments, R7 and R7' are joined to each other to form a substituted or unsubstituted aromatic 5 - or 6 - membered heterocyclic ring. In some embodiments, R7 and R7' are joined to each other to form a substituted or unsubstituted 5 - or 6 - membered heterocyclic ring. In some embodiments, R7 and R7' are joined to each other to form a substituted or unsubstituted 6 - membered heterocyclic ring. In some embodiments, R7 and R7' are joined to each other to form piperidine. In some embodiments, R7 and R7' are joined to each other to form tetrahydropyran. In some embodiments, R7 and R7' are joined to each other to form a substituted or unsubstituted 5 - membered heterocyclic ring. In some embodiments, R7 and R7' are joined to each other to form pyrrolidine.In some embodiments, R7 and R7' are joined to each other to form tetrahydrofuran.

[0210] In some embodiments, R7 and R7' of Structural Formula I(c) are different from each other. In some embodiments, R7 and R7' of Structural Formula I(c) are not H, F, Cl, a C1-C5 straight-chain or branched-chain or C3-C8 cyclic alkoxy, a C1-C5 straight-chain or branched-chain haloalkoxy, or a C1-C5 straight-chain or branched-chain substituted or unsubstituted alkyl. Each corresponds to a separate embodiment of the present invention.

[0211] In some embodiments, R7'' of Structural Formulas I(i) - I(o) is H. In some embodiments, R7'' of Structural Formulas I(i) - I(m) is F, Cl, Br, I, OH, O-R 20 , SH, R8-OH, R8-SH, -R8-O-R 10 , R8-(C3-C8 cycloalkyl), R8-(3-8 membered heterocycle), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R 10 )(R 11 ), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 , R8-C(O)-R 10 , C(O)H, C(O)-R 10 , a C1-C5 straight-chain or branched-chain C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10)、C1-C5 linear or branched substituted or unsubstituted alkyl, C1-C5 linear or branched substituted or unsubstituted alkenyl, C1-C5 linear or branched or C3-C8 cyclic haloalkyl, C1-C5 linear or branched or C3-C8 cyclic alkoxy (optionally at least one methylene group (CH2) in the alkoxy is replaced by an oxygen atom), C1-C5 linear or branched thioalkoxy, C1-C5 linear or branched haloalkoxy, C1-C5 linear or branched alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl, substituted or unsubstituted 3- to 8-membered heterocyclic ring, substituted or unsubstituted aryl, or substituted or unsubstituted benzyl. Each corresponds to a separate embodiment of the present invention. In some embodiments, R7´´ is F, Cl, Br, I, C1-C5 linear or branched alkyl, OH, alkoxy (e.g., OMe), amide (e.g., C(O)N(R)2), C(O)-pyrrolidine, C(O)-piperidine, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), (e.g., N(CH3)2, NH2), CF3, aryl, phenyl, heteroaryl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclobutanol), substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., pyran, oxetane, piperidine, pyrazole, methylpyrazole, triazole, imidazole), halophenyl, (benzyloxy)phenyl, CN, and NO2 and is further substituted with at least one substituent selected therefrom. Each corresponds to a separate embodiment of the present invention.

[0212] In some embodiments, R7´´ in Structural Formulas I(i)-(o) is H. In some embodiments, R7´´ is F. In some embodiments, R7´´ is Cl. In some embodiments, R7´´ is Br. In some embodiments, R7´´ is I. In some embodiments, R7´´ is CF3. In some embodiments, R7´´ is a linear or branched, substituted or unsubstituted C1-C5 alkyl. In some embodiments, R7´´ is a linear or branched, unsubstituted C1-C5 alkyl. In some embodiments, the alkyl is isopropyl, methyl, or ethyl. Each corresponds to a separate embodiment of the present invention. In some embodiments, R7´´ is a linear or branched, substituted C1-C5 alkyl. In some embodiments, R7´´ is isopropyl. In some embodiments, R7´´ is methyl. In some embodiments, R7´´ is ethyl. In some embodiments, R7´´ is a linear or branched C1-C5 or cyclic C3-C8 alkoxy (optionally, at least one methylene group (CH2) in the alkoxy is replaced by an oxygen atom). In some embodiments, R7´´ is a linear C1-C5 alkoxy. In some embodiments, R7´´ is methoxy. In some embodiments, R7´´ is a linear or branched C1-C5 or cyclic C3-C8 haloalkyl. In some embodiments, R7´´ is a linear or branched C1-C5 haloalkyl. In some embodiments, the haloalkyl is CHF2. In some embodiments, R7´´ is a cyclic C3-C8 haloalkyl. In some embodiments, R7´´ is a substituted or unsubstituted C3-C8 cycloalkyl. In some embodiments, the cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl. Each corresponds to a separate embodiment of the present invention. In some embodiments, the cycloalkyl is cyclopropyl. In some embodiments, the cycloalkyl is cyclohexyl. In some embodiments, R7´´ is a substituted or unsubstituted 3- to 8-membered heterocyclic ring.In some embodiments, R7´´ is morpholine. In some embodiments, R7´´ is pyran. In some embodiments, R7´´ is oxetane. In some embodiments, R7´´ is pyrrolidine. In some embodiments, R7´´ is 3,3-difluoropyrrolidine. In some embodiments, R7´´ is imidazole. In some embodiments, R7´´ is pyrazole. In some embodiments, R7´´ is triazole. In some embodiments, R7´´ is piperazine. In some embodiments, R7´´ is piperidine. In some embodiments, R7´´ is piperidin-2-one. In some embodiments, R7´´ is piperidin-4-ol. In some embodiments, R7´´ is dioxazole. In some embodiments, R7´´ is 2-oxopyrrolidine.

[0213] In some embodiments, R7' and R7'' of Structural Formulas I(j) - I(o) are attached to each other to form a substituted or unsubstituted saturated, unsaturated, or aromatic 3 - 8 membered carbocyclic or heterocyclic ring (but not limited to, for example, cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine. Each corresponds to a separate embodiment of the present invention). In some embodiments, R7' and R7'' are attached to each other to form a substituted or unsubstituted saturated, unsaturated, or aromatic 5 - or 6 - membered carbocyclic or heterocyclic ring. In some embodiments, R7' and R7'' are attached to each other to form an unsubstituted saturated or unsaturated 5 - membered carbocyclic ring. In some embodiments, R7' and R7'' are attached to each other to form an unsubstituted saturated or unsaturated 6 - membered carbocyclic ring. In some embodiments, R7' and R7'' are attached to each other to form cyclohexyl. In some embodiments, R7' and R7'' are attached to each other to form a substituted saturated or unsaturated 5 - membered carbocyclic ring. In some embodiments, R7' and R7'' are attached to each other to form cyclohexyl. In some embodiments, R7' and R7'' are attached to each other to form a substituted saturated or unsaturated 6 - membered carbocyclic ring. In some embodiments, R7' and R7'' are attached to each other to form a substituted or unsubstituted aromatic 6 - membered carbocyclic ring. In some embodiments, R7' and R7'' are attached to each other to form a substituted or unsubstituted aromatic 5 - or 6 - membered heterocyclic ring. In some embodiments, R7' and R7'' are attached to each other to form a substituted or unsubstituted 5 - or 6 - membered heterocyclic ring. In some embodiments, R7' and R7'' are attached to each other to form a substituted or unsubstituted 6 - membered heterocyclic ring. In some embodiments, R7' and R7'' are attached to each other to form piperidine. In some embodiments, R7' and R7'' are attached to each other to form tetrahydropyran. In some embodiments, R7' and R7'' are attached to each other to form a substituted or unsubstituted 5 - membered heterocyclic ring. In some embodiments, R7' and R7'' are attached to each other to form pyrrolidine.In some embodiments, R7' and R7'' are joined to each other to form tetrahydrofuran.

[0214] In some embodiments, R7' and R7'' of structural formula I(c) and / or I(i) - I(o) are different from each other. In some embodiments, R7' and R7'' of structural formula I(c) and / or I(i) - I(n) are not H, F, Cl, a linear or branched C1 - C5 or cyclic C3 - C8 alkoxy, a linear or branched C1 - C5 haloalkoxy, or a linear or branched, substituted or unsubstituted C1 - C5 alkyl. Each corresponds to a separate embodiment of the present invention.

[0215] In some embodiments, R7''' of structural formula I(i) is H. In some embodiments, R7''' of structural formula I(i) is F, Cl, Br, I, OH, O - R 20 , SH, R8 - OH, R8 - SH, - R8 - O - R 10 , R8 - (C3 - C8 cycloalkyl), R8 - (3 - 8 membered heterocycle), CF3, CD3, OCD3, CN, NO2, - CH2CN, - R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8 - N(R 10 )(R 11 ), R9 - R8 - N(R 10 )(R 11 ), B(OH)2, - OC(O)CF3, - OCH2Ph, NHC(O) - R 10 , NHCO - N(R 10 )(R 11 ), COOH, - C(O)Ph, C(O)O - R 10 , R8 - C(O) - R 10 , C(O)H, C(O) - R 10 , C1 - C5 linear or branched C(O) - haloalkyl, - C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH - R 10) C1-C5 linear or branched substituted or unsubstituted alkyl, C1-C5 linear or branched substituted or unsubstituted alkenyl, C1-C5 linear or branched or C3-C8 cyclic haloalkyl, C1-C5 linear or branched or C3-C8 cyclic alkoxy (optionally at least one methylene group (CH2) in the alkoxy is replaced by an oxygen atom), C1-C5 linear or branched thioalkoxy, C1-C5 linear or branched haloalkoxy, C1-C5 linear or branched alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl, substituted or unsubstituted 3- to 8-membered heterocyclic ring, substituted or unsubstituted aryl, or substituted or unsubstituted benzyl. Each corresponds to a separate embodiment of the present invention. In some embodiments, R7´´´ is F, Cl, Br, I, C1-C5 linear or branched alkyl, OH, alkoxy (e.g., OMe), amide (e.g., C(O)N(R)2), C(O)-pyrrolidine, C(O)-piperidine, N(R)2, NH(R 10 ) N(R 10 )(R 11 ) (e.g., N(CH3)2, NH2), CF3, aryl, phenyl, heteroaryl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclobutanol), substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., pyran, oxetane, piperidine, pyrazole, methylpyrazole, triazole, imidazole), halophenyl, (benzyloxy)phenyl, CN, and NO2, and is further substituted with at least one substituent selected from the group consisting of. Each corresponds to a separate embodiment of the present invention.

[0216] In some embodiments, R7''' of Structural Formula I(i) is H. In some embodiments, R7''' is F. In some embodiments, R7''' is Cl. In some embodiments, R7''' is Br. In some embodiments, R7''' is I. In some embodiments, R7''' is CF3. In some embodiments, R7''' is a straight-chain or branched-chain, substituted or unsubstituted C1-C5 alkyl. In some embodiments, R7''' is a straight-chain or branched-chain, unsubstituted C1-C5 alkyl. In some embodiments, the alkyl is isopropyl, methyl, or ethyl. Each corresponds to a separate embodiment of the present invention. In some embodiments, R7''' is a straight-chain or branched-chain, substituted C1-C5 alkyl. In some embodiments, R7''' is isopropyl. In some embodiments, R7''' is methyl. In some embodiments, R7''' is ethyl. In some embodiments, R7''' is a straight-chain or branched-chain C1-C5 or C3-C8 cyclic alkoxy (optionally, at least one methylene group (CH2) in the alkoxy is replaced by an oxygen atom). In some embodiments, R7''' is a straight-chain C1-C5 alkoxy. In some embodiments, R7''' is methoxy. In some embodiments, R7''' is a straight-chain or branched-chain C1-C5 or C3-C8 cyclic haloalkyl. In some embodiments, R7''' is a straight-chain or branched-chain C1-C5 haloalkyl. In some embodiments, the haloalkyl is CHF2. In some embodiments, R7''' is a C3-C8 cyclic haloalkyl. In some embodiments, R7''' is a substituted or unsubstituted C3-C8 cycloalkyl. In some embodiments, the cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl. Each corresponds to a separate embodiment of the present invention. In some embodiments, R7''' is a substituted or unsubstituted 3- to 8-membered heterocyclic ring. In some embodiments, R7''' is morpholine.In some embodiments, R7''' is pyran. In some embodiments, R7''' is oxetane. In some embodiments, R7''' is pyrrolidine. In some embodiments, R7''' is 3,3-difluoropyrrolidine. In some embodiments, R7''' is imidazole. In some embodiments, R7''' is pyrazole. In some embodiments, R7''' is triazole. In some embodiments, R7''' is piperazine. In some embodiments, R7''' is piperidine. In some embodiments, R7''' is piperidin-2-one. In some embodiments, R7''' is piperidin-4-ol. In some embodiments, R7''' is dioxazole. In some embodiments, R7''' is 2-oxopyrrolidine.

[0217] In some embodiments, R7'''' of Structural Formula I(i) is H. In some embodiments, R7'''' of Structural Formula I(i) is F, Cl, Br, I, OH, O-R 20 , SH, R8-OH, R8-SH, -R8-O-R 10 , R8-(C3-C8 cycloalkyl), R8-(3- to 8-membered heterocycle), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R 10 )(R 11 ), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 , R8-C(O)-R 10 , C(O)H, C(O)-R 10 , C1-C5 linear or branched C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10)(R 11 )、SO2R、SO2N(R 10 )(R 11 )、CH(CF3)(NH-R 10 )、a straight-chain or branched-chain, substituted or unsubstituted alkyl having 1 to 5 carbon atoms, a straight-chain or branched-chain, substituted or unsubstituted alkenyl having 1 to 5 carbon atoms, a straight-chain or branched-chain or cyclic haloalkyl having 1 to 5 carbon atoms or 3 to 8 carbon atoms, a straight-chain or branched-chain or cyclic alkoxy having 1 to 5 carbon atoms (optionally, at least one methylene group (CH2) in the alkoxy is substituted by an oxygen atom), a thioalkoxy having 1 to 5 carbon atoms in a straight-chain or branched-chain, a haloalkoxy having 1 to 5 carbon atoms in a straight-chain or branched-chain, an alkoxyalkyl having 1 to 5 carbon atoms in a straight-chain or branched-chain, a substituted or unsubstituted cycloalkyl having 3 to 8 carbon atoms, a substituted or unsubstituted heterocyclic ring having 3 to 8 members, a substituted or unsubstituted aryl, or a substituted or unsubstituted benzyl. Each corresponds to a separate embodiment of the present invention. In some embodiments, R7´´´´ is F, Cl, Br, I, a straight-chain or branched-chain alkyl having 1 to 5 carbon atoms, OH, an alkoxy (e.g., OMe), an amide (e.g., C(O)N(R)2), C(O)-pyrrolidine, C(O)-piperidine, N(R)2, NH(R 10 )、N(R 10 )(R 11 ), (e.g., N(CH3)2, NH2), CF3, an aryl, a phenyl, a heteroaryl, a substituted or unsubstituted cycloalkyl having 3 to 8 carbon atoms (e.g., cyclobutanol), a substituted or unsubstituted heterocyclic ring having 3 to 8 members (e.g., pyran, oxetane, piperidine, pyrazole, methylpyrazole, triazole, imidazole), a halophenyl, (benzyloxy)phenyl, CN, and NO2, and is further substituted with at least one substituent selected from the group consisting of. Each corresponds to a separate embodiment of the present invention.

[0218] In some embodiments, R7′′′′ of Structural Formula I(i) is H. In some embodiments, R7′′′′ is F. In some embodiments, R7′′′′ is Cl. In some embodiments, R7′′′′ is Br. In some embodiments, R7′′′′ is I. In some embodiments, R7′′′′ is CF3. In some embodiments, R7′′′′ is a linear or branched, substituted or unsubstituted C1-C5 alkyl. In some embodiments, R7′′′′ is a linear or branched, unsubstituted C1-C5 alkyl. In some embodiments, the alkyl is isopropyl, methyl, or ethyl. Each corresponds to a separate embodiment of the present invention. In some embodiments, R7′′′′ is a linear or branched, substituted C1-C5 alkyl. In some embodiments, R7′′′′ is isopropyl. In some embodiments, R7′′′′ is methyl. In...

Claims

1. A compound represented by the following structural formula I(j), or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, N-oxide, reverse amide analog, prodrug, isotopic variant (e.g., deuterated analog), PROTAC, pharmaceutical, or any combination thereof. In the formula, X ２ , X ３ , and X ４ are, independently of each other, CH; X １０ is N, CH, or C(R) (e.g., C(CH ２ ), OH, C(CH ２ ), ２ -OH, C(NH-CH ２ -cyclopropyl), C(CH ３ ), C(cyclopropyl), C(isopropoxy), C(COOH)); Ring W is a saturated, unsaturated or aromatic monocyclic, fused ring, bridged ring or spiro ring of 3 to 10 membered carbocyclic or heterocyclic ring (e.g., morpholine (2-morpholine, or 3-morpholine), tetrahydrofuran, tetrahydropyran, oxetane, pyrrolidine, pyrrolidin-2-one, pyrrolidin-3-one, imidazole, pyrazole, isoxazolidine, piperazine, piperidine, piperidin-2-one, oxadiazole, triazole, 2-oxopyrrolidine, cyclopropyl, 2,2-dimethylpyrrolidine, 4-azaspiro[2.4]heptane, pyrrolidin-3-one-O-methyloxime, 2-oxa-5-azaspiro[3.4]octane, 1,4-dioxo-6-azaspiro[4.4]nonane, 3,3-dimethylmorpholine, 1-methylpiperazine, 4,7-diazaspiro[2.5]octane, bicyclo[1.1.1]pentane, 2,5-diazabicyclo[2.2.1]heptane, piperazine, piperazine-2-one); W １ is CH ２ , C=O, or CH(R １０ )(for example, CHCH ３ ); R ７ ' and R ７ '' are, independently of each other, H, F, Cl, Br, I, OH, O - R ２０ , SH, R ８ - OH, R ８ - SH, - R ８ - O - R １０ , R ８ - (C ３ - C ８ cycloalkyl), R ８ - (3 - to 8 - membered heterocyclic ring), CF ３ , CD ３ , OCD ３ , CN, NO ２ , - CH ２ CN, - R ８ CN, NH ２ , NHR, N(R) ２ , NH(R １０ ), N(R １０ )(R １１ ), R ８ - N(R １０ )(R １１ ), R ９ - R ８ - N(R １０ )(R １１ ), B(OH) ２ , - OC(O)CF ３ , - OCH ２ Ph, NHC(O) - R １０ , NHCO - N(R １０ )(R １１ ), COOH, - C(O)Ph, C(O)O - R １０ , R ８ - C(O) - R １０ , C(O)H, C(O) - R １０ , C １ - C ５ of linear or branched C(O) - haloalkyl, - C(O)NH ２ , C(O)NHR, C(O)N(R １０ )(R １１ ), SO ２ R, SO ２ N(R １０ )(R １１ ), CH(CF ３ )(NH - R １０ ), C １ - C ５ The linear or branched, substituted or unsubstituted alkyl (e.g., isopropyl, methyl, ethyl), C １ -C ５ The linear or branched, substituted or unsubstituted alkenyl, C １ -C ５ The linear or branched or C ３ -C ８ The cyclic haloalkyl (e.g., CHF ２ ), C １ -C ５ The linear or branched or C ３ -C ８ The cyclic alkoxy (e.g., methoxy) (optionally, at least one methylene group (CH ２ ) in the alkoxy is replaced by an oxygen atom), C １ -C ５ The linear or branched thioalkoxy, C １ -C ５ The linear or branched haloalkoxy, C １ -C ５ The linear or branched alkoxyalkyl, C ３ -C ８ The substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclohexyl), the substituted or unsubstituted 3- to 8-membered heterocycle (e.g., morpholine, pyran, oxetane, pyrrolidine, 3,3-difluoropyrrolidine, imidazole, pyrazole, triazole, piperazine, piperidine, piperidin-2-one, piperidin-4-ol, dioxazole, 2-oxopyrrolidine), the substituted or unsubstituted aryl, or the substituted or unsubstituted benzyl; or R ７ ' and R ７ '' are bonded to each other to form a substituted or unsubstituted saturated, unsaturated or aromatic 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); R ２０ is represented by the following structural formula: In the formula, R is H, F, Cl, Br, I, OH, SH, alkoxy, NH(R １０ ), NH-CH ２ -cyclopropyl, N(R １０ )(R １１ ), CF ３ , CN, NO ２ , COOH, C １ -C ５ 's straight-chain or branched-chain substituted or unsubstituted alkyl (e.g., methyl, ethyl, CH ２ -OH, CH ２ -CH ２ -OH, CH ２ -CH ２ -O-CH ２ -CH ２ -O-CH ３ , CH ２ -O-CH ２ -CH ２ -O-CH ３ ), C ３ -C ８ 's substituted or unsubstituted cycloalkyl, cyclopropyl, C １ -C ５ 's straight-chain or branched-chain alkoxy, isopropoxy, C １ -C ５ 's straight-chain or branched-chain haloalkyl (e.g., CHF ２ , CF ３ , CF ２ CH ３ , CH ２ CF ３ , CF ２ CH ２ CH ３ , CH ２ CH ２ CF ３ , CF ２ CH(CH ３ ) ２ , CF(CH ３ )-CH(CH ３ ) ２ ), R ８ -aryl (e.g., CH ２ -Ph), -R ８ -O-R ８ -O-R １０ (e.g., (CH ２ ) ２ -O-(CH ２ ) ２ -O-CH ３ ), -R ８ -O-R １０ (CH ２ -OH, CH ２ -CH ２ -OH), -R ８ -R １０ (for example, (CH ２ )) ２ -O-CH ３ ), a substituted or unsubstituted aryl (for example, phenyl), or a substituted or unsubstituted heteroaryl (for example, pyridine (2-pyridine, 3-pyridine, or 4-pyridine)); R ３０ is H, R ２０ , F, Cl, Br, I, OH, SH, alkoxy, N(R) ２ , NH(R １０ ), N(R １０ )(R １１ ), CF ３ , CN, NO ２ , C １ -C ５ 's straight-chain or branched-chain substituted or unsubstituted alkyl (e.g., methyl, ethyl, CH ２ -CH ２ -O-CH ２ -CH ２ -O-CH ３ , CH ２ -O-CH ２ -CH ２ -O-CH ３ ), C １ -C ５ 's straight-chain or branched-chain alkoxy, C １ -C ５ 's straight-chain or branched-chain haloalkyl (e.g., CHF ２ , CF ３ , CF ２ CH ３ , CH ２ CF ３ , CF ２ CH ２ CH ３ , CH ２ CH ２ CF ３ , CF ２ CH(CH ３ ) ２ , CF(CH ３ )-CH(CH ３ ) ２ ), R ８ -aryl (e.g., CH ２ -Ph), -R ８ -O-R ８ -O-R １０ (e.g., (CH ２ ) ２ -O-(CH ２ ) ２ -O-CH ３ ), -R ８ -O-R １０ , -R ８ -R １０ (e.g., (CH ２ )) ２ -O-CH ３ )), a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2-pyridine, 3-pyridine, or 4-pyridine)); R ２００ is H, R ２０ , F, Cl, Br, I, OH, SH, alkoxy, NH ２ , N(R) ２ , NH(R １０ ), N(R １０ )(R １１ ), CF ３ , CN, NO ２ , C １ -C ５ 's straight-chain or branched-chain substituted or unsubstituted alkyl (e.g., methyl, ethyl, CH ２ -CH ２ -O-CH ２ -CH ２ -O-CH ３ , CH ２ -O-CH ２ -CH ２ -O-CH ３ ), C １ -C ５ 's straight-chain or branched-chain alkoxy (e.g., methoxy), C １ -C ５ 's straight-chain or branched-chain haloalkyl (e.g., CHF ２ , CF ３ , CF ２ CH ３ , CH ２ CF ３ , CF ２ CH ２ CH ３ , CH ２ CH ２ CF ３ , CF ２ CH(CH ３ ) ２ , CF(CH ３ )-CH(CH ３ ) ２ ), R ８ -aryl (e.g., CH ２ -Ph), -R ８ -O-R ８ -O-R １０ (e.g., (CH ２ ) ２ -O-(CH ２ ) ２ -O-CH ３ ), -R ８ -O-R １０ , -R ８ , -R １０ (for example, (CH ２ )) ２ -O-CH ３ ), a substituted or unsubstituted aryl (for example, phenyl), or a substituted or unsubstituted heteroaryl (for example, pyridine (2-pyridine, 3-pyridine, or 4-pyridine)); Or, R ２００ and the carbon atom bonded thereto is C=O, C=N-O(R) (e.g., C=N-O-CH ３ ), or, C(R) ２ (e.g., C(CH ３ )) ２ , CF ２ ); Each R ８ is, independently of one another, [CH ２ ｐ and p is from 1 to 10;​ R ９ is [CH] ｑ or [C] ｑ where q is from 2 to 10; R １０ and R １１ are, independently of one another, H, C １ -C ５ linear or branched, substituted or unsubstituted alkyl (e.g., methyl, ethyl, CH ２ -cyclopropyl, CH ２ -CH ２ -O-CH ３ ), C １ -C ５ linear or branched, substituted or unsubstituted haloalkyl (e.g., CH ２ CF ３ ), C １ -C ５ linear or branched alkoxy (e.g., O-CH ３ ), R ２０ , C(O)R, or S(O) ２ R; or R １０ and R １１ are bonded to each other to form a substituted or unsubstituted 3- to 8-membered heterocyclic ring (for example, piperazine, piperidine); n is an integer from 0 to 4 (e.g., 1, 2).

2. The compound according to Claim 1, wherein Ring W is A saturated monocyclic 3- to 8-membered heterocyclic ring, preferably morpholine (2-morpholine, or 3-morpholine), tetrahydrofuran, tetrahydropyran, oxetane, pyrrolidine, isoxazolidine, piperazine, piperidine; An unsaturated monocyclic 3- to 8-membered heterocyclic ring, preferably pyrrolidin-2-one, pyrrolidin-3-one, imidazole, pyrazole, piperidin-2-one, piperazine-2-one, oxadiazole, triazole, 2-oxopyrrolidine; A saturated spiro ring of 3 to 10 membered heterocyclic ring, preferably 4-azaspiro[2.4]heptane, 2-oxa-5-azaspiro[3.4]octane, 1,4-dioxo-6-azaspiro[4.4]nonane, 4,7-diazaspiro[2.5]octane; A saturated bridged ring of a 3- to 10-membered heterocyclic ring, preferably bicyclo[1.1.1]pentane, 2,5-diazabicyclo[2.2.1]heptane; or, A saturated monocyclic 3- to 8-membered carbocyclic ring (i.e., cycloalkyl), preferably cyclopropyl; R ２００ is H, OH, F, NH ２ , C １ -C ５ of linear or branched alkoxy, methoxy, CN, C １ -C ５ of linear or branched substituted or unsubstituted alkyl (e.g., methyl), C １ -C ５ of linear or branched haloalkyl, or CHF ２ ; or R ２００ and the carbon atom to which it is attached is C=O, C=N−O(R) (e.g., C=N−O−CH ３ ), or C(R) ２ (e.g., C(CH ３ )) ２ , CF ２ ); X ２ and X ３ is CH; X ４ is N or CH; X １０ is N, CH, C(CH ２ ), OH, C(CH ２ ), ２ OH, C(NH-CH ２ -cyclopropyl), C(CH ３ ), C(cyclopropyl), C(isopropoxy), or C(COOH); R ７ ' is a linear or branched, substituted or unsubstituted alkyl of H, F, Cl, CF ３ , C １ -C ５ of a linear or branched, substituted or unsubstituted alkyl, preferably methyl, C １ -C ５ of a linear or branched or C ３ -C ８ of a cyclic alkoxy, preferably methoxy, C ３ -C ８ of a substituted or unsubstituted cycloalkyl, preferably cyclopropyl or cyclohexyl, or a substituted or unsubstituted aryl; R ７ is H or F; n is 1 or 2; Or a compound that is any combination thereof.

3. The compound according to claim 1 or 2, wherein The compound is represented by any of the structural formulas described in the following table.

4. The compound according to any one of claims 1 to 3, wherein The compound is (R)-2-(2-Fluoro-4-(pyrrolidin-2-yl)phenyl)-N-(3-(4-fluoropiperidin-1-yl)propyl)benzo[d]imidazo[2,1-b]thiazole-7-carboxamide, (S)-2-(2-Fluoro-4-(pyrrolidin-2-yl)phenyl)-N-(3-(4-fluoropiperidin-1-yl)propyl)benzo[d]imidazo[2,1-b]thiazole-7-carboxamide, or A compound that is not 2-(2-Fluoro-4-(pyrrolidin-2-yl)phenyl)-N-(3-(4-fluoropiperidin-1-yl)propyl)benzo[d]imidazo[2,1-b]thiazole-7-carboxamide.

5. A compound represented by the following structural formula I(n), or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, N-oxide, reverse amide analog, prodrug, isotope variant (e.g., deuterated analog), PROTAC, pharmaceutical, or any combination thereof. In the formula, X ２ , X ３ , and X ４ are, independently of one another, nitrogen or CH; X １０ is N, CH, or C(R) (e.g., C(CH ２ ), OH, C(CH ２ ), ２ -OH, C(NH-CH ２ -cyclopropyl), C(CH ３ ), C(cyclopropyl), C(isopropoxy), C(COOH)); Ring W is a saturated, unsaturated or aromatic monocyclic, fused ring, bridged ring or spiro ring of 3 to 10 membered carbocyclic or heterocyclic rings (e.g., morpholine (2-morpholine, or 3-morpholine), tetrahydrofuran, tetrahydropyran, oxetane, pyrrolidine, pyrrolidin-2-one, pyrrolidin-3-one, pyrrolidinone, imidazole, pyrazole, isoxazolidine, piperazine, piperidine, piperidin-2-one, oxadiazole, triazole, 2-oxopyrrolidine, cyclopropyl, 4-azaspiro[2.4]heptane, pyrrolidin-3-one-O-methyloxime, 2-oxa-5-azaspiro[3.4]octane, 1,4-dioxa-6-azaspiro[4.4]nonane, 4,7-diazaspiro[2.5]octane, bicyclo[1.1.1]pentane, 2,5-diazabicyclo[2.2.1]heptane, piperazine, piperazine-2-one); R ２００ is H, R ２０ , F, Cl, Br, I, OH, SH, alkoxy, methoxy, NH ２ , N(R) ２ , NH(R １０ ), N(R １０ )(R １１ ), CF ３ , CN, NO ２ , C １ -C ５ 's linear or branched substituted or unsubstituted alkyl (e.g., methyl, ethyl, CH ２ -CH ２ -O-CH ２ -CH ２ -O-CH ３ , CH ２ -O-CH ２ -CH ２ -O-CH ３ ), C １ -C ５ 's linear or branched alkoxy (e.g., methoxy), C １ -C ５ 's linear or branched haloalkyl (e.g., CHF ２ , CF ３ , CF ２ CH ３ , CH ２ CF ３ , CF ２ CH ２ CH ３ , CH ２ CH ２ CF ３ , CF ２ CH(CH ３ ) ２ , CF(CH ３ )-CH(CH ３ ) ２ ), R ８ -aryl (e.g., CH ２ -Ph), -R ８ -O-R ８ -O-R １０ (e.g., (CH ２ ) ２ -O-(CH ２ ) ２ -O-CH ３ ), -R ８ -O-R １０ , -R ８ , -R １０ (e.g., (CH ２ )) ２ , -O-CH ３ ), a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2-pyridine, 3-pyridine, or 4-pyridine)); Or, R ２００ and the carbon atom bonded thereto is C=O, C=N-O(R) (e.g., C=N-O-CH ３ ), or, C(R) ２ (e.g., C(CH ３ )) ２ , CF ２ ); R ５ is H, or C １ -C ５ which is a linear or branched alkyl (e.g., methyl); R ６ is H, C １ -C ５ linear or branched alkyl (e.g., methyl, ethyl, isopropyl), CD ３ or a substituted or unsubstituted saturated or unsaturated monocyclic, fused ring, bridged ring or spiro ring 3- to 10-membered carbocyclic or heterocyclic ring (e.g., piperidine (2, 3, or 4-piperidine), 1-methylpiperidine (1-methyl-3-piperidine, 1-methyl-4-piperidine), 3-fluoro-1-methylpiperidine, 1-(2, 2, 2-trifluoroethyl)piperidine, azetidine, 1-methyl-azetidine (1-methyl-3-azetidine), morpholine, pyrrolidine, pyrrolidinone, quinuclidine, tetrahydropyran (4-tetrahydropyran, or 3-tetrahydropyran), tetrahydrofuran, azaspiro[3.3]heptane, 8-methyl-8-azabicyclo[3.2.1]octane, dioxane, 1, 3-dioxane, imidazole, trifluoromethyl-oxetane, hydroxy-tetrahydrofuran, azepan-2-one, azabicyclohexane, 4, 4-difluorocyclohexane, cyclopropyl); R ７ ´ and R ７ ´´ are, independently of each other, H, F, Cl, Br, I, OH, O-R ２０ , SH, R ８ -OH, R ８ -SH, -R ８ -O-R １０ , R ８ -(C ３ -C ８ -cycloalkyl), R ８ -(3- to 8-membered heterocyclic ring), CF ３ , CD ３ , OCD ３ , CN, NO ２ , -CH ２ CN, -R ８ CN, NH ２ , NHR, N(R) ２ , NH(R １０ ), N(R １０ )(R １１ ), R ８ -N(R １０ )(R １１ ), R ９ -R ８ -N(R １０ )(R １１ ), B(OH) ２ , -OC(O)CF ３ , -OCH ２ Ph, NHC(O)-R １０ , NHCO-N(R １０ )(R １１ ), COOH, -C(O)Ph, C(O)O-R １０ , R ８ -C(O)-R １０ , C(O)H, C(O)-R １０ , C １ -C ５ of linear or branched C(O)-haloalkyl, -C(O)NH ２ , C(O)NHR, C(O)N(R １０ )(R １１ ), SO ２ R, SO ２ N(R １０ )(R １１ ), CH(CF ３ )(NH-R １０ ), C １ -C ５ A linear or branched, substituted or unsubstituted alkyl (e.g., isopropyl, methyl, ethyl), C １ -C ５ A linear or branched, substituted or unsubstituted alkenyl, C １ -C ５ A linear or branched or C ３ -C ８ A cyclic haloalkyl (e.g., CHF ２ ), C １ -C ５ A linear or branched or C ３ -C ８ A cyclic alkoxy (e.g., methoxy) (optionally, at least one methylene group (CH ２ ) in the alkoxy is replaced by an oxygen atom), C １ -C ５ A linear or branched thioalkoxy, C １ -C ５ A linear or branched haloalkoxy, C １ -C ５ A linear or branched alkoxyalkyl, C ３ -C ８ A substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclohexyl), a substituted or unsubstituted 3- to 8-membered heterocycle (e.g., morpholine, pyran, oxetane, pyrrolidine, 3,3-difluoropyrrolidine, imidazole, pyrazole, triazole, piperazine, piperidine, piperidin-2-one, piperidin-4-ol, dioxazole, 2-oxopyrrolidine), a substituted or unsubstituted aryl, or a substituted or unsubstituted benzyl; or R ７ ' and R ７ '' are bonded to each other to form a substituted or unsubstituted saturated, unsaturated or aromatic 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); R ２０ is represented by the following structural formula: Wherein, R is H, F, Cl, Br, I, OH, SH, alkoxy, NH(R １０ ), NH-CH ２ -cyclopropyl, N(R １０ )(R １１ ), CF ３ , CN, NO ２ , COOH, C １ -C ５ 's straight-chain or branched-chain substituted or unsubstituted alkyl (e.g., methyl, ethyl, CH ２ -OH, CH ２ -CH ２ -OH, CH ２ -CH ２ -O-CH ２ -CH ２ -O-CH ３ , CH ２ -O-CH ２ -CH ２ -O-CH ３ ), C ３ -C ８ 's substituted or unsubstituted cycloalkyl, cyclopropyl, C １ -C ５ 's straight-chain or branched-chain alkoxy, isopropoxy, C １ -C ５ 's straight-chain or branched-chain haloalkyl (e.g., CHF ２ , CF ３ , CF ２ CH ３ , CH ２ CF ３ , CF ２ CH ２ CH ３ , CH ２ CH ２ CF ３ , CF ２ CH(CH ３ ) ２ , CF(CH ３ )-CH(CH ３ ) ２ ), R ８ -aryl (e.g., CH ２ -Ph), -R ８ -O-R ８ -O-R １０ (e.g., (CH ２ ) ２ -O-(CH ２ ) ２ -O-CH ３ ), -R ８ -O-R １０ , -R ８ -R １０ (for example, (CH ２ )) ２ -O-CH ３ ), substituted or unsubstituted aryl (for example, phenyl), or substituted or unsubstituted heteroaryl (for example, pyridine (2-pyridine, 3-pyridine, or 4-pyridine)); R ３０ is H, R ２０ , F, Cl, Br, I, OH, SH, alkoxy, N(R) ２ , NH(R １０ ), N(R １０ )(R １１ ), CF ３ , CN, NO ２ , C １ -C ５ 's straight-chain or branched-chain substituted or unsubstituted alkyl (e.g., methyl, ethyl, CH ２ -CH ２ -O-CH ２ -CH ２ -O-CH ３ , CH ２ -O-CH ２ -CH ２ -O-CH ３ ), C １ -C ５ 's straight-chain or branched-chain alkoxy, C １ -C ５ 's straight-chain or branched-chain haloalkyl (e.g., CHF ２ , CF ３ , CF ２ CH ３ , CH ２ CF ３ , CF ２ CH ２ CH ３ , CH ２ CH ２ CF ３ , CF ２ CH(CH ３ ) ２ , CF(CH ３ )-CH(CH ３ ) ２ ), R ８ -aryl (e.g., CH ２ -Ph), -R ８ -O-R ８ -O-R １０ (e.g., (CH ２ ) ２ -O-(CH ２ ) ２ -O-CH ３ ), -R ８ -O-R １０ , -R ８ -R １０ (e.g., (CH ２ )) ２ -O-CH ３ )), a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2-pyridine, 3-pyridine, or 4-pyridine)); Each R ８ is, independently of one another, [CH ２ ｐ and p is from 1 to 10;​ R ９ is [CH] ｑ or [C] ｑ where q is from 2 to 10; R １０ and R １１ are, independently of one another, H, C １ -C ５ linear or branched, substituted or unsubstituted alkyl (e.g., methyl, ethyl, CH ２ -cyclopropyl, CH ２ -CH ２ -O-CH ３ ), C １ -C ５ linear or branched, substituted or unsubstituted haloalkyl (e.g., CH ２ CF ３ ), C １ -C ５ linear or branched alkoxy (e.g., O-CH ３ ), R ２０ , C(O)R, or S(O) ２ R; or R １０ and R １１ are bonded to each other to form a substituted or unsubstituted 3- to 8-membered heterocyclic ring (for example, piperazine, piperidine); n is an integer from 0 to 4 (e.g., 1, 2). **Claim 6** The compound according to claim 5, wherein X ２ and X ３ is CH; X ４ is CH or nitrogen; Ring W is A saturated monocyclic 3- to 10-membered heterocyclic ring, preferably morpholine (e.g., 2-morpholine, or 3-morpholine), tetrahydrofuran, tetrahydropyran, pyrrolidine, isoxazolidine, piperazine, piperidine; An unsaturated monocyclic 3- to 10-membered heterocyclic ring, preferably piperidin-2-one; A spiro ring of 3 to 10 membered heterocyclic rings, preferably 4-azaspiro[2.4]heptane, 2-oxa-5-azaspiro[3.4]octane, 1,4-dioxa-6-azaspiro[4.4]nonane, 4,7-diazaspiro[2.5]octane; A bridged ring of 3 to 10 membered heterocyclic rings, preferably bicyclo[1.1.1]pentane, 2,5-diazabicyclo[2.2.1]heptane; or, An unsaturated monocyclic 3- to 10-membered heterocyclic ring, preferably pyrrolidin-2-one, pyrrolidin-3-one, piperazine-2-one, piperidin-2-one, pyrrolidin-3-one-O-methyloxime; R ２００ is H, OH, CN, NH ２ , C １ -C ５ linear or branched substituted or unsubstituted alkyl of, C １ -C ５ linear or branched alkoxy (e.g., methoxy) of, or C １ -C ５ linear or branched haloalkyl (e.g., CHF ２ ); or R ２００ and the carbon atom to which it is attached is C=O, C=N-O(R) (e.g., C=N-O-CH ３ ), or C(R) ２ (e.g., C(CH ３ )) ２ , CF ２ ); R ５ is H, or a straight-chain or branched-chain alkyl of C １ -C ５ such as methyl; R ６ is H, C １ -C ５ of a linear or branched, substituted or unsubstituted alkyl, preferably methyl, ethyl, or isopropyl, CD ３ , a substituted or unsubstituted saturated monocyclic 3- to 10-membered heterocyclic ring, preferably piperidine (e.g., 2, 3, or 4-piperidine), 1-methylpiperidine (e.g., 1-methyl-3-piperidine, 1-methyl-4-piperidine), 3-fluoro-1-methylpiperidine, 1-(2,2,2-trifluoroethyl)piperidine, azetidine, 1-methyl-azetidine (e.g., 1-methyl-3-azetidine), morpholine, tetrahydropyran (e.g., 4-tetrahydropyran, or 3-tetrahydropyran), tetrahydrofuran, dioxane, 1,3-dioxane, a saturated bridged or spiro 3- to 10-membered heterocyclic ring, preferably 8-methyl-8-azabicyclo[3.2.1]octane, or a substituted or unsubstituted saturated monocyclic 3- to 10-membered carbocyclic ring (i.e., cycloalkyl), preferably 4,4-difluorocyclohexane, cyclopropyl; R ７ ' and R ７ '' are, independently of one another, H or F; Or a compound which is any combination thereof. **Claim 7** The compound according to claim 5 or 6, wherein R ６ The carbocyclic or heterocyclic ring defined by is further substituted with at least one substituent selected from F, Cl, Br, I, C １ -C ５ straight-chain or branched-chain alkyl of, OH, alkoxy (e.g., OMe), amide, C(O)N(R) ２ , C(O)-alkyl, C(O)-pyrrolidine, C(O)-piperidine, N(R) ２ , NH(R １０ ), N(R １０ )(R １１ ), N(CH ３ ), ２ NH ２ , CF ３ , aryl, phenyl, heteroaryl, C ３ -C ８ substituted or unsubstituted cycloalkyl (e.g., cyclobutanol), substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., pyran, oxetane, piperidine, pyrazole, triazole, imidazole) of, C １ -C ５ straight-chain or branched-chain haloalkyl (e.g., CH ２ CF ３ , CHF ２ ), halophenyl, (benzyloxy)phenyl, CN, and NO ２ . **Claim 8** The compound according to any one of claims 5 to 7, wherein R ６ The substituted or unsubstituted ring is piperidine (2, 3, or 4-piperidine), 1-methylpiperidine (e.g., 1-methyl-3-piperidine, 1-methyl-4-piperidine), 3-fluoro-1-methylpiperidine, 1-(2,2,2-trifluoroethyl)piperidine, azetidine, 1-methyl-azetidine (e.g., 1-methyl-3-azetidine), morpholine, tetrahydropyran (e.g., 4-tetrahydropyran, or 3-tetrahydropyran), tetrahydrofuran, dioxane, 1,3-dioxane, 8-methyl-8-azabicyclo[3.2.1]octane, 4,4-difluorocyclohexane, or cyclopropyl, a compound. **Claim 9** The compound according to any one of claims 5 to 8, wherein The compound is represented by any of the structural formulas shown in the following table. **Claim 10** A compound represented by the following structural formula I(o), or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, N-oxide, reverse amide analog, prodrug, isotope variant (e.g., deuterated analog), PROTAC, pharmaceutical, or any combination thereof. In the formula, X ２ , X ３ , and X ４ are, independently of one another, nitrogen or CH; X ５ , X ６ , X ７ , X ８ , and X ９ are, independently of one another, a nitrogen atom or a carbon atom; X １０ is N, CH, or C(R) (e.g., C(CH ２ ), OH, C(CH ２ ), ２ -OH, C(NH-CH ２ -cyclopropyl), C(CH ３ ), C(cyclopropyl), C(isopropoxy), C(COOH)); R １ is a substituted or unsubstituted alkyl of H, F, Cl, Br, I, OH, SH, CF ３ , C １ -C ５ such as CH ２ OH), a linear or branched or C １ -C ５ of a cyclic haloalkyl, C ３ -C ８ ; a linear or branched or substituted or unsubstituted or C １ -C ５ of a cyclic alkoxy of C ３ -C ８ ; R ２ is a substituted or unsubstituted alkyl of C １ -C ５ (e.g., CH ２ OH, CH ２ OCH ３ ), a 3- to 8-membered carbocyclic or heterocyclic ring (e.g., oxetane); or R １ and R ２ are bonded to each other to form a 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopropyl, oxetane); R ３ and R ４ are, independently of one another, H, Me, C １ -C ５ substituted or unsubstituted alkyl (e.g., methoxyethylene, methylaminoethyl, aminoethyl), -R ８ -O-R １０ (e.g., (CH ２ )) ２ -O-CH ３ ), R ８ -N(R １０ )(R １１ )(e.g., (CH ２ )) ２ -NH(CH ３ )), C ３ -C ８ substituted or unsubstituted cycloalkyl (e.g., cyclopropyl), substituted or unsubstituted 5- to 7-membered heterocyclic ring (e.g., pyrrolidine, methylpyrrolidine, piperidine), or, R ２０ ; or R ３ and R ４ are bonded to each other to form a 3- to 8-membered heterocyclic ring (for example, pyrrolidine, pyrrolidone, 2-oxopyrrolidine, piperidine, morpholine, piperazine, imidazole); R ５ is H, or a straight-chain or branched-chain alkyl of C １ -C ５ (e.g., methyl); R ６ is H, C １ -C ５ linear or branched alkyl of H, C (e.g., methyl, ethyl), substituted or unsubstituted saturated or unsaturated monocyclic, fused ring, bridged ring or spiro ring 3- to 10-membered heterocyclic ring (e.g., piperidine, 1-methylpiperidine, 3-fluoro-1-methylpiperidine, azetidine, 1-methyl-azetidine, morpholine, pyrrolidine, pyrrolidinone, quinuclidine, tetrahydropyran, tetrahydrofuran, azaspiro[3.3]heptane, 8-methyl-8-azabicyclo[3.2.1]octane, dioxane, 1,3-dioxane, imidazole, trifluoromethyl-oxetane, hydroxy-tetrahydrofuran, azepan-2-one, azabicyclohexane), or, (CH ２ ３ )-4-fluoropiperidine;​ R ７ ´ and R ７ ´´ are, independently of each other, H, F, Br, I, OH, O-R ２０ , SH, R ８ -OH, R ８ -SH, -R ８ -O-R １０ , R ８ -(C ３ -C ８ of cycloalkyl), R ８ -(3- to 8-membered heterocyclic ring), CF ３ , CD ３ , OCD ３ , CN, NO ２ , -CH ２ CN, -R ８ CN, NH ２ , NHR, N(R) ２ , NH(R １０ ), N(R １０ )(R １１ ), R ８ -N(R １０ )(R １１ ), R ９ -R ８ -N(R １０ )(R １１ ), B(OH) ２ , -OC(O)CF ３ , -OCH ２ Ph, NHC(O)-R １０ , NHCO-N(R １０ )(R １１ ), COOH, -C(O)Ph, C(O)O-R １０ , R ８ -C(O)-R １０ , C(O)H, C(O)-R １０ , C １ -C ５ of linear or branched C(O)-haloalkyl, -C(O)NH ２ , C(O)NHR, C(O)N(R １０ )(R １１ ), SO ２ R, SO ２ N(R １０ )(R １１ ), CH(CF ３ )(NH-R １０ ), C １ -C ５ a linear or branched, substituted or unsubstituted alkyl (e.g., isopropyl, methyl, ethyl), C １ -C ５ a linear or branched, substituted or unsubstituted alkenyl, C １ -C ５ a linear or branched or C ３ -C ８ a cyclic haloalkyl (e.g., CHF ２ ), C １ -C ５ a linear or branched or C ３ -C ８ a cyclic alkoxy (e.g., methoxy) (optionally, at least one methylene group (CH ２ ) in the alkoxy is replaced by an oxygen atom), C １ -C ５ a linear or branched thioalkoxy, C １ -C ５ a linear or branched haloalkoxy, C １ -C ５ a linear or branched alkoxyalkyl, C ３ -C ８ a substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclohexyl), a substituted or unsubstituted 3- to 8-membered heterocycle (e.g., morpholine, pyran, oxetane, pyrrolidine, 3,3-difluoropyrrolidine, imidazole, pyrazole, triazole, piperazine, piperidine, piperidin-2-one, piperidin-4-ol, dioxazole, 2-oxopyrrolidine), a substituted or unsubstituted aryl, or a substituted or unsubstituted benzyl; or R ７ ' and R ７ '' are bonded to each other to form a substituted or unsubstituted saturated, unsaturated or aromatic 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); R ２０ is represented by the following structural formula: In the formula, R is H, F, Cl, Br, I, OH, SH, alkoxy, NH(R １０ ), NH-CH ２ -cyclopropyl, N(R １０ )(R １１ ), CF ３ , CN, NO ２ , COOH, C １ -C ５ 's straight-chain or branched-chain substituted or unsubstituted alkyl (e.g., methyl, ethyl, CH ２ -OH, CH ２ -CH ２ -OH, CH ２ -CH ２ -O-CH ２ -CH ２ -O-CH ３ , CH ２ -O-CH ２ -CH ２ -O-CH ３ ), C ３ -C ８ 's substituted or unsubstituted cycloalkyl, cyclopropyl, C １ -C ５ 's straight-chain or branched-chain alkoxy, isopropoxy, C １ -C ５ 's straight-chain or branched-chain haloalkyl (e.g., CHF ２ , CF ３ , CF ２ CH ３ , CH ２ CF ３ , CF ２ CH ２ CH ３ , CH ２ CH ２ CF ３ , CF ２ CH(CH ３ ) ２ , CF(CH ３ )-CH(CH ３ ) ２ ), R ８ -aryl (e.g., CH ２ -Ph), -R ８ -O-R ８ -O-R １０ (e.g., (CH ２ ) ２ -O-(CH ２ ) ２ -O-CH ３ ), -R ８ -O-R １０ , -R ８ -R １０ (for example, (CH ２ )) ２ -O-CH ３ ), substituted or unsubstituted aryl (for example, phenyl), or substituted or unsubstituted heteroaryl (for example, pyridine (2-pyridine, 3-pyridine, or 4-pyridine)); R ３０ is H, R ２０ , F, Cl, Br, I, OH, SH, alkoxy, N(R) ２ , NH(R １０ ), N(R １０ )(R １１ ), CF ３ , CN, NO ２ , C １ -C ５ 's straight-chain or branched-chain substituted or unsubstituted alkyl (e.g., methyl, ethyl, CH ２ -CH ２ -O-CH ２ -CH ２ -O-CH ３ , CH ２ -O-CH ２ -CH ２ -O-CH ３ ), C １ -C ５ 's straight-chain or branched-chain alkoxy, C １ -C ５ 's straight-chain or branched-chain haloalkyl (e.g., CHF ２ , CF ３ , CF ２ CH ３ , CH ２ CF ３ , CF ２ CH ２ CH ３ , CH ２ CH ２ CF ３ , CF ２ CH(CH ３ ) ２ , CF(CH ３ )-CH(CH ３ ) ２ ), R ８ -aryl (e.g., CH ２ -Ph), -R ８ -O-R ８ -O-R １０ (e.g., (CH ２ ) ２ -O-(CH ２ ) ２ -O-CH ３ ), -R ８ -O-R １０ , -R ８ -R １０ (e.g., (CH ２ )) ２ -O-CH ３ )), a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2-pyridine, 3-pyridine, or 4-pyridine)); Each R ８ is, independently of one another, [CH ２ ｐ where p is from 1 to 10;​ R ９ is [CH] ｑ or [C] ｑ where q is from 2 to 10; R １０ and R １１ are, independently of each other, H, C １ -C ５ linear or branched, substituted or unsubstituted alkyl (e.g., methyl, ethyl, CH ２ -cyclopropyl, CH ２ -CH ２ -O-CH ３ ), C １ -C ５ linear or branched, substituted or unsubstituted haloalkyl (e.g., CH ２ CF ３ ), C １ -C ５ linear or branched alkoxy (e.g., O-CH ３ ), R ２０ , C(O)R, or S(O) ２ R; or R １０ and R １１ are bonded to each other to form a substituted or unsubstituted 3- to 8-membered heterocyclic ring (for example, piperazine, piperidine); n is an integer from 0 to 4 (e.g., 1, 2).

11. The compound according to claim 10, wherein R １ is H; R ２ is a substituted alkyl of C １ -C ５ (e.g., CH ２ OH, CH ２ OCH ３ ), or a 3- to 8-membered heterocyclic ring (e.g., oxetane); R ３ and R ４ are each independently H; R ５ is H, or C １ -C ５ which is a linear or branched alkyl (e.g., methyl); R ６ is a straight-chain or branched-chain alkyl of C １ -C ５ such as methyl or ethyl, (CH ２ ), ３ -4-fluoropiperidine, or tetrahydropyran; R ７ ' is F; R ７ is H; n is 1; or any combination thereof, a compound.

12. The compound according to claim 10 or 11, wherein the compound is represented by any of the structural formulas described in the following table.

13. A compound represented by any of the structural formulas described in the following table, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, N-oxide, reverse amide analog, prodrug, isotope variant (e.g., deuterated analog), PROTAC, pharmaceutical, or any combination thereof.

14. The compound according to any one of claims 1 to 13, wherein the compound is a c-MYC mRNA translation regulator, c-MYC mRNA transcription regulator, c-MYC inhibitor, or any combination thereof.

15. The compound according to any one of claims 1 to 14, and a pharmaceutically acceptable carrier, a pharmaceutical composition.

16. For the manufacture of a pharmaceutical for the treatment, suppression, reduction of severity, reduction of risk of onset, or inhibition of cancer in a subject, the compound according to any one of claims 1 to 14 or the pharmaceutical composition according to claim 15.

17. The compound according to claim 16, wherein the cancer is selected from the group consisting of breast cancer, ovarian cancer, acute myeloid leukemia, chronic myeloid leukemia, Hodgkin lymphoma, Burkitt lymphoma, diffuse large B-cell lymphoma, prostate cancer, colon cancer, gastric cancer, primary central nervous system lymphoma, glioblastoma, medulloblastoma, melanoma, non-small cell lung cancer, germinal center-derived lymphoma, esophageal squamous cell carcinoma, osteosarcoma, bladder cancer, pancreatic cancer, lung adenocarcinoma, BRAFV600E thyroid cancer, choroid plexus carcinoma, colorectal cancer associated with colitis, epithelial ovarian cancer, colorectal cancer, pancreatic cancer, and uterine cancer; the cancer is early-stage cancer, advanced cancer, invasive cancer, metastatic cancer, drug-resistant cancer, or any combination thereof; the subject has previously received treatment by chemotherapy, immunotherapy, radiotherapy, biological therapy, surgical intervention, or any combination thereof; The compound is administered in combination with an anti-cancer therapy; or a compound that is any combination thereof.

18. A compound according to claim 17, wherein the anti-cancer therapy is chemotherapy, immunotherapy, radiotherapy, biological therapy, surgical intervention, or any combination thereof.

19. A compound according to any one of claims 1 to 14 or a pharmaceutical composition according to claim 15, for use in suppressing, reducing, or inhibiting tumor growth in a subject.

20. A method for regulating c-MYC mRNA translation or c-MYC mRNA transcription in a cell, comprising the step of contacting a cell with a compound according to any one of claims 1 to 14, thereby regulating c-MYC mRNA translation or c-MYC mRNA transcription in the cell.

21. A method according to claim 20, wherein the method is by regulating c-MYC mRNA splicing (inclusion or exclusion of untranslated regions, or alternative use of exons); by regulating c-MYC mRNA modification; by regulating the interaction between an RNA-binding protein and c-MYC mRNA to change the localization of the mRNA; by regulating the localization of c-MYC mRNA in the cytoplasm; by regulating ribosomes and ribosome accessory factors for c-MYC mRNA; by reducing the amount of c-MYC protein in the cell; or by any combination thereof.

Images